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While we and others have prospectively identified potential origins of leukaemic stem 
cells (LSCs) resulting in phenotypically identical myeloid leukaemia, the functional differences 
among these origin-specific LSCs have not been vigorously investigated. Recently, our lab has 
shown that β-catenin, which is dispensable for normal HSCs, is essential for MLL LSCs, 
highlighting it as a potential therapeutic target for selective eradication of LSCs while sparing 
normal HSCs.  Here, I investigated the role of β-catenin in LSCs of distinctive cellular origins 
using both RTTA (in vitro) and bone marrow transplantation (in vivo) assays. I demonstrated 
that conditional deletion of β-catenin abolished the leukaemogenic potential of LSK-Meis1-
Hoxa9 pre-LSCs whereas CMP-Meis1-Hoxa9 pre-LSCs were able to develop into LSCs in vivo 
regardless of β-catenin status. Interestingly, conditional inactivation of β-catenin abolished the in 
vivo leukaemogenic property of GMP-MLL pre-LSCs whereas LSK-MLL pre-LSCs were still able 
to induce leukaemia in vivo in the absence of β-catenin, revealing functional differences in 
origin-specific LSCs in spite of their ability to induce phenotypically identical leukaemia.  Since a 
major function of β-catenin is to mediate stem cell self-renewal, I hypothesized the presence of 
multiple alternative self-renewal pathways in normal HSCs that may allow the LSK/HSC-origin 
specific LSCs overcoming inactivation of β-catenin.  Hox genes have been previously shown by 
others and us as key players in mediating self-renewal in normal and malignant 
haematopoiesis.  Consistently, Hoxa9 exhibited functions as β-catenin in mediating developing 
of MLL pre-LSCs originated from GMP but not HSCs. To test if Hoxa9 may compensate the loss 
of β-catenin in LSK-MLL pre-LSCs, I have created a conditional β-catenin/Hoxa9 knockout 
model where a combination of these two molecules can be inactivated in normal HSCs and 
various myeloid progenitors.  As a result, I demonstrated that specific inactivation of β-catenin 
or Hoxa9 abolished the oncogenic potentials of GMP-MLL pre-LSCs, but not LSK-MLL pre-
LSCs.  Strikingly, inactivation of both pathways suppressed oncogenic transformation by LSK-
MLL pre-LSCs and resulted in down-regulation of several Meis1-Hoxa9 target genes. Among 
them is Prmt1, which has been identified as a critical epigenetic modifying enzyme associated 
with an oncogenic MLL fusion complex. Prmt1 knockdown inhibited clonogenic activity of LSK-
MLL-ENL LSC with Hoxa9 or β-catenin knockout, suggesting Prmt1 as a key modulator for 
transformation of LSK-MLL-ENL LSC. Together, I have demonstrated, for the first time, specific 
molecular and functional differences among origin-specific LSCs, in which crosstalk between 
multiple self-renewal pathways inherited from the cell of origins may determine the biology of 
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Chapter 1 Introduction 
1.1 Haematopoietic stem cells and normal haematopoiesis  
Stem cells are defined as cells which possess hallmark abilities to long-term self-renew 
(i.e. to maintain stem cell pool) and differentiate into multi-lineage cell types. Stem cells can be 
classified into two main groups: 1. the pluripotent stem cells, such as embryonic stem cells, 
which are able to give rise to fully functional ectoderm, mesoderm and endoderm 
developmental tissues and organs; 2. Lineage-specific multipotent stem cells, among which 
haematopoietic stem cells (HSCs) that can differentiate into mature cells of all haematopoietic 
lineages such as neutrophils, eosinophils, basophils, monocytes, erythrocytes, megakaryocytes, 
and lymphocytes (Metcalf 2007, Copland M. 2009). In human adult bone marrow, the frequency 
of HSCs are estimated to be around 1 in 3 × 106 (Pettengell et al. 1994, Wang et al. 1997).  
Each normal HSC is capable to divide approximately 70 times during its lifespan (finite self-
renewal) (Vickers et al. 2000) to maintain HSC pool as well as differentiate into functional 
mature blood cells.  As first pointed out by Weissman’s group in the late eighties, there are two 
subsets of HSCs, long-term reconstituting HSCs (LT-HSCs, or ‘true’ HSCs) and short-term 
reconstituting HSCs which can differentiate into multipotent progenitors (MPPs) with little or no 
self-renewal capacity (Weissman et al. 2001, Dalerba et al. 2007, Z 2010). In murine bone 
marrow, a rare population of cells with true HSC-enrich population (Spangrude et al. 1988, 
Okada et al. 1992, Luis et al. 2012) was identified as being negative for lineage-specific 
markers, and positive for high levels of stem-cell antigen 1 (Sca1), and stem cell factor receptor 
c-Kit, thus collectively called Lin-Sca1+c-Kit+ (LSK) (Scheller et al.). Additional cell surface 
markers including Thy1.1low, CD34low/-, CD38-, SLAM markers (CD48-, and CD150+), fms-related 
tyrosine kinase 3 (Flt3 or Flk2)- and rhodamine123low (Kiel et al. 2005, Yilmaz et al. 2006, 
Passegue et al. 2003) have also been proposed to further define LT-HSCs markers. In contrast 
to LT-HSCs, murine short-term HSCs have acquired CD34+ and CD38+ (Randall et al. 1996) 
and became positive for Flt3/Flk2 (Christensen and Weissman 2001), whereas MPPs are 
CD34+ CD38- and Flt3+ (Adolfsson et al. 2001, Yang et al. 2005).  
Using a combination of Linlow/-, Thy1.1low, c-Kithigh, and Sca-1+ markers, the frequency of 
LT-HSC and ST-HSC in mouse bone marrow were estimated to be around 1:5000 and 1:1000, 
respectively (Passegue et al. 2003) (Figure 1.1). Using severe combined immunodeficient 
mouse (SCID)-repopulating cell assay, human HSCs were first identified as rare Lin- Thy1.1+ 
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CD34+ and CD38neg/low cells (Morrison et al. 1995, Doulatov et al. 2012, Bhatia et al. 1998) and 
more recently defined as Lin- CD34+CD38- CD90+ CD45RA+ cells (Figure 1). Since the vast 
majority of human HSCs isolated from cord blood and bone marrow express CD34+ (Bhatia et 
al. 1998) , CD34 has also been used as a marker to enrich in HSCs for bone marrow 
transplantation (Z 2010), although  some reports showed that transplantation with CD34-  
population can also lead to a  positive repopulation (Smith 2003, Haar and Ackerman 1971). 
These findings illustrate the fact that both the definition and the identification of HSCs should 
take functional assays into account instead of just immunophenotype and cell surface markers 
analyses (Z 2010).  
Haematopoiesis is a very complex but hierarchically well-orchestrated process leading 
to the production and maintenance of the different blood cell types originating from HSCs 
(Figure 1) during normal development or after physiological stresses such as in illness, trauma, 
or depletion of bone marrow cells following chemotherapy or irradiation (Kondo et al. 2003). 
During mammalian development, primitive haematopoiesis first occurs in the yolk sac.  At 
around day 7.5 of mouse embryonic stage (E7.5), structure named blood islands start producing 
myelo-erythroid progenitors (red blood cell precursors) then lymphoid precursors (Figure 1.2).  
After circulation occurs, blood cells are found at other haematopoietic sites.  At around E10.5, 
HSCs can be detected in the aorta-gonad mesonephros (AGM) region then in the placenta. 
Definitive haematopoiesis happens in the fetal liver (E13.5), thymus, spleen and finally the bone 
marrow (Figure 1.2) (Orkin and Zon 2008, Costa et al. 2012, Rudolph 2010). 
In adult, about 1013 of bone marrow cells are produced every day to maintain 
homeostasis as life span of mature blood cells is limited e.g. red blood cell and granulocyte are 
about 90 days and a few hours, respectively.) (Copland M. 2009). Because normal 
haematopoiesis is a complex process governed by many different genes, pathways and 
epigenetic regulation events, it is thought that HSCs with a longer lifespan are at risk of 
accumulating unwanted alterations or mutations, which would be harmful for the preservation of 
their self-renewal and/or differentiation properties. Such events nonetheless can happen, with 
the consequence being that some cells escape their normal regulation and dominantly expand 
in an uncontrolled way: functional HSCs get progressively replaced, which results in the 
development of various haematological malignancies (‘blood cancers’ or leukemias).  
 


















Figure 1.2: Sites of haematopoietic development in mouse. A) Primitive haematopoiesis first 
happens in yolk sac and later at aorta-gonad mesonephros (AGM) region, placenta, and fetal 
liver. B) haematopoiesis in specific location responds to produce specific blood lineages. C) 
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1.2 Acute myeloid leukaemia  
Acute myeloid leukaemia (AML) is a disorder affecting haematopoietic progenitors, and 
is highly heterogeneous e.g. in cellular morphology, immunophenotype, genetic alterations, 
prognosis and therapeutic response (Drach 2008). In addition, genetics polymorphisms of 
particular locus such as NAD(P)H quinine oxidoreductase 1 (NQO1) C609T, cytochrome P450 
family (CYP1A1*2B (Valine)), Ras, Flt3, and c-Kit (Estey and Dohner 2006) also increase a risk 
of predisposing to AML. From a pathological perspective, any genetic alteration of multipotent 
haematopoietic progenitors can possibly alter their normal growth, proliferation, and 
differentiation and be responsible for the disease (Mrozek et al. 2009). AML is the most frequent 
myeloid leukaemia in adults with a prevalence of 3.8 per 100000 individuals, rising to 17.9 per 
100000 in 65+ year-old adults (Estey and Dohner 2006). Symptoms associated with the  
accumulation of cancer cells or blasts in AML patient bone marrow include anemia, fatigue, 
bleeding, and infection (Lowenberg et al. 1999). Apart from de novo AML, secondary AML can 
develop in patients with other haematologic malignancies e.g. severe congenital neutropenia, 
Fanconi’s anemia, Bloom’s syndrome, myelodysplastic syndromes. Furthermore, treatment with 
alkylating agents in some cancers such as Hodgkin’s and non-Hodgkin’s lymphoma, ovarian 
cancer, breast cancer, and multiple myeloma (van Leeuwen 1996) are able to induce secondary 
AML. In addition, therapy-related AML has been found in acute lymphoblastic leukaemia patient 
who received epipodophyllotoxins (topoisomerase II inhibitors) (Pui et al. 1991). 
Analysis of samples for cell morphology, immunophenotype, chromosomal/molecular 
abnormalities that have prognosis significances is critical for the risk stratification of patients 
before treatment (Figure 1.3) (Grimwade et al. 2010). Two general classification systems have 
been proposed for AML diagnosis: the French-American-British FAB system (Table 1.1) 
identifies and classifies AML based on morphology and cytochemistry as well as a dominant 
presence of more than 30% of blasts cells in bone marrow, whereas the current WHO 
classification (Table 1.2) relies on cytogenetic findings and the blast threshold was decreased 
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Table 1.1: The French-American-British (FAB) classification. 
 
Table 1.2: World Health Organization (WHO) classification of AML.  
AML with certain genetic abnormalities 
• AML with a translocation between chromosomes 8 and 21 
• AML with a translocation or inversion in chromosome 16 
• AML with changes in chromosome 11q23 
• APL (M3), which usually has translocation between chromosomes 15 and 17 
AML with multilineage dysplasia (more than one abnormal myeloid cell type is involved) 
AML related to previous chemotherapy or radiation 
AML not otherwise specified (includes cases of AML that don't fall into one of the above groups; 
similar to the FAB classification) 
• Undifferentiated AML (M0) 
• AML with minimal maturation (M1) 
• AML with maturation (M2) 
• Acute myelomonocytic leukemia (M4) 
• Acute monocytic leukemia (M5) 
• Acute erythroid leukemia (M6) 
• Acute megakaryoblastic leukemia (M7) 
• Acute basophilic leukemia 
• Acute panmyelosis with fibrosis 
• Myeloid sarcoma (also known as granulocytic sarcoma or chloroma) 
Undifferentiated or biphenotypic acute leukaemias (leukaemias that have both lymphocytic and 
myeloid features). Sometimes called ALL with myeloid markers, AML with lymphoid markers, or 




FAB subtype Name % of adult AML 
patients 
Prognosis compared 
to average for AML 
M0 Undifferentiated acute myeloblastic 
leukemia 
5% Worse 
M1 Acute myeloblastic leukemia with 
minimal maturation 
15% Average 
M2 Acute myeloblastic leukemia with 
maturation 
25% Better 
M3 Acute promyelocytic leukemia (Raza-
Egilmez et al.) 
10% Best 
M4 Acute myelomonocytic leukemia 20% Average 
M4 eos Acute myelomonocytic leukemia with 
eosinophilia 
5% Better 
M5 Acute monocytic leukemia 10% Average 
M6 Acute erythroid leukemia 5% Worse 
M7 Acute megakaryoblastic leukemia 5% Worse 
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Because AML is a heterogeneous disease, the therapeutic strategy, prognosis and 
treatment outcome vary in different subtypes of AMLs. In acute promyelocytic leukaemia (Raza-
Egilmez et al.) with t(15;17)(q22;q21)/PML-RARA, patients are typically given all-trans retinoic 
acid (ATRA) and undergo a anthracycline-based protocol, whereas other subtypes of AML (e.g. 
t(8;21)(q22;q22)/RUNX1-RUNX1T1 or inv(16)(p13q22)/t(16;16)(p13;q22)/CBFB-MYH11) are 
commonly treated with intensive chemotherapy (cytarabine) with a favorable outcome. In 
contrast, treatment of AML patients with 3q abnormalities, deletion of 5 (del (5q)), monosomies 
of chromosome 5 and/or 7, patients with complex karyotype, or patient with MLL 
rearrangements (11q23) has very poor outcomes (Slovak et al. 2000). Differences in prognosis 
and treatment outcome of AML are significantly influenced by recurring chromosomal and/or 
genetic abnormalities that harbor oncogenic transcription factors (Schoch et al. 2001, Suciu et 
al. 2003, Haferlach et al. 2004, Breems et al. 2008). Thus, understanding the molecular 
regulation and pathways controlled by different leukaemia-association transcription factors 
(LATF) is mandatory to grasp the biology of the diseases and design effective tailored 


















Figure 1.3: Survival curves reveal different overall survivals of AML patients as grouped based 
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1.3 Transcription factors involved in acute myeloid leukaemia  
Chromosomal translocations frequently observed in AML are responsible for the 
encoding aberrant transcriptional regulatory elements that alter the growth, self-renewal, 
proliferation, and differentiation of normal HSCs. About 65% of acute leukaemia patients harbor 
specific chromosomal translocations or abnormal chromosomal rearrangements (Figure 1.4) 
(Look 1997). These mostly target genes coding transcription factors that are critical for the 
regulation of normal haematopoiesis, and thus their deregulations play a fundamental role in the 
establishment and maintenance of leukaemia. The most commonly deregulated transcription 
factors are Homeobox (Hox) genes, MLL, AML1, PML-RARα, MN1, CBP/P300, c-Myc, 
ERG/TLS (Crans and Sakamoto 2001). In the present report, I will focus on some of the most 
important LATFs, which include members of Hox family, MLL, and MN1.  
 
Figure 1.4: Most common chromosomal translocations and rearrangements in AML and their 
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1.3.1 The Hox gene family  
In human, about 39 Hox genes have been identified.  In mammals, these genes are 
located next to each other in four clusters: HoxA to HoxD, located on four different 
chromosomes. Hox genes are highly conserved from Drosophila melanogaster to human and 
can be categorized into 13 groups based on their similarity of structure and function compared 
to Drosophila HomC cluster (Figure 1.5) (Morgan 2006, Shah N. 2010, Eklund 2011). These 
genes encode homeodomain transcription factors that are critical for the embryonic 
development as well as for mammalian definitive haematopoiesis (Eklund 2007).  In the 
development of mammalian embryo, organ specific expression of Hox proteins have been 
identified including Hox1-4 dominantly expressed in the head, Hox5-7 in the thorax, and Hox8-
11 in abdomen and pelvis (Eklund 2006, Eklund 2007, Eklund 2011). Hox proteins are also 
found essential for haematopoiesis and the maintenance of HSC pool (Frohling et al. 2007). 
Generally, Hox1-4 are highly expressed in CD34+ CD38- population (enriched for HSC) while 
down regulation of those proteins is observed in more differentiated CD34-/+ CD38+ progenitors, 
which at the contrary dominantly express Hox7-11 (Sauvageau et al. 1994, Kawagoe et al. 
1999).  
Deregulation of Hox genes such as HoxB3, B4, A7-11 is observed in various 
leukaemias. In a mouse model, overexpression of HoxB3 leads to myeloproliferative disorder 
with accumulation of myeloid progenitors and abnormal development of early B-lymphocytes.  
High expression of Hoxa10 drives the expansion of megakaryocytic progenitors and reduces 
the number of B-lymphoid and monocytic cells, ultimately developing AML (Look 1997, 
Thorsteinsdottir et al. 1997). Furthermore, deregulation of Hoxa9 is commonly observed in AML 
(Golub et al. 1999, Lawrence et al. 1999). Kroon et al. (Kroon et al. 1998), showed that the co-
expression of Hoxa9 and Meis1 resulted in the rapid development of leukaemia in a murine 
model. Although the deregulation of Hox genes, notably Hoxa9, and of their targets, is 
frequently observed in AML, the mechanisms that control the Hox genes expression in normal 
haematopoiesis and AML are not fully understood. Among the regulators of Hox genes are 
mixed lineage leukaemia (http://atlasgeneticsoncology.org/Genes/MLL.html) and Cdx proteins 
(Krivtsov et al. 2006, Schumacher and Magnuson 1997). 
 
 




Figure 1.5: Homology of mammalian Hox genes with Drosophila melanogaster HomC gene and 
chromosomal location of both human and mouse (Schumacher and Magnuson 1997). 
1.3.2  Mixed lineage leukaemia  
Mixed lineage leukaemia (http://atlasgeneticsoncology.org/Genes/MLL.html) gene, also 
known as HRX and ALL-1, is a gene homolog to Drosophila melanogaster trithorax (Trx) and it 
is located on human chromosome 11q23 (Yu et al. 1995). In drosophila, Trx protein is essential 
for the maintenance of cell type-specific pattern of HomC gene expression during 
embryogenesis (Yagi et al. 1998). In the mouse, mutations of MLL lead to severe embryo 
malformations such as growth retardation, haematopoietic defects, bidirectional homeotic 
deformation of the skeletal axis, sternum abnormalities. Moreover, MLL knockout alters the 
normal expression of Hox genes resulting in early death of embryos around day E10.5-E16.5 
(McMahon et al. 2007, Jude et al. 2007). McMahon et al. (McMahon et al. 2007) showed that 
fetal liver of MLL knockout mice exhibited haematopoietic defects e.g. reduction in the number 
of quiescent HSCs and of both long-term and short-term HSCs. Although the conditional 
knockout mice had normal blood cells count, liver, spleen and thymus, MLL knockout bone 
marrow cells had impaired reconstitution ability in recipient mice. In addition, using a slightly 
different conditional murine model, Jude et al. (Jude et al. 2007) demonstrated that MLL is 
critical for the maintenance of adult HSCs and a deletion of MLL leads to rapid progression of 
bone marrow failure. Moreover, those MLL deficient cells lost their self-renewal capacity 
(selectively lost from mixed bone marrow chimeras) as well as their ability to intact with bone 
marrow environment. Together these data highlight the critical functions of MLL and Hox genes 
in in HSC self-renewal.  
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Interestingly, MLL is often translocated in AML and ALL (acute lymphoid leukaemia), 
and MLL rearrangement is an independent poor prognostic factor (Krivtsov and Armstrong 
2007). The leukaemogeneic properties of MLL and mechanism of Hox genes deregulation have 
been extensively studied in MLL-translocation-bearing leukaemias (e.g. MLL fusions such as 
MLL-AF4 or t(4;11)(21q23), MLL-AF9 or t(9;11)(p22;q23), MLL-ENL or t(11;19)(q23;p13.3), 
MLL-AF10 or t(10;11)(q12;q23), and MLL-AF6 or t(6;11)(q27;q23) (Krivtsov and Armstrong 
2007). In AML cases, approximately 5-10% of both children and adult patients harbor MLL 
rearrangements (Krivtsov and Armstrong 2007). The prevalence of different MLL fusion partners 
has been found to vary in adult and paediatric leukaemia (Figure 1.6). To date, there are about 
73 MLL translocations and more than 50 protein partners have been cloned 
(http://atlasgeneticsoncology.org/Genes/MLL.html), which however share similar clinical entities 
and gene expression signatures (Slany 2009).  
MLL is a DNA binding protein with a N-terminal DNA-binding domain and a C-terminal 
SET domain. In the nucleus, MLL forms a chromatin modifying complex with several other 
proteins. The N-terminal region is able to bind unmethylated DNA via the CxxC domain whereas 
the SET domain is responsible for histone methyltransferase activity (Figure 1.7) (Nakamura et 
al. 2002). The MLL complex is likely recruited by several transcription factors such as p53 and 
β-catenin (also known as Ctnnb1) to initiate transcription (Dou et al. 2005, Sierra et al. 2006). 
Remarkably, the transcription of Hox gene appears to be particularly dependent on MLL 
complex (Milne et al. 2002, Yokoyama et al. 2004). MLL rearrangements disrupt the association 
of the complex and therefore deregulate the transcription of its targets, especially Hox genes 
e.g. Hoxa 4, 5, 9 and 10 in pediatric MLL (Ross et al. 2004). Together, it has been suggested 
that the deregulation of Hox genes expression mediated by pathological MLL rearrangements 
leads to leukaemogenesis via uncontrolled proliferation and impairment of the differentiation of 
early haematopoietic stem/progenitor cells.  
Of note, a cofactor of Hox called Meis1 is abundant in MLL leukaemia in parallel with 
Hoxa9 activation (see also section 1.3.1). Upregulation of Hoxa9 increases the number of 
HSCs, indicating self-renewal and co-expression of Hoxa9 and Meis1 are able to induce 
leukaemia in murine model (Kroon et al. 1998). In addition, Meis1-mediated apoptosis in several 
murine and human leukaemia cell lines is blocked by co-expressing Hoxa9 (Wermuth and 
Buchberg 2005).  
 





Figure 1.6: Relative frequencies of MLL rearrangements in childhood and adult leukaemias 
(Krivtsov and Armstrong 2007).  
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1.3.3 AML1-ETO 
Chromosomal translocations t(8;21)(q22;q22)  resulting in AML1-ETO fusion is the most 
frequent one in AML (Z 2010). It accounts for up to 40% of the AML-M2 subtype in the FAB 
classification, with granulocytic differentiated leukemic blasts being observed (Elagib and 
Goldfarb 2007).  
AML1 (also known as RUNX1 or CBFα2) is located on chromosome 21 and critical for 
early haematopoiesis (Sroczynska et al. 2009).  AML1 transcription factor  can bind several 
target sequences of genes involved in tissue-specific expression of haematopoietic genes like 
granulocyte-macrophage colony-stimulating factor (GM-CSF), macrophage stimulating-factor 
(M-CSF) and interleukin 3 (IL-3) (Crans and Sakamoto 2001). Its N-terminus (RUNXT domain) 
is a close homolog to the drosophila pair-rule protein runt and is essential for heterodimerization 
with CBFβ to bind specific DNA target sequences (Daga et al. 1992). While CBFβ alone is not 
able to directly bind the target sequence (Wang et al. 1993, Ogawa et al. 1993), its dimerization 
with AML1 is critical for the regulation of downstream target gene expression.  
Fusion partner of AML1, ETO, is a homolog of Drosophila melanogaster Nervy and is 
located on human chromosome 8q22 (Crans and Sakamoto 2001). ETO possessed 
homodimerization and heterodimerization abilities and could form a complex that functions as a 
transcriptional regulator (Downing 1999). There is further evidence to suggest that ETO 
functions as a transcriptional regulator by corporation with nuclear co-repressors N-CoR and 
Sin3A to mediate histone deacetylation (Wang et al. 1998, Lutterbach et al. 1998). ETO Nervy 
region 2 (NHR2) invariably found in AML1-ETO fusion has a role in suppressing the 
transcriptional activity of AML1, which results in the blockage of myeloid cells differentiation (Liu 
et al. 2006).  
In human AML with t(8;21)(q22;q22), the most common aberrant transcript is known as 
full-length AML1-ETO (AE; AML1 exons 1-5 fused to ETO exons 2-11) that contains 752 amino 
acids with N-terminal of AML1 (RUNX1), DNA binding domain, and ETO protein (Moroi and 
Sato 1975).  AML1-ETO fusion protein is able to induce stem cell self-renewal and disrupt 
normal haematopoiesis, however AML1-ETO expression alone is not sufficient to induce 
leukaemi (Yuan et al. 2001, Roudaia et al. 2009). As a consequence, secondary mutations are 
required for AML1-ETO leukaemia (de Guzman et al. 2002). In addition to the full-length AE, 
Yan et al. (Yan et al. 2006), identified a variant transcript of AML1-ETO known as AML1-ETO 
9a (AE9a) which contains additionally the exon 9a of ETO gene. This variant has the ability to 
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rapidly induce leukaemia in a mouse model. Moreover, co-expression of AE and AE9a 
synergistically blocks myeloid cells in a more immature stage than using AE9a alone, and has 
an early disease onset.   
1.3.4 PML-RARα  
Acute promyelocytic leukaemia  is characterized by the t(15;17)(q22;q21) reciprocal 
translocation between human chromosomes 15 and 17 that results in the expression of two 
chimeric proteins called PML/RARα and RARα/PML (Grimwade et al. 1997).  
RARα gene located on chromosome 17q21 encodes a retinoic acid receptor and is a 
member of the nuclear hormone receptor superfamily. This family of receptors is involved in 
normal differentiation and growth inhibition of several cell types (Leid et al. 1992, Mangelsdorf et 
al. 1995, Chambon 1995). Its fusion partner, PML, maps to chromosome 15q22 and belongs to 
the RING finger protein family.   PML regulates several biological functions ranging from 
regulation of interferon function and immunosurveillance to pro-apoptotic and tumor suppressor 
functions. In addition, PML/RARα with co-transcriptional repression property results in blocking 
the accession of transcription factors to specific target sequence. APL has a dominant 
leukaemic phenotype comparable to committed myeloid progenitors (promyelocytic cells) that 
do not possess self-renewal capacity in a normal (i.e. non leukaemic) situation. Consequently, 
suppression of target genes including genes that function in normal differentiation of myeloid 
cells leads to the development of APL (leukaemic cells are arrested at the promyelocytic stage) 
(Testa et al. 1998, Zhong et al. 2000).  APL is a subtype of AML that shows defects in the 
regulation of transcriptional factors involved in HSC differentiation and self-renewal processes. 
Current therapeutic treatment of APL with PML/RARα is all-trans retinoic acid (ATRA)-induced 
transcription activation of PML/RARα downstream targets and differentiation of APL cells (So et 
al. 2000).  
1.3.5 MN1 
MN1 is an evolutionarily conserved gene located on chromosome 22 that was first 
identified as a fusion target of t(4;22) in meningioma (Grosveld 2007). MN1 interacts with 
vitamin D receptor resulting in suppression of the proliferation of osteoblast cell line (Sutton et 
al. 2005).  Similarly, growth inhibition of epithelial cells could be induced by MN1 expression 
(Kang et al. 2003). These suggest potential functions of MN1 in regulating growth and 
proliferation.  
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In AML, MN1 fuses with TEL in t(12;22)(p13;q12) (Grosveld 2007). MN1 is also found 
overexpressed in patients with inv(16) (Ross et al. 2004), patients with expressing EVI1 (Valk et 
al. 2004), and in adult AML with normal karyotype (Heuser et al. 2006). High expression of MN1 
correlates with poor outcome and ATRA resistance in AML (Heuser et al. 2007, Meester-Smoor 
et al. 2008).  Quantitative RQ-PCR analysis revealed that MN1 is expressed at low level in 
mouse HSC but not in CMP, CLP, and MEP, whereas high expression of MN1 can be observed 
in GMP population, suggesting MN1 could be a regulator of GMP-derived myelopoiesis (Carella 
et al. 2007). Recently Heuser et al. (Heuser et al. 2011) however showed that CMP but not 
GMP could be a target for MN1 induced leukaemia, which requires the formation of a complex 
with MEIS1-AbdB-like Hox protein for its leukaemogeneic properties.   
1.4 Leukaemic stem cells (LSCs) 
Leukaemia is the first human malignancy where cancer stem cells or leukaemic stem 
cells (LSCs) have been functionally isolated. LSCs are defined as leukaemic cells with infinite 
self-renewal capacity that sustain the growth of malignant tumors and recapitulate the disease 
upon transplantation (Bonnet 2005). In 1997, using a xenograft quantitative assay to identify 
and characterize stem cells in vivo, Bonnet and Dick (Bonnet and Dick 1997) made the pioneer 
observation that SCID leukaemia initiating cells (SL-IC) have self-renewal capacity whilst 
retaining the potential to differentiate and that these cells dominantly expressed CD34+ but not 
CD38 (similarly to normal HSCs) in all tested AML.  This finding showed that, like normal 
haematopoiesis, AML is organized as a hierarchy and suggested that LSCs may derive from 
HSCs (in opposition to derive from committed progenitor cells). However, like for normal HSCs, 
functional biological assays are the gold standard to characterize LSCs rather than just relying 
on morphology and immunophenotype. Although CD34+ CD38- cell were identified as human 
LSCs, recent report by Bonnet group (Taussig et al. 2010) demonstrate that about one-half of 
LSCs are restricted into CD34− fraction, whereas CD34+ fraction contained normal multilineage 
hematopoietic repopulating cells. Thus, characterization of human LSC based on 
immunophenotyping may not be trivial and LSC therapies targeting against surface antigens 
can be challenging. 
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1.4.1 The origin of leukaemic stem cells   
It is unclear from which cells do the LSCs originate from the normal HSCs hierarchical 
system e.g., HSCs and/or from more committed progenitor populations. Retroviral 
transduction/transformation assay (RTTA) involving the transduction of specific LATF into sorted 
distinct haematopoietic population is a powerful tool to identify possible targets of oncogenes 
and also decipher the origin of LSCs. So et al. (So et al. 2003) demonstrated that MLL-GAS7 
could induce multi-lineage leukaemia in multipotent progenitor (MPP) but not in common 
myeloid progenitor (CMP) or common lymphoid progenitor (CLP) derived cells. On the other 
hand, a different fusion, MLL-ENL, was able to induce AML in HSC, CMP, and 
granulocyte/monocyte committed progenitor (GMP) (Cozzio et al. 2003).  Interestingly, Heuser 
et al., (Heuser M. 2011), reported that CMP but not GMP was a target for MN1-induced 
leukaemia and that the transformation capacity of MN1 required the MEIS1/Abdb-like Hox 
protein complex. Consistently, overexpression of MEIS1 and Hoxa9 or Hoxa10 was able to 
render GMPs susceptible to MN1-induce leukaemia, suggesting different functional requirement 
in LSCs derived from different cellular origins. 
APL with PML-RARα is thought to originate from committed progenitors rather than 
HSCs: Turhan et al., (Turhan et al. 1995) showed by RT-PCR that only CD34+CD38+ 
(committed progenitors) but not CD34+CD38- (HSCs) cells express PML-RARα transcripts. 
These findings suggested that possibly HSC are not the origin of LSCs in APL.  However, 
fluorescent in situ hybridization (Jude et al.) evidence indicated that some APLs actually 
express PML-RARAα in CD34+CD38- cells. This would suggest that the transcription activity of 
PML-RARα is inhibited in CD34+CD38- transformed cells and also that a fraction of APL is 
sustained by cells derived from HSCs.  
1.4.2 Clinical significance of the molecular pathways that are critical for the 
development of leukaemic stem cells    
The recent development of the stem cell biology field has provided new insights into 
cancer biology and discloses some of mechanisms involved in the generation of cancer stem 
cells. It is clear that self-renewal capacity is a hallmark of normal stem cells as well as cancer 
stem cells.  Several pathways such as the Hedgehog, Hox, polycomb/Mll, PTEN, telomerase, 
GSK3 and Wnt/β-catenin pathways involved in self-renewal of HSCs have also been implied in 
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LSCs (Copland M. 2009). In the following sections, I will discuss Hox, BMI1, GSK3 and the 
Wnt/β-catenin pathway. 
1.4.2.1 Hox gene family in the development of LSC 
As described in previous section (1.3.1 The Homeobox gene family), Hox proteins, 
highly expressed in primitive self-renewing HSCs and down-regulated in more differentiated 
progenitors, are important for normal haematopoiesis, self-renewal as well as leukaemogenesis. 
In mouse models, over-expression of Hoxa9 but not Hoxb4 alone was able to induce leukaemia 
(Huntly and Gilliland 2005). In human AML, chromosomal translocation between Nup98 and 
Hoxa9 or HoxD13 has been observed, and overexpression of Hoxa9 is of poor prognosis 
(Golub et al. 1999, Anderson and Slotkin 1975, Raza-Egilmez et al. 1998). Furthermore, 
expression of several Hox transcripts (e.g. Hoxb3, Hoxb8, and Hoxa9) has been associated 
with leukaemogenesis (Thorsteinsdottir et al. 1997, Perkins et al. 1990, Sauvageau et al. 1997). 
The deregulation of Hox gene expression can be mediated by the upstream Hox-regulators 
such as MLL and CDX proteins (Mlodzik and Gehring 1987). Chromosomal translocation 
between CDX2 and TEL, t(12;13) has also been reported in AML and it is believed that 
alteration of CDX2 by TEL might be a cause of leukaemogenesis (Chase et al. 1999).  
1.4.2.2 BMI1 
There are two polycomb group (PcG) repressive complexes, polycomb repressive 
complex 1 (PRC1) and 2 (PRC2). BMI1 belongs to PRC1 and is a critical molecule for the 
maintenance of several somatic stem cells self-renewal including HSCs (Lessard and 
Sauvageau 2003, Park et al. 2003, Iwama et al. 2004, Mills 2010). BMI1 also plays a role in the 
maintenance of multipotent property of both HSCs and MPPs via a suppression of particular 
lineage gene promoters (e.g., Ebf1 and Pax5 of B-cell lineage developmental regulator genes). 
Loss of Bmi1 promotes expression of Ebf1 and Pax5 in HSCs/MPPs, leading to enhanced 
lymphopoiesis and a marked reduction in HSC/MPPs (Oguro et al. 2010). In addition, BMI1 
regulates cell senescence by targeting Ink4a/Arf locus that encodes a cyclin kinase inhibitor 
p16Ink4a and a tumor suppressor p19Arf. Deletion of both p16Ink4a and p19Arf in BMI deficient mice 
leads to de novo impaired self-renewal potential of HSCs (Oguro et al. 2006). In a murine 
model, Meis1-Hoxa9 induced LSC isolated from fetal liver of BMI1 deficient mice lost their ability 
to long-term engraft in secondary recipient mice and progressed to terminal differentiation and 
apoptosis, indicating its critical function in LSC maintenance (Lessard and Sauvageau 2003).  
Chapter 1 Introduction 
37  
Our lab and others have further addressed the role of Bmi1 in LSC induced by LATFs 
by revealing a novel functional crosstalk between BMI1 and MLL/Hoxa9 in leukaemia 
development.  We showed that Hox-associated MLL-AF9 was able to transform BMI1 knockout 
cells, whereas AML1-ETO and PML-RARα that failed to activate Hoxa9 cannot transformed 
BMI1 knockout cells. The leukaemogeneic property of MLL-AF9 was impaired by suppression of 
both BMI1 and Hoxa9.  Additionally, Bmi1 deficient cells transduced with AML1-ETO could 
overcome senescence via the ectopic activation of Hoxa9, which suppresses p16ink4a/p19ARF, 
targets of BMI1 (Smith et al. 2011). The other study Yuan et al. (Yuan et al. 2011), reported that 
BMI deficient GMP cells transformed with MLL-AF9 were immortalized in vitro with a decrease 
number of LSCs that induced leukaemia with a more differentiated phenotype. Co-suppression 
of p16 and p19 in BMI1 knockout cells could partially rescue the leukaemogeneic potential of 
BMI knockout GMP-MLL-AF9 cells in vivo. Together, these studies reveal a critical function of 
BMI1 in LSC self-renewal, and suggest that the combined targeting of BMI1 and Hoxa9 could 
be a way to eradicate LSCs.  
1.4.2.3 GSK3 and its inhibitors  
The conserved glycogen synthase kinase 3 family (GSK3) including GSK3α, GSK3β, 
and GSK3β2 is involved in several signaling pathways e.g. Hedgehog and Wnt/beta-catenin 
pathways to modulate cell division, stem cell self-renewal, differentiation. GSK3 is a 
serine/threonine kinase that is a key mediator in many human diseases. While inactivating 
mutations of GSK3 has been observed in several types of cancers (Cohen and Goedert 2004), 
GSK3 can function as a tumor promoter to support proliferation in some malignancies (Chen et 
al. 2009). Targeting of GSK3 may be a therapeutic option for GSK3-dependent cancers such as 
MLL leukaemia (Wang et al. 2008). GSK3 was able to maintain MLL LSC by promoting 
conditional association of CREB and its coactivator TORC and CBP with a homeodomain 
protein MEIS1 [(Wang et al. 2010)]. Since Hoxa9 and its co-factor MEIS1 play critical roles in 
MLL-induced leukaemia and other subtypes of AML, GSK3 inhibition can be a therapeutic 
strategy to target broad spectrum of AML by impairing the HoxA9/Meis1-induced proliferation 
and self-renewal of LSCs. 
 Recently, our group reported that MLL LSCs that acquired resistance to GSK3 
inhibitors could be resensitized by the suppression of β-catenin expression (Yeung et al. 2010). 
These findings make the connection between MLL-induced leukaemia, GSK3 resistance, and 
Wnt/β-catenin pathway in the development of drug resistant MLL LSC. However, it is less clear 
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whether targeting of LSC with GSK3 alone or combined with the suppression of critical 
molecules involving in LSC self-renewal such as β-catenin could be an efficient therapeutic 
option to eradicate other type of LSCs.  
1.5 Wnt/β-catenin involvement in LSC development and self-
renewal 
β-catenin is an adherence junction protein coded by the Ctnnb1 gene located on human 
chromosome 3 (p22.1) playing a crucial role in the development and maintenance of cell 
epithelial layers. The protein was first identified in association with the cell adhesion molecule 
complex (Mulloy et al.) E-cadherin (in the E-Cadherin-catenin complex). β-catenin functions as 
a linker between E-cadherin and α-catenin to the actin cytoskeleton protein in cell-to-cell 
adhesion process (Brault et al. 2001). In addition, McCrea et al. (McCrea et al. 1991), and Butz 
et al. (Butz et al. 1992), demonstrated that the Drosophila Armadillo homologue β-catenin is an 
important part of Wnt signalling pathway (Brault et al. 2001, Barker and Clevers 2000). Recent 
studies demonstrated that Wnt signaling pathway is critical for control cell proliferation, 
differentiation, cell polarity, and cell fate during the development of embryo as well as adult 
homeostasis. Unsurprisingly, genetic alterations of the Wnt pathway lead to several birth 
defects, cancers and other diseases (Clevers 2006). 
There are three different Wnt signaling pathways: the canonical Wnt/β-catenin pathway, 
the non-canonical planer cell polarity pathway, and the Wnt/Ca2+ pathway (Clevers 2006). Here, 
I will focus on the Wnt/β-catenin canonical cascade as there is strong evidence for its 
involvement in the control of normal and malignant haematopoiesis.  
In the absence of Wnt, cytoplasmic β-catenin is part of the destruction complex with 
Axin protein, tumor suppressor adenomatous polyposis coli (APC), GSK3, and casein kinase 1 
(CK1). GSK3 and CK1 consecutively phosphorylate β-catenin at its N-terminus targeting it for 
proteosomal degradation after the recognition of E3 ubiquitin ligase β-Trcp. As a consequence, 
T cell factor/lymphoid enhancer factor (TCF-LEF)/Groucho interacts with histone deacetylase 
(HDAC) and Wnt target genes are not activated (Figure 1.8 A). In the presence of Wnt ligand, 
the co-receptor complex is formed between Frizzled (Fz) and low-density lipoprotein receptor-
related protein 6 (LRP6) or close family member LRP5, which leads to the recruitment of 
Dishevelled (Dvl). This allows the phosphorylation and activation of LRP5/6 after Axin 
recruitment to the co-receptor complex. This process means that the destruction complex is 
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dismantled and thus the Axin-mediated β-catenin phosphorylation/degradation is blocked, 
leading to an accumulation of β-catenin in the nucleus where it gets active and functions as a 
co-activator for TCF to activate Wnt target genes such as c-Myc, n-Myc, cyclin D, Tcf-1, Sox9, 
and CD44 (Figure 1.8 B) (http://www.stanford.edu/group/nusselab/cgi-bin/wnt/ , MacDonald et 
al. 2009).  
Since Wnt/β-catenin canonical pathway is very important in homeostasis and regulation 
of cell proliferation, differentiation and cell fate decision, cell development, mutations of its 
components are commonly found in many diseases such as hereditary defects and cancers 
(MacDonald et al. 2009). Mutations of tumor suppressors APC and Axin have been reported in 
many tumors including Familiar Adenomatous Polyposis tumor (FAP) (Nishisho et al. 1991), 
sporadic colorectal cancers (Kinzler and Vogelstein 1996). Abraham et al. (Abraham et al. 
2001), demonstrated that 75% of sporadic juvenile nasopharyngeal angiofibromas carried beta 
catnin mutations. Moreover, Moreno-Brueno et al. (Moreno-Bueno et al. 2001), reported that 
high expression of β-catenin have been found in all 40 of the pilomatricomas they studied, and 
further investigation revealed that 3 of 11  (26%) samples carried mutations on the GSK3β site 
responsible for its phosphorylation activity. β-catenin mutations are also found in reproductive 
organs tumors including the endometrial and prostate cancers (Voeller et al. 1998, Ashihara et 
al. 2002). An example of activating mutations on β-catenin lies in hepatocellular carcinoma 
associated with hepatitis C (HCC) (Huang et al. 1999, Legoix et al. 1999, Wong et al. 2001). 
Moreover, the study of Satoh et al. (Satoh et al. 2000), revealed that about 14 % of HCCs 
harbored activating mutations on the phosphorylation sites of beta catenin and about 9 % 
carried inactivating mutation of tumor suppressor, Axin1 gene. Thus, based on many those 















Figure 1.8: Wnt/β-catenin pathway in the absence (A) or in the presence of Wnt ligand (B) 
(MacDonald et al. 2009). 
In the present report, I will focus on the role of Wnt/β-catenin in self-renewal its potential 
as a therapeutic target for haematopoietic malignancies. Involvement of β-catenin in the control 
of normal haematopoiesis and its pathogenesis emerged in the report by Reya et al. (Reya et 
al. 2000) showing that proliferation of B lymphocyte progenitors were significantly controlled by 
Wnt/β-catenin signaling pathway. They subsequently further investigated the impact of β-
catenin on HSC regulation, and found that transduced HSCs with activated β-catenin could 
retain cells in an immature state which express c-kit+ Thy1.1lo Lin– Sca-1+ (see phenotype of 
HSCs in section 1.1). In addition, they demonstrated that all recipient mice transplanted with 
activated β-catenin-transduced HSCs cells could engraft and reconstitute the haematopoietic 
system (myeloid and lymphoid lineages) with a high level of chimerism. These results revealed 
a role for active β-catenin in blocking differentiation whilst promoting HSC proliferation (Reya et 
al. 2003). A few years later, Scheller et al. (Scheller et al. 2006), using Cre-LoxP technology to 
modulate the activation of β-catenin in mice, elegantly demonstrated an important function of β-
catenin in the control of normal haematopoiesis. They found that constitutive activation of β-
catenin lead to the death of the recipient mice because of HSCs fail to repopulate the 
haematopoietic system and an arrest in multilineage differentiation. Furthermore, Kirstetter et al. 
(Kirstetter P 2006), demonstrated that activation of Wnt signalling for HSCs by conditional 
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expression of a stable form of β-catenin (β-catS33Y) leads to block differentiation and 
maturation of multilineage myeloid progenitors which are caused by the alteration of several 
critical cell signalling molecules including Cdkn1a, sfpi1, Hoxb4, Bmi1, and integrin.  These 
results suggest that super-physiological level of β-catenin may have inhibitory effects on normal 
HSC functions. 
In contrast to the study of the gain of function of β-catenin in normal haematopoiesis, 
Cobas et al. (Cobas M 2004), demonstrated that inducible Cre-loxP-mediated deletion of β-
catenin (MxCre) in bone marrow cells could not affect self-renew capacity of β-catenin deficient 
bone marrow cells. β-catenin deficient cells able to reconstitute and give rise to all full functional 
hematopoietic lineages (myeloid, erythroid, and lymphoid).  Moreover, Jeannet et al. (Jeannet G 
2008) reported that HSCs with combined genetic deletion of β-catenin and γ-catenin are able to 
maintain their long-term repopulation capacity as well as multilineage differentiation of both 
myeloid and lymphoid lineages. Interestingly, subsequent experiments by this group revealed 
that T-cell development via TCF-1 activation is independent of a functional interaction of β-
catenin and γ-catenin (reference). In addition, Prlic and Bevan (Prlic M 2011), demonstrated that 
conditionally deletion of β-catenin in mature T cells did not affect memory T cell functions, in which 
migration and response to chronic infection or lymphopenia induced proliferation. Apart from 
genetic modification approaches, the investigation of role of β-catenin in normal haematopoiesis by 
ectopic expression of Wnt/β-catenin inhibitor using GSK3β (Chase et al.) also did not resulting in the 
alteration of HSC differentiation (Moon RT 2004). These results indicated that β-catenin is 
dispensable for both hematopoiesis and lymphopoiesis.  
Alongside its major function in normal haematopoiesis, there have been many reports 
evaluating the role of Wnt/β-catenin pathway in leukemogenesis. In chronic myeloid leukemia 
(CML), loss of β-catenin results in a self-renewal defect of CML LSCs (Zhao et al. 2007). In the 
absence of β-catenin, the progression of CML mediated by BCR-ABL fusion gene slowed down, 
whereas acute lymphoblastic leukemia (ALL) development was unaffected. This clearly showed 
that different requirements of β-catenin exist in different types of leukaemia induced by BCR-
ABL. Lu et al. (Lu et al. 2004), observed that important Wnt ligands including Wnt3, Wnt5b, 
Wnt6, Wnt10a, Wnt14, and Wnt16 as well as Fzd3 receptor are overexpressed and activated in 
B cell chronic lymphocytic leukemia (CLL) compared to normal B cells. Targeting of GSK3 by 
SB-216763 helped promoting CLL survival, whereas the nonsteroidal anti-inflammatory drug R-
Etodolac induced CLL cells apoptosis.  For the role of β-catenin in normal HSC, Zhao et al. 
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reported a loss of long-term stem cell maintenance upon serial transplant although β-catenin 
deficient mice were able to have seemingly functional HSCs.  On the other hand, other studies 
showed that bone marrow cells derived from mice deficient in β-catenin or even in combination 
with γ-catenin did not have any obvious haematopoietic defects under both normal and stress 
conditions and are capable of fully reconstituting hematopoietic systems upon bone marrow 
trans-plantation into syngeneic mice (Cobas et al. 2004, Jeannet et al. 2008, Koch et al. 2008).  
These results suggest a largely dispensable function of β-catenin in normal HSCs with the 
potential exception of under special extremely conditions.   
In AML, Muller-Tidow et al. (Muller-Tidow et al. 2004), further highlighted the 
importance of the Wnt/beta-catenin pathway using a high-density oligonucleotide arrays to 
identify candidate genes in U937 human leukaemic cell line, after transfection with three 
different LATFs i.e. AML1-ETO, PML-RARα, PLZF-RARα. They found that among the genes 
controlled by those LATFs (38 down-regulated and 14 up-regulated) many are components of 
the Wnt/β-catenin pathway like γ-catenin and β-catenin as well as TCF /LEF, cyclin D1 and c-
Myc.  
Wang et al., 2010 (Wang Y 2010), studied the impact of β-catenin on self-renewal 
property and the development of LSCs by transducing either HSCs (purified as Lin- c-Kit+ Sca-
1+) or more differentiated progenitors -GMPs (purified as Lin- c-Kit+ Sca-1- FcRγ+ CD34+) with 
MLL-AF9 fusion or Meis1 and Hoxa9 oncogenes. Strikingly, there was no significant difference 
between HSCs and GMPs when co-transduced with Meis1 and Hoxa9 oncogenes or MLL-AF9 
in terms of proliferation, cell cycle analysis, apoptotic rate, immunophenotype or the cell 
morphology during six week in culture. However, after transplantation of the transformed cells 
into recipient mice, 93% of mice transplanted with MLL-AF9 GMPs and 70% of mice 
transplanted with Meis1-Hoxa9 HSCs developed AML.  In contrast, only 4% (1 out of 23 mice) 
with Meis1-Hoxa9 GMPs developed AML. Active β-catenin was expressed in Meis1-Hoxa9 
HSCs and MLL-AF9 GMPs but not in normal GMPs and the Meis1-Hoxa9 GMPs derived cells, 
suggesting that active β-catenin was required for the Meis1-Hoxa9 GMPs to develop the 
disease.  Consistently transduction of Meis1-Hoxa9 GMPs with the active β-catenin resurrected 
its transformation ability and induced leukemia in mice similar to those by Meis1-Hoxa9 LSKs. In 
contrast, knockout β-catenin in Meis1-Hoxa9 HSCs or MLL-AF9 GMPs compromised their 
leukaemogenic potentials in mice.  
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On the other hand, our group (Yeung et al. 2010) demonstrated that β-catenin was 
activated during the development of MLL LSCs. Using global expression analysis of the pre-
leukemic-like state MLL-ENL transformed cells (pre-LSC) and the MLL-ENL LSC enriched 
population, we found that several Wnt/β-catenin components including Frizzled 4/6 and Wnt 
targets such as cyclin D2 were upregulated in the MLL-LSCs compared to MLL-pre-LSC. 
shRNA mediated down-regulation of β-catenin reverted the MLL LSCs to a pre-LSC like state 
which were sensitive to GSK3 inhibitor (GSK3i) treatment,  suggesting that β-catenin might 
functions in the establishment of drug resistance in MLL leukemia. Also, the validity of the β-
catenin silencing approach was also confirmed in human leukemic cell lines and primary 
samples (Yeung et al. 2010, Gandillet et al. 2011). In addition, complete knockout of β-catenin 
in LSC abolished oncogenic property after transplantation to mice. Hence, β-catenin is required 
for the development of MLL-ENL LSCs. Since β-catenin is largely dispensable for normal HSC 
functions, these findings highlight the therapeutic potentials of targeting β-catenin in MLL LSCs.  
However, further cellular and molecular dissection of the functions of Wnt/β-catenin pathway 
involved in various LSCs of distinctive cellular origins are absolutely fundamental to understand 
the pathology of the disease and design effective therapeutics strategies. 
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Chapter 2 Objectives  
Human acute leukaemia is characterized by the presence of specific and recurring genetic 
mutations that frequently result in deregulation of transcriptional program of the targeted cells. 
Emerging evidence indicate that the biology, clinical behaviour and therapeutic responses of 
leukemic cells are largely dependent on the initiating genetic events. Thus, characterization of 
the molecular functions and the origins of these genetic mutations are essential for better 
understanding the biology of the disease and the development of specific inhibitors for cancer 
therapy. Recently, our group demonstrated the critical function of β-catenin in the development 
of MLL LSCs and its function in the establishment of drug resistant MLL LSCs derived from c-Kit 
positive cells. However, it is still largely unknown whether β-catenin also plays the same role in 
the development and maintenance of LSCs derived from different HSC/progenitors induced by 
common LATFs. In my PhD project, I investigated the impact of β-catenin in the initiation and 
maintenance of LSCs induced by some of the most common LATFs including MLL-AF9, MLL-
ENL, MN1, Meis1-Hoxa9, and E2A-PBX1.  I also studied the requirement of β-catenin in LSCs 
derived from different haematopoietic populations.  
The specific aims of my PhD project are followings:  
1) To explore the origin of leukemic stem cells initiated from certain types of LATFs 
and their β-catenin dependency 
2) To identify downstream targets of β-catenin in different LSCs and explore potential 
therapeutic targets in different LSCs 
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Chapter 3 Materials and methods  
3.1 Mice 
6-7 week-old C57BL/6 (CD45.2) or SJL (CD45.1) mice were used as bone marrow 
donors and recipients. β-cateninfloxed/floxed and Hoxa9 null mice have been used in our group 
published data (Yeung et al. 2010) (Smith et al. 2011).  
3.2 β-catenin fl/fl, compound Hoxa9 knockout and β-catenin fl/fl 
mice and Cre mediated deletion of β-catenin  
Conditionally-inducible mouse systems were used to assess particular functions of β-
catenin in different LSCs after transformation by some of the most frequent LATFs. Cre induced 
deletion is a powerful tool both in vitro and in vivo experiments and allows researchers to induce 
somatic mutations in a tissue-specific and temporary-specific manner (Cheon and Orsulic 
2011).  
The Cre/loxP inducible system is comprised of two main components: a modified floxed 
allele (‘floxed allele’ standing for a gene of interest flanked by two loxP sites) and a 
conditionally-inducible Cre expression. Cre is 38 KDa integrase that recognizes a 34 base pair 
sequence called loxP site. These are required for the integration and duplication of 
bacteriophage genome into and out of the host genome (Sternberg and Hamilton 1981). When 
Cre is expressed, the recognition between Cre recombinase and loxP sites results in site 
specific recombination between two loxP sites and mediates a deletion of the floxed portion of 
the allele. In the ER-Cre system, Cre is induced via tamoxifen to mediate the conditional 
deletion of a target gene. The way this system works is via the interaction between a nuclear 
hormone receptor (NHR) such as the estrogen receptor and its antagonist, tamoxifen. In the 
absence of estrogen or tamoxifen (4OHT), NHR is localized in cytoplasm and suppressed by 
the binding of heat shock protein 90 (hsp90). When estrogen or tamoxifen are added, NHR is 
freed from hsp90 segregate, which results in the dimerization and translocation of NHR into 
nucleus to mediate the expression of genes containing nuclear hormone-responsive promoter. 
A variation of the system is seen when Cre is fused to the estrogen receptor (ER-Cre). In such a 
case, after administration of tamoxifen, Cre becomes activated and translocated to the nuclear 
to mediate gene recombination/deletion by recognizing specific loxP sequence (Garcia and Mills 
2002). 
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Another available tools is self-inactivating hit-and-run Cre, which aims at minimizing long-
term toxicity caused by the persistence of Cre expression (Silver and Livingston 2001). The 
general principle of hit-and-run Cre is as follows: hit-and-run Cre vector contains Cre encoding 
gene flanked by loxP sites, and this hit-and-run Cre vector gets transduced (e.g. retroviral 
vector) into the host genome that contains the floxed target sequence. Cre gets expressed and 
mediates the deletion of target genes as well as excising itself (Figure 3.1). Although this 
system is therefore able to avoid long-term toxicity of Cre expression, it can be technically 
challenging since only an optimal expression level of Cre can mediate both a complete deletion 
of target genes and the mediated excision of itself.  
 
Figure 3.1: Generation of hit-and-run Cre retroviral vector and mechanism of action to mediate 
the deletion of target sequence (Silver and Livingston 2001). 
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Initially, in my first experiments, I used the Rosa26-LacZ/Ctnnb1fl/fl (R/C) mouse line that 
have been used in our group recent published data (Yeung et al. 2010), which has the region 
between exon 2 and 6 of β-catenin being flanked by loxP sites (Ctnnb1 floxed allele). In 
addition, a reporter Lac Z sequence has been placed under the control of ubiquitous Rosa26 
promoter, with a transcriptional stop flanked by Lox P sites.  In the presence of Cre, LoxP sites 
of both Ctnnb1fl/fl and Rosa26 promoter are cleaved, which allowed Cre to recombine Ctnnb1 
(i.e. beta catenin) sequence rendering beta-catenin inactive as well as activation of LacZ 
transcription of β-galactosidase that can be used for monitoring/tracing purposes using a 
specific substrate (FDG) (Figure 3.2). Assuming that the ability and activity of Cre to mediate the 
deletion of both target sequences are equal, then, FDG responsive cells will have the completed 
excision of Ctnnb1 exons 2 to 6 and referred subsequently to as  ‘β-catenin deficient cells’.  
 
Figure 3.2: Cre mediated deletion of Ctnnb1 floxed allele and of Lac Z promoter region flanked 
by loxP sites.  
In addition to this mouse strain, Rosa26Cre-/Rosa26-YFP/Ctnnb1fl/fl mice have also 
been generated to overcome a few anticipated potential shortcomings of the R/C mice (Cre 
leakiness, cell death during FDG staining process). The Cre ER fusion and yellow fluorescent 
protein YFP (the stop codon being flanked by loxP sites) encoding sequences are placed under 
the control of two distinct Rosa26 promotors (i.e. a single Rosa26 doesn’t drive the expression 
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of both Cre and YFP in this system) (Figure 3.3). The mice were generated after breeding with 
homozygous Ctnnb1 floxed mice. Administration of tamoxifen results in the Cre mediated 
deletion of both Ctnnb1 floxed alleles and the stop codon in front of the YFP sequences. 
Consequently, β-catenin deleted cells can be detected and purified based on the expression of 
YFP signal. Additionally, this mouse line would allow the assessment of β-catenin function in 
vivo by treating the mice with 4OHT. Areas to be investigated include the requirement of β-
catenin for the maintenance of LSC at the onset of the disease. This can be done by directly 
injecting tamoxifen into recipient mice that were transplanted with transformed Ctnnb1 floxed 
cells.  
 
Figure 3.3: Generation of Rosa26Cre/Rosa26YFP/Ctnnb1fl/fl mouse line and tamoxifen mediates 
deletion of Ctnnb1fl/fl alleles and stop codon of YFP promoter.  
 Finally, I also generated a compound conditional knockout line with an inducible β-
catenin allele (Rosa26-Cre/Rosa26-YFP/Ctnnb1fl/fl) together with Hoxa9 null alleles which have 
been used in our group published data (Smith et al. 2011). This mouse line was fertile and 
showed phenotypically normal when compared to wild type mouse. In the end of this report, I 
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used this mouse line to further investigate the role of β-catenin and Hoxa9 in the development 
of leukaemia initiating cells transformed by different LATFs. 
3.3 Retroviral transduction/transformation assays (RTTAs)  
RTTAs were previously described in detail by our lab (Zeisig and So 2009), here I would 
briefly describe each step in the following section of the material and methods part of my thesis.  
3.3.1 Plasmid and Virus preparation   
The murine stem cell virus plasmids (pMSCV) carrying different leukaemia association 
transcription factors including MLL-AF9, MLL-ENL, AM1L-ETO, E2A-PBX1, E2A-HLF, PML-
RARα, Meis1-Hoxa9, MN1, Nup98-Meis1,  hit-and-run cre, and pMSCV-IRES-CreTAM-puromycin 
plasmids were obtained from the clone database of the Leukemia and Stem Cell Biology group, 
Haemato-Oncology, King’s College London (Kwok et al. 2009, Yeung et al. 2010, Kwok et al. 
2010, Smith et al. 2011). All Plasmid DNAs were propagated and prepared using standard 
plasmid DNA kits from Qiagen/Fermantas according to the manufacturer’s instructions. The day 
before transfection, three million of GP2-293 cells (Clonetech) were seeded in 8 ml of D10 
medium (Dulbecco’s Modified Eagle Medium (DMEM), with 10fetal bovine serum (FBS), 100 
IU/ml of penicillin and streptomycin). Transfection were performed using Calcium precipitation 
with the mixture of 414 µl of H2O, 15 µg of 1 µg/µl of each DNA construct, 8 µg of 1.0 µg/µl 
pVSV-G (Vesicular Stomatitis Virus Glycoprotein Epitope), 2 µg of 0.5 µg/µl GFP (Green 
Fluorescent Protein, Clontech) plasmid, 61 µl of 2M CaCl2, and 500 µl  of 2 times HBS. 
Transfected cells were incubated overnight at 37° C, 5 % CO2. The transfection efficacy was 
determined 16 to 18 hours later by monitoring the GFP signal of transfected cells under the 
fluorescence microscope. Two days after transfection, virus supernatants were collected by 
aspirating the culture medium with a 10 ml syringe and filtered through a 0.45 µm filter into an 
ultra-centrifuge tube. Virus was subsequently concentrated using the Optima™ L-100 XP 
Ultracentrifuge, Beckman Coulter at 25,000 rpm, 4° C for 3 hours. The supernatant was then 
carefully removed leaving about 3 ml of culture medium at the bottom of centrifuge tube without 
any disturbance. The concentrated virus supernatant was resuspended by pipetting several 
times up and down, and stored in 200µl aliquots in 1.5 ml microcentrifuge tubes at -80°C.  
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3.3.2 Isolation of haematopoietic stem/progenitor cells (c-kit+) from mouse bone 
marrow 
The femurs and tibias bone from R/C and wild type mice were prepared and c-Kit + 
(CD117) cells were isolated using the MACS, Miltenyi Biotech technology according to the 
manufacturer’s instruction. Briefly, bone marrow from femur and tibias were flushed into 15 ml 
conical-base tube with 10 ml SM using 10 ml syringe (Terumo®, Belgium) attached with 25G 
needle (Terumo®, Belgium). Bone marrow cells were centrifuged (Allegra® X-15R centrifuge, 
Beckman Coulter) at 1300 g, 22 °C for 5 minutes. Then the supernatant was carefully removed 
and the cell pellet was incubated in 1 ml red cell lysis buffer (10 mM KHCO3, 150 mM NH4Cl, 
and 0.1 mM EDTA) for 10 minutes at room temperature. After 10 minutes, the red blood cells 
lysis reaction was stopped by adding 10 ml of SM (phosphate buffer saline (PBS) with 0.2 % 
FCS, 100 IU/ml penicillin and 100 µg/ml streptomycin) and cells were then filtrated into the 50 
ml conical-base tube using 40 µM nylon cell strainer (BD Falcon™) to obtain single cell 
mononuclear cells. Cells were then centrifuged at 1300 g, 22 °C for 5 minutes, washed once 
with 10 ml SM, reuspended in 500 ul SM and were incubated with 15 µl of c-kit beads for 30 
minutes at 4° C. After incubation, cells were washed with 30 ml of SM, while the MS column 
was pre-equilibrated with 500 µl of SM. After centrifugation, supernatant was carefully removed 
and cells were resuspended with 500 µl of SM. The cell suspension was applied to the 
equilibrated MS column, where c-Kit negative cells passed through the column by gravity while 
c-kit positive were retained. Cells were washed twice with 500 µl of SM in the MS column still 
attached onto the magnetic stand. The MS column was then removed from magnetic stand and 
purified c-Kit positive cells were collected onto 1.5 ml sterile microcentrifuge tube by adding 1 ml 
of SM onto the column and then flushing the column with the plunger into the labelled tube.   
Cells (20k for single spinoculation or 40k for double spinoculation) were plated in a 96-well plate 
in 200 ul R10 supplemented with 20 ng/ml SCF and 10 ng/ml of each IL3 and IL6 and incubated 
overnight at 37°C with 5% CO2. 
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3.3.3 Haematopoietic stem cells /progenitors sorting  
To sort functionally defined haematopoietic populations I followed and adapted the 
protocol from Yeung and So, 2009 (Yeung and So 2009). Briefly, bone marrow cells from 
femurs and tibias of 5-10 mice were collected into 50 ml tube.  They were resuspended and 
filtered through a 40 µm nylon cell strainer. Bone marrow cells were then mixed gently and 
pelleted by centrifugation at 1300 g, 22 °C for 5 minutes. Cell pellet was then resuspended with 
1 ml of red cell lysis buffer and incubated at room temperature for 10 minutes. After 10 minutes, 
10 ml of SM was added to the cells and the cells were pelleted by centrifugation at 1300 g, 22 
°C for 5 minutes. Cells were then resuspended in 2.5 ml of SM and incubated with 1 in 40 
dilution of unconjugated primary antibody (rat IgG) including Ter119 (TER-119 clone), Mac1 
(M1/70 clone), Gr1 (RB6-8C5 clone), CD3e (145-2C11 clone), CD4 (RM4-5 clone), CD8α (53-
6.7 clone), and B220 (RA3-6B2 clone) (75 µl of each antibody) at 4°C for 30 minutes. A 10ul 
aliquot of unstained cells were also mixed with 400 µl of SM and stored at 4° C for 
compensation use. Stained cells were then washed once with 10 ml of SM, pelleted at 1300 g, 
22 °C for 5 minutes and resuspended in 3 ml of SM. A 10 ul aliquot of unsorted cells were also 
kept at 4° C until use. Dynabead sorting (sheep anti-rat, IgG, Dynal, Invitrogen) was performed 
according to the manufacturer’s instructions. 3 ml of stained cells were incubated with prepared 
Dynabeads at 4° for 30 minutes (using rotator to allow cells bind to beads efficiently during 
incubation).  Unbound-lineage depleted cells were then purified according to Dynabeads 
protocol. Lineage-depleted cells were then counted and pelleted by centrifugation as described 
above. Both Lineage-depleted and Lineage-positive control cells were then resuspended with 
1:50 dilution of goat anti-rat-PECy5 in SM at 4°C for 30 minutes (total volume was 500 µl for 
lineage-depleted and 200 µl for control/compensation cells). After incubation, stained cells were 
washed once with 10 ml of SM, pelleted by centrifugation, and supernatant was removed. Then 
cells were incubated with blocking rat IgG antibody (Sigma) using 250 µl for lineage-depleted 
and 100 µl for lineage-positive control cells at 4°C for 30 minutes. Cells were then washed once 
with 10 ml of SM, pelleted by centrifugation, and supernatant was removed. Cells were then 
resuspended in master mix of SM and conjugated antibodies including c-Kit-PE (1:100), Sca1-
PECy-7 (1:50), CD34-FITC (1:25), and CD16/32-APC (1:75) to make a final volume of 500 µl for 
lineage-depleted and incubated at 4° C for 30 minutes in dark. Cells were then washed once 
and pellet as described above. Finally, cells were stained with 1:1000 PI (1mg/ml) in SM/PBS. 
Stained cells were then subjected to sort HSC, CMP, GMP, and MEP using BD ARIA cell sorter 
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(BD Bioscience). Sorted cells (0.5 to 2 × 104) were seeded in sterile 96-well plate containing 
with R20/20 supplemented with 20 ng/ml SCF and 10 ng/ml of each IL3 and IL6 and incubated 
overnight at 37C with 5% CO2. 
3.3.4 Colony-forming cell assay in methylcellulose medium 
To confirm the purity of HSC/progenitors sorting, I performed the colony-forming cell 
assay (CFC) to access the proliferation and differentiate patterns of each sorted populations 
(HSC, CMP, GMP, and MEP) by their ability to form different colonies in semisolid medium. 
Briefly, complete medium for myeloid lineage cells was prepared by adding 20 ng/ml SCF, 10 
ng/ml IL3, 10 ng/ml IL6, 10 ng/ml GM-CSF, 5 unit Erythropoietin, 100 IU/ml penicillin, and 100 
µg/ml streptomycin into methylcellulose medium (M03234, StemCell Technology). 1 ml of 
complete medium was aliquot into 1 ml Eppendorf tubes with appropriate labelled (LSK, CMP, 
GMP, and MEP) using 18G blunt-end needle attached to a 1 ml syringe. Viable purified LSK, 
CMP, GMP, and MEP cells were counted using a haematocytometer and 1,000 cells were 
plated into prepared medium and mixed by vortexing and briefly spun down. A 1 ml syringe 
attached with 18G blunt-end needle was used to aspirate and to dispense the 
methylcellulose/cell mix into one well of a 12-well culture plate. Remaining methylcellulose/cell 
mix was again briefly spun down and transferred into the same well of the 12-well plate. To 
prevent the methylcellulose medium from drying out during incubation (approximately 5 to 7 
days), sterile water or PBS was added into the free first and last row of 12-well plate before 
putting into the 37° C, 5% CO2 incubator for 7 to 10 days. After 7 days, colony-forming unit of 
each sorted HSC progenitors were characterised and numbered based on their discrete in 
colony morphologies according to Mouse Colony-Forming Cell (CFC) Assays Using Methocult® 
Technical Manual (version 3.1.1), StemCell Technologies. 
3.3.5 Serial replating in methylcellulose medium  
To investigate the role of β-catenin in development of LSC induced by different LATF, 
several transduction strategies using purified c-Kit positive cells and different sorted HSC 
progenitors (LSK, CMP, GMP, and MEP) were performed. These included; 1) single 
transduction with only specific LATF; and 2) co-transduction with both specific LATF and Cre 
virus (hit-and-run/Cre ER) prior the 1st plating.   Briefly, frozen concentrated virus was thawed in 
water bath at 37 °C and the centrifuge was pre-warmed to 32°C prior to spinoculatoin. Most of 
R10 medium (about 150 µl) was removed from cells in a 96 wells-plate without disturbing the 
cell pellet on the bottom of the well. Next, 100 µl of thawed and pre-warmed LATF virus for 
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single spinoculation (or 100 µl of both LATF and Cre viruses for double spinoculation) 
supplemented with 5 µl of master mix of 4.6 µl R10, 0.1 µl of each 20 ng/ml SCF, 10 ng/ml of 
IL3, 10 ng/ml of IL6, and polybrene (10mg/ml) was added to the cells and mixed well.  
Spinoculation was carried out by centrifugation at 800g, 32° C for 2 hours. After spinoculation, 
cells were placed back into the incubator.  The next day methylcellulose medium supplemented 
with 20 ng/ml SCF, 10 ng/ml IL3, 10 ng/ml IL6, 10 ng/ml GM-CSF, 100 IU/ml penicillin, and 100 
µg/ml streptomycin was pre-warmed in waterbath at 37°C.  0.9ml aliquots were dispensed into 
1.5ml Eppendorf tubes using 18G blunt-end needle attached to a 1 ml syringe. Antibiotics were 
added and mixed into medium according to each LATF or Cre-ER construct in an optimal 
concentration (1mg/ml geneticin, 1 mg/ml hygromycin, and 1.3 µg/ml puromycin for neomycin, 
hygromycin and puromycin resistant viruses, respectively). For the single spinoculations, 
transduced cells were transferred into 0.9 ml methylcellulose medium, mixed well by vortexing 
and briefly spun down. A 1 ml syringe attached with 18G blunt-end needle was used to aspirate 
and to dispense the methylcellulose/cell mix into one well of a 24-well culture plate (only the 2nd 
and 3rd row of the 24 well plate were used, see below). Remaining methylcellulose/cell mix was 
again briefly spun down and transferred into the same well of the 24-well plate. To prevent the 
methylcellulose medium from drying out during incubation (approximately 5 to 7 days), sterile 
water or PBS was added into the free first and last row of 24-well plate before putting it back 
into the 37° C, 5% CO2 incubator for 5 to 7 days. For co-transduction experiments, spinoculation 
was repeated once with identical conditions.  After a total of two overnight incubations, 
transduced cells were plated into methylcellulose medium as described above. 5 to 7 days after 
plating, colony formation of transduced cells was counted under a light microscope.  Non-
transduced cells were not able to survive and form colonies due to the antibiotic selection. The 
number and type of colonies were scored and recorded. Colonies were harvested in 8 ml SM 
and transferred into a 15 ml conical base test tube using a 10 ml pipette. Cells were incubated 
in 37°C water bath for 1-2 hours to dissolve methylcellulose before they were centrifuged at 
1300 g, 22 °C for 5 minutes.  Cells were reuspended in 500 to 1,000 µl of SM depending on 
initial numbers of colonies (e.g., 1 ml for more than 100 colonies, 500 µl for less than 100 
colonies).  Viable cells were counted using a haematocytometer, and 10000 cells were re-plated 
into 0.9 ml methylcellulose supplemented with cytokines as described above for the first round 
of plating. Five to seven days after the plating, the numbers as well as colony morphologies 
were scored and recorded again.  Cells were then subjected to a third round of plating using the 
Chapter 3 Materials and methods 
54  
same method as described above. This re-plating was carried out up to 8 times. It is important 
to point out that only transformed cells with enhanced the self-renewal property form colonies in 
the third round of plating and beyond, while non-transformed cells do form colonies in the initial 
round of plating but fail to form colonies in the third round of plating as they differentiate and 
stop proliferating. Transformed cells were then immunophenotypically analyzed using FACS  
(described on immunophenotyping section) and cell lines of each transformed cell was 
established by growing transformed cells in R20/20 supplemented with the same cytokine mix 
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Figure 3.4: Schematic demonstrates a modified retroviral transduction and transformation 
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3.4 Mouse β-catenin and Hoxa9 genotyping  
To determine and confirm Ctnnb1 and Hoxa9 genotypes of haematopoietic progenitor 
cells were isolated from bone marrow of Rosa26-LacZ/Ctnnb1fl/fl, Rosa26-Cre/Rosa26-
YFP/Ctnnb1fl/fl, Rosa26-Cre/Rosa26-YFP/Ctnnb1fl/fl/Hoxa9-/-, and wild type mice before and after 
transduced with each LATF and Cre systems. For Ctnnb1 genotyping, allele specific PCR 
according to Brault et al (2001) (Brault et al. 2001) was performed using 0.5 µM of each primers 
(Table 3.1 and figure 3.5), 1X Dream Green buffer (Fermentas), 0.2 mM dNTP mix (Roche), 0.5 
unit of DreamTag™ Green DNA Polymerase (Fermentas) using the following PCR condition: 
denaturing at 94 °C for 4 minutes, 30 cycles of 94 °C for 30 seconds, 56 °C for 30 seconds, 72 
°C for 30 seconds, final extension at 72 °C for 30 seconds. The specific amplified Ctnnb1 alleles 
(wild type; 221 bp, floxed; 324 bp, and deleted; 500 bp) were separated on 1.5% agarose gel. 
Similar PCR cocktail was used for both Hoxa9 wild type and knockout genotyping. Primers 
specific amplified to Hoxa9 wild type and knockout alleles were listed in table 3. PCR conditions 
of both Hoxa9 wild type and knockout were following denaturing at 94 °C for 4 minutes, 30 
cycles of 94 °C for 30 seconds, 62 °C for 30 seconds, 72 °C for 30 seconds, final extension at 
72 °C for 30 seconds. Specific PCR products (wild type approximately to 140 bp and knockout 
approximately to 100 bp) were separated on 1.5% agarose gel. 
Table 3.1: Table shows Ctnnb1 and Hoxa9 specific primers. 
Primer Sequence (5’ to 3’) 
RM41 AAG GTA GAG TGA TGA AAG TTG TT 
RM42 CAC CAT GTC CTC TGT CTA TTC 
RM43 TAC ACT ATT GAA TCA CAG GGA CTT 
Hoxa9 Wild type Forward CAC AAA GGG GCT CTA AAT CC 
Hoxa9 Wild type Reverse AGC ACA TAC AGC CAA TAG CG 
Hoxa9 K/O Forward AAG GCA GGT CAA GAT CTC CGA 
Hoxa9 K/O Reverse TCG CCT TCT TGA CGA GTT CTT 
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Figure 3.5: Schematic illustrates Ctnnb1 floxed allele and the primers binding site (applied from 
Brault et al. (Brault et al. 2001). 
3.5 Isolation of LacZ positive cell using Fluorescence-activated cell 
sorting (FACS)  
The Rosa26-LacZ/Ctnnb1fl/fl (R/C) mice are homozygous for the Ctnnb1 allele flanked by 
loxP sites, and possess the Rosa26 LacZ transgene regulated by a transcriptional stop signal 
flanked by loxP sites (figure 10). As described in the RTTA assay, the haematopoietic 
progenitors isolated from bone marrow of both R/C and wild type mice were co-transduced with 
viruses carrying LATFs and Hit and Run Cre or the inducible Cre ER viruses. When the Cre was 
expressed from either the transient Hit and Run Cre or the inducible Cre-ER (mediated by 
Tamoxifen (4-OHT) incubation), it would delete the Ctnnb1 gene and remove the transcriptional 
stop in the Rosa26 LacZ reporter. To isolate cells that transiently expressed Cre, LacZ 
expressing cells were sorted using the FDG (Fluorescein Digalactoside) as a fluorogenic 
substrate for β-galactosidase which is encoded by LacZ gene.  
Briefly, to prepare 20 mM stock FDG solution, a 1:1 mixture of 38 µl DMSO and 38 µl 
ethanol was prepared and added to dissolve 5 mg FDG powder (Molecular Probes, Invitrogen). 
Next, 304.4 µl of ice cold H2O was added to the solution to make 20 mM of 8:1:1 for 
H2O:DMSO:ethanol FDG stock solution.  They were stored as 20ul aliquots at -20 °C in dark. 
For cell staining, a 20 µl aliquot of 20 mM FDG was diluted with 180ul sterile 37° C H2O to make 
a 10x working FDG solution. Cells were counted and up to 1 X 106 cells and resuspended in 50 
µl of culture medium or SM. 50 µl of 10x working FDG solution was added into the cells 
suspension and immediately incubated for exactly 1 minute in 37° C wate rbath. Then 1 ml of 
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ice cold medium or SM was quickly added, and incubated on ice for 30-60 minutes. Cells were 
then centrifuged at 1300 g, 22°C for 5 minutes, supernatant was removed, and washed once 
again with ice cold SM. Cells were resuspended in 500 µl of SM medium containing a 1:1000 
dilution of 1 mg/ml propidium iodide and transferred into sterile FACS tube with lids and placed 
on ice until sorting. Fluorescein positive and negative cells were sorted using the BD FACSAria 
Special Order System, BD Biosciences (figure 3.6). Finally, sorted cells were counted and 
plated out in methylcellulose medium to continue the serial replating assay. 
 
Figure 3.6: FDG positive cells sorting after Cre mediated deletion of β-catenin. FACS shows 
GFP positive (P3 and P5 gates) and GFP negative cells (P4 and P6 gates) after FDG staining 
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3.6 Cre-ER mediated deletion of β-catenin in Rosa26-Cre/Rosa26-
YFP/Ctnnb1fl/fl and Rosa26-Cre/Rosa26-YFP/Hoxa9-/-/Ctnnb1fl/fl 
and the Isolation of YFP positive cell using Fluorescence-
activated cell sorting (FACS)  
Taking the advantage of the two new mouse lines, Rosa26-Cre/Rosa26-YFP/Ctnnb1fl/fl 
and Rosa26-Cre/Rosa26-YFP/Hoxa9-/-/Ctnnb1fl/fl with stably integrated ER-Cre and floxed YFP 
alleles in Rosa26 loci, I aimed to overcome the shortcomings associated with the R/C line and 
viral expression of Cre such as (1) Cre leakiness, (2) induction issue, and (3) cell death during 
FDG staining. Furthermore, another advantage of these new mouse line is the ability to reliably 
mediate β-catenin deletion after disease onset by tamoxifen administration in vivo. Different 
haematopoietic cell populations isolated from Rosa26-Cre/Rosa26-YFP/Ctnnb1fl/fl and Rosa26-
Cre/Rosa26-YFP/Hoxa9-/-/Ctnnb1fl/fl mice were transduced with different LATFs such as MLL-
AF9 and MLL-ENL and subjected for RTTA (as described in chapter 3.2.5). After the first round, 
transformed cells were serially replated into two different replating conditions; 1) second round 
without tamoxifen and 2) second round with 20nM tamoxifen.  At this round, Cre-ER mediated 
deletion of β-catenin was occurred in transformed cells with tamoxifen treatment as well as 
subsequently activated the expression of YFP signal. Thus, the number of YFP positive cells 
was represented to the amount of transformed cells with β-catenin deletion or vice versa. To 
purify the YFP positive/β-catenin deleted cell, I used the fluorescent cell activated sorting 
(FACS) technology. In brief, second round number of colony and colony morphologies were 
scored and recorded in both control and tamoxifen treatment cells. Colonies from both control 
and tamoxifen treated cells were harvested in 8 ml SM and transferred into a 15 ml conical base 
test tube using a 10 ml pipette. Cells were incubated in 37°C water bath for 1-2 hours to 
dissolve methylcellulose before they were centrifuged at 1300 g, 22 °C for 5 minutes.  Cells 
were washed once with 10 ml of SM by pipetting up and down several times and centrifuged at 
1300 g, 22 °C for 5 minutes. Cells were resuspended in 300 to 500 µl of 1:1000 PI (1mg/ml) in 
SM/PBS depending on initial numbers of colonies (e.g., 300 ml for less than 100 colonies, 500 
µl for more than 100 colonies).  YFP positive cells were sorted using the BD FACSAria Special 
Order System, BD Biosciences (figure 3.7). Finally, sorted cells were counted and plated out in 
methylcellulose medium to continue the serial replating assay. 
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Figure 3.7: YFP positive cells sorting after Cre mediated a deletion of β-catenin. FACS shows 
YFP positive (YFP+) and YFP negative cells (YFP-) after 2nd round of replating with 20 nM 
tamoxifen and those cells were subjected to sorting, assuming that YFP positive cells were β-
catenin deleted cells. 
3.7 Cell culture  
Primary transformed cells were cultured in R20/20 (RPMI1640, 20% FCS, 20% WEHI, 
100 U/ml penicillin, and 100 µg/ml streptomycin). WEHI, a conditioned medium (source of IL-3) 
was prepared by growing WEHI cells in R10 for three days. WEHI media was then harvested 
using 0.22 µm filter and frozen at -20° C until use. Medium was replaced or replenished when 
the colour changed to yellow before cultured cells grew too dense. Generated cell lines were 
then frozen in cryotubes by resuspending them in freezing medium (90% FCS and 10% DMSO) 
and stored in -80°C or in liquid nitrogen.   
3.8 Western blotting 
To confirm the β-catenin knockout, western blotting was performed according to Yeung et 
al. 2010 (Yeung et al. 2010).  1-2 × 106 cells/ml were washed with phosphate buffer saline 
(PBS) for three times. Then cells were lysed by adding 2X sample buffer at 1 × 106 cells/100 µl. 
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Lysate samples were sonicated to shear DNA and to reduce sample viscosity by the 
Diagenode, Bioruptor® at high pulse for 5 minutes. After sonication, samples were placed at 95 
to 100 °C for 5 minutes. 20 µl of each protein sample and 10 µl of protein ladder (PageRulerTM 
Plus Prestained Protein Ladder, Fermentas) were separated on 10% gradient SDS 
polyacrylamide gels (NEXT GELTM, Amresco) at 150 V for 80 minutes, then blotted onto a 
nitrocellulose membrane (AmershamTM HybondTM ECL) at 100 V for 1 hour. The transferred 
membrane was blocked with 2.5% milk dissolved in phosphate-buffered saline containing 0.1% 
Tween 20 (PBS-T) for 30 to 60 minutes at room temperature (RT). Then membrane was probed 
with a 1 in 2,000 dilution of mouse anti-β-catenin antibody (clone 14/Beta-Catenin, BD) for 1 
hour at RT or overnight at 4°C. After probing the membrane with the primary antibody, it was 
washed with PBS-T (5 minutes, 4 times) and incubated with secondary antibody, peroxidise-
conjugated goat anti-mouse IgG (heavy and light chains (Jackson ImmunoResearch 
Laboratory, INC.) or the goat polyclonal IgG β-actin antibody conjugated with HRP (Actin (I-19; 
SC-1616) HRP, Santa Cruz Biotechnology) for 1 hour at room temperature. Then the 
membrane was washed with PBS-T (5 minutes, 4 times). Chemiluminescent signal of 
conjugated antibodies were detected by using ECl Western Blotting Detection System, 
Amersham™, GE Healthcare, UK. according to a manufacturer’s instructions. Then signals 
were developed on X-Ray film (Amersham HyperfilmTM ECL) using the Photon imaging system. 
The expected size of β-catenin and β-actin (control protein) proteins are 92 kDa and 43 kDa, 
repectively. 
3.9 Immunophenotyping using FACS 
Cells were harvested after the third round of plating, 104-105 cells in a volume of 200ul 
were stained in FACS tubes with master mix of FACS antibodies including c-Kit (D7 clone), 
Mac-1 (M1/70 clone), Gr-1 (RB6-8C5 clone), B220 (RA3-6B2 clone), CD4 (RM4-5 clone), and 
CD8a (53-6.7 clone) in FACS tubes (1ul of each antibody per sample, mixed well keep in dark 
before use). One unstained control tube contained only 200 µl of 104-105 cells in PBS/medium 
without any antibody. Sample tubes were incubated at 4°C in the dark for 10-30 minutes. After 
incubation, samples were then washed twice with 4 ml PBS/SM by centrifugation at 1,300 g, 22° 
C for 5 minutes. They were then resuspended in 400 µl of SM with 1 µg/ml propidium iodine. 
Finally, the expression of cell surface markers was analyzed using a LSRII flow cytometer (BD 
Bioscience).  
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3.10 Cell cycle analysis using propidium iodide 
Cells were harvested after the third round of plating, 106 were washed twice with cold 
PBS and resuspened in 300 µl of cold PBS in FACS tubes. Cells were fixed by adding 900 µl of 
cold absolute ethanol by dropwise while vortexing. Fixed cells were incubated in fridge for at 
least 1 hour. Cells were washed twice with cold PBS and resuspended in 300 µl of propidium 
iodide staining solution (3.8 mM sodium citrate, 40 ug/ml PI (Sigma, P 4170) in PBS) and 
subsequently added 15 µl of RNase A stock solution (10µg/ml) and incubated in fridge for 3 
hours. Finally, the cell cycle profile was analyzed using a LSRII flow cytometer (BD Bioscience). 
3.11 Transplantation (in vivo leukaemogenic assay) 
Transplantation experiment was performed according to our previous reports (Yeung et 
al. 2010, Smith et al. 2011).  Briefly, five to ten mice per condition were sub-lethally irradiated 
with 1,100 rad in split doses. I transplanted a mixture of 105-106 of pre-LSCs for primary and 
102-105 LSCs for secondary transplantation together with 2 x 105 rescue total bone marrow cells 
isolated from bone marrow of a mouse with carrying the same CD45 (CD45.1 or CD45.2) 
marker was prepared in 150ul PBS for transplantation. At least 1 hour after the 2nd irradiation, 
recipient mice were placed one by one into a cylindrical mouse restrainer for tail vein injection. 
Finally, transplanted mice were returned into their cage.   
When the transplanted mouse showed signs of sickness (e.g. loss of condition and/or 
paralyze legs), mouse was then sacrificed and organs including spleen, liver and bone marrows 
were taken for analysis. FACS analysis for CD45 markers could be used to distinguish donor 
from recipient cells. Moreover, using a panel of antibodies as described in 3.8 allows 
determining the immunophenotype of leukemic cells and comparisons with the 
immunophenotype of the original transplanted cells. Note that leukemic mice usually display 
enlarged spleen and pale/white bone marrow, and leukaemic cells commonly infiltrate to other 
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3.12 RNA sequencing 
To analyse the transcriptional changes and targets critical for β-catenin and/or Hoxa9 
functions, high throughput RNA sequencing was performed on different RNA samples extracted 
from different MLL-ENL transformed cells.  Briefly, RNA from 1-5 x 106 different pre-LSCs or 2 x 
104 to 2 x 105 normal haematopoietic stem/progenitor cells were extracted using mirVana™ 
miRNA Isolation Kit, Life Technologies, according to a manufacture’s instruction.  Quality and 
amount of extracted RNA was determined using the Agilent 2100 bioanalyzer (Agilent 
Technologies, Clara, California). 0.1-1 µg of total RNA depleted of rRNA, were fragmented to 
generate cDNA library with appropriated RNA index (adaptor), and enriched cDNA fragments 
using TruSeq Stranded Total RNA LT Sample Prep Kit, Illumina® according to according to a 
manufacture’s instruction. cDNA fragments were clustered, sequenced, and analysis using  
using HiSeq™ 2000 Sequencing System, Illumina® at the  Department of Haematological 
Medicine, King's College London.  
RNA sequencing data was analysed by Mr. Sam Tung Hoi, PhD student who is 
specialised in bioinformatics. In brief, Sequenced reads were aligned to mouse genome (mm9) 
using TopHat version 2.0.9 (Kim D 2013).  Differential expression analysis was performed using 
DESeq2, Bioconductor DESeq2 v1.2.10 software (Love MI 2014) and Limma, Limma v.3.18.13  
software (GK 2005). Gene Set Enrichment Analysis (GSEA) was performed using Pre-ranked 
tool version 2.0.13 with 10,000 permutations. A full list of genes with the logarithmic fold change 
from DESeq2 or Limma was input into GSEA as gene ranking metric. A normalized enrichment 
score (NES) for each gene set was calculated by Kolmogorov-Smirnov-like statistic and the 
significance level of NES was computed to yield an estimated false discovery rate (FDR) 
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3.13 Quantitative Reverse Transcriptase Polymerase Chain Reaction 
(qRT-PCR) 
Total RNA from purified HSC, CMP, and GMP and different pre-LSCs were extracted 
using mirVana™ miRNA Isolation Kit, Life Technologies or NucleoSpin RNA Isolation Kit, 
Macherey-Nagel (MN) according to a manufacturer’s instructions. Total RNA concentration was 
measured by using NanoDrop 8000 instrument, Thermo Fisher Scientific. cDNA was 
synthesised by using SuperScript III (Invitrgen) followed by PCR using Veriti® Thermal Cycler, 
Applied Biosystems®. In brief, 10 µl master mix of 1-5 µg RNA, 1 µl of 50 µM oligo (dT)20, and 1 
µl of 10 mM dNTP was incubated at 65° C for 5 minutes then place on ice for at least 1 minute. 
cDNA synthesis master mix was prepared by adding 4 µl of 10X RT buffer, 2 µl of 50 mM 
MgCl2, 2 µl of 0.1 M DTT, 1 µl of RNaseOUT™ (40 U/µl), and 1 µl of SuperScript® III RT (200 
U/µl). 10 µl of cDNA synthesis master mix was added to each RNA/primer mix, gently mix, and 
briefly spun down. cDNA synthesis condition was following 50 °C for 50 minutes, 85 °C for 5 
minutes, and hold at 4 °C. Real time PCR was performed to quantify the expression level of 
interested genes (table 3.2 and table 3.3) using Fast SYBR® Green Master Mix or TaqMan® 
Fast Universal Master Mix on the StepOnePlus™ Real-Time PCR System, Applied 
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Table 3.2: Primers pairs for qRT-PCR using SYBR green detection reagents 
Target genes Sequences 
Mouse Ctnnb1 5-ATGGAGCCGGACAGAAAAGC-3’ 
5’-CTTGCCACTCAGGGAAGGA-3’ 
Mouse Mpl 5’- TCACCTTGGTGACTGCTCTG -3’ 
5’- CCACAAAGCATGCCTCAGTC -3’ 
Mouse Cebpα 5’-GCA AAG CCA AGA AGT CGG TG-3’ 
5’-CAC CTT CTG TTG CGT CTC CA-3’ 
Mouse Gata1 5’- CTC TCA TCC GGC CCA AGA AG -3’ 
5’- AGC TTG AAA TAG AGG CCG CA -3’ 
Mouse Mmp8 5’- CTTTCAACCAGGCCAAGGTA-3’ 
5’- GAGCAGCCACGAGAAATAGG-3’ 
Mouse Mmp9 5’-TGTCATCCAGTTTGGTGTCG-3’ 
5’-AATGGGCATCTCCCTGAAC-3’ 
Mouse Ruvbl2 5’-TCCGAGAAGGGAAGATTGC-3’ 
5’-TGGCTGTGAATGGTGTGTC-3’ 
Mouse Prmt1 5’-ACCCTCACATACCGCAACTC-3’ 
5’-CAGCAAACATGCAGAGGATG-3’ 
Mouse Ruvbl1 5’-AGACAGAGGTGCTGATGGAGA-3’ 
5’-GGGGTTCTCTGTCTCACAGG-3’ 
Mouse Nolc1 5’-CAAAGCTTCAGAGAGCAGCA-3’ 
5’-GTCTGACTGCCTTGGCTTG-3’ 
Mouse C1qbp 5’-TCCCAAGATGTCTGGAGATTG-3’ 
5’- GTTGGAGGGATGCTGTTGTT-3’ 
Mouse Tgfbr3 5’-TCCCAGAAGCTGCCAAAGTGT-3’ 
5’-GACTCCTTCATGTTTGGAACA-3’ 
Mouse Irf4 5’-CTACCCCATGACAGCACCTT-3’ 
5’-TGACTGGTCAGGGGCATAAT-3’ 
Mouse Tgm2 5’-GATGACCAGGCCAGACCTAC-3’ 
5’-CGAAGGGTGCATCATACTTG-3’ 
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Table 3.3: Primers pairs for qRT-PCR using TaqMan® detection reagents (Dickson GJ 2009).  
Target genes Primers and probes sequences 
Mouse Hoxa5 5’-TCCCATCGCTTCCCTACCT-3’ 
5’-GCTTTGGAACAGCCTACAGCTT-3’ 
FAM-ACCCATTGCAAAGTTCAGGGCATAAGGT-TAMRA 
Mouse Hoxa7 5’-AGCTTGGAAATTCTGCTCACTTCT-3’ 
5’-TCTGATGTCATGGCCAAATTTG-3’ 
FAM-ACCCATTGCAAAGTTCAGGGCAT AAGGT-TAMRA 
Mouse Hoxa9 5’-GCCGGCCTTATGGCATTAA-3’ 
5’-CAGGGACAAAGTGTGAGTGTCAA-3’ 
FAM-TGAACCGCTGTCGGCCAGAAGG-TAMRA 




Mouse Hoxb4 5’-CCCTGGATGCGCAAAGTT-3’ 
5’-AATTCCTTCTCCAGCTCCAAGA-3’ 
FAM-AAGCGCTCTCGGACCGCCTACAC-TAMRA 
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3.14 Prmt1 Knockdown 
shRNAs constructs including GFP-tagged PRMT1 shRNA  and GFP-tagged vector 
control were previously published by our group (Cheung et al., 2007) and obtained from the 
clone database of the Leukemia and Stem Cell Biology group, Haemato-Oncology, King’s 
College London. Plasmids and viruses were prepared as described in section 3.2.1. 1-2 x 106 
LSC cells were resuspended in 3 ml of fresh R20/20 and transferred into each individual well of 
6 wells culture plate (control and test wells). 1 ml of concentrated viruses including GFP-tagged 
PRMT1 shRNA  and GFP-tagged vector control and 3 µl polybrene (10mg/ml) were added into 
each well with appropriate labelled,  mixed by pipette up and down several time. Spinoculation 
was carried out by centrifugation at 800g, 32° C for 2 hours. After spinoculation, cells were top 
up with 4 ml of R20/20 and placed back into the incubator. The day after, transduced cells were, 
determined the number of GFP positive cells, and sorted GFP positive cells by FACS. 
Transduced cells were expanded in R20/20, extracted RNA to measure the expression of Prmt1 
by qRT-PCR, and studied the impact of Prmt1 knockdown in different LSCs in both in vitro 
colony forming assay and in recipient mouse.  
3.15 Statistical analysis 
In this study, number of colonies during each transformation assays were manually 
counted under microscope following with the calculation of mean and standard deviation using 
Microsoft excel (2007). In real time quantitative RT-PCR (RQ-PCR) assays, Ct (cycle threshold) 
values of each sample was normalised with GAPDH control gene and calculated to relative 
gene expression using Microsoft excel (2007). The log-rank test and Gehan-Breslow-Wilcoxon 
test were used to compare survival curves. LDA plots were performed by using the limdil 
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Chapter 4 Results 
4.1 The role of β-catenin in transformation of haematopoietic 
stem/progenitor (c-kit+) cells by various LATFs 
During the generation of a conditionally inducible Rosa26-Cre/Rosa26-YFP/Ctnnb1fl/fl 
mouse, I used the Rosa26-LacZ/Ctnnb1fl/fl (R/C) mouse to investigate the role of β-catenin in 
the development of AML LSCs transformed by different LATFs such as MLL-ENL, MLL-AF9, 
E2A-PBX1, and MN1. The preliminary data of my initial experiments using c-Kit+ cells isolated 
from bone marrow of R/C mouse are described below. 
4.1.1 Establishment of c-Kit+ E2A-PBX1 LSCs is independent of β-catenin  
After optimising the experimental conditions such as the amount of CreER virus and the 
concentration of tamoxifen, I was able to achieve a complete deletion of Ctnnb1 using 10nM 
tamoxifen in the second round of replating of c-kit+ cells from R/C mice co-transduced with Cre-
ER and E2A-PBX1 (Figure 4.1) as confirmed by PCR and Western blot (Figure 4.1B and 4.1C). 
Interestingly, E2A-PBX1 expressing cells with a complete β-catenin deletion showed similar 
number of colonies (figure 4.1A), colony morphology (figure 4.1A), and immunophenotype 
(figure 4.1D) when compared with E2A-PBX1 transformed wild type cells, suggesting that β-
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Figure 4.1 Establishment of pre-LSCs by E2A-PBX1 is independent of β-catenin. A)  Relative 
colony numbers (top) and colony morphologies (bottom) of c-Kit+ cells transformed by E2A-
PBX1 during replating assay. B) and (C) PCR genotyping of Ctnnb1 status and Western blot 
using antibodies specific for β-catenin and β-actin on E2A-PBX1 pre-LSCs from the indicated 
genotypes. D) Immunophenotypic analysis using flow cytometry of wild type (top), Ctnnb1fl/fl 
(middle) and Ctnnb1del/del (bottom) E2A-PBX1 pre-LSCs. 
To further investigate whether β-catenin is required for E2A-PBX1 LSC development in 
vivo, E2A-PBX1 pre-LSCs derived from Ctnnb1fl/fl and Ctnnb1del/del genetic backgrounds were 
transplanted into syngeneic C57BL6 mice for disease development. 2 of 5 (40%) mice that 
received either Ctnnb1fl/fl or Ctnnb1del/del E2A-PBX1 pre-LSCs developed leukaemia with very 
similar latencies (p = 0.8985) (Figure 4.2). PCR genotyping of Ctnnb1 status of leukemic cells 
confirmed the presence of the floxed or the deleted Ctnnb1 alleles accordingly (Figure 4.3A and 
4.3B). The results strongly suggest that β-catenin is not required for the development of E2A-
PBX1 LSC derived from c-Kit+ cells. 
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Figure 4.2: Establishment of E2A-PBX1 is β-catenin independent. Survival curves of mice 
transplanted with Ctnnb1fl/fl and Ctnnb1del/del E2A-PBX1 pre-LSC (n=5 for each group). 
 
Figure 4.3: PCR genotyping of Ctnnb1 status on genomic DNA isolated from mouse 
transplanted with E2A-PBX1 pre-LSC. (A) 147-2 and (B) 147-8 which were transplanted with 
Ctnnb1del/del and Ctnnb1fl/fl, E2A-PBX1 pre-LSCs, respectively.  
After I initiated my studies using R/C line, this model suffered from a number of 
shortcomings associated with viral expression of Cre such as (1) Cre leakiness/toxicity due to 
the level/copy of Cre expression, (2) induction issue, and (3) cell death during FDG staining.  
Thus after my successful generation of the new mouse line Rosa26-Cre/Rosa26-YFP/Ctnnb1fl/fl, 
which can be reliably mediate β-catenin deletion even after disease onset by tamoxifen 
administration in vivo, I switched all my experiments using this much improved model. The 
obtained results using c-Kit+ cells isolated from bone marrow of this new mouse line  to 
investigate the role of β-catenin in the development of AML LSCs transformed by MN1 and 
MLL-ENL are described below. 
 
p = 0.8985 
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4.1.2 c-Kit+ MN1 LSCs is β-catenin independent 
To test the feasibility of using Rosa26-Cre/Rosa26-YFP/Ctnnb1fl/fl mouse, I investigated 
the functional requirement of β-catenin in mouse AML initiated by MN1 oncogene which is 
commonly overexpressed in AML. In in vitro transformation assay, knockout of β-catenin in c-
Kit+ MN1 pre-LSCs did not affect the cloning efficiency and colony morphology when compared 
to the c-Kit+ MN1 pre-LSCs with Ctnnb1fl/fl (figure 4.4).  
  
 
Figure 4.4: Establishment of c-Kit+ MN1 pre-LSC is independent of β-catenin. A) Absolute 
colonies number (top) and colony morphologies (bottom) of c-Kit+ cells transformed by MN1 
during replating assay. B) Genotyping of Ctnnb1 on gDNA extracted from c-Kit+ MN1 
transformed cells after CRE-ER mediated deletion of Ctnnb1 gene with 20nM tamoxifen 
treatment and YFP sorting. C) Western blot shows a complete deletion of β-catenin in c-Kit+ 
MN1 transformed cells.  
To investigate the role of β-catenin in the development of MN1 LSCs in vivo, these pre-
LSCs were transplanted into syngeneic recipient mice (n=5 for each group). All mice (100%) 
that received c-Kit+ MN1 pre-LSCs with Ctnnb1fl/fl (n=7) or Ctnnb1del/del (n=8) developed 
leukaemia with very short latency (p = 0.0401) (median survival = 36.7 and 48.2 days, 
respectively). Similar to primary transplantation, secondary recipient mice that were 
transplanted with either MN1 with Ctnnb1fl/fl or MN1 with Ctnnb1del/del LSCs rapidly showed signs 
of leukaemia with median survival of 13 and 19.4 days, respectively (figure 4.5). Together the 







































Figure 4.5: β-catenin is not required for the initiation of c-Kit+ MN1 LSC. A) Survival curve of 
mice transplanted with c-Kit+ MN1 pre-LSCs with Ctnnb1fl/fl (n = 7), c-Kit+ MN1 pre-LSCs with 
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p = 0.0401 
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4.1.3 β-catenin is critical for the development of c-Kit+ MLL-ENL LSCs 
To functionally validate the new mouse line, I sought to confirm published data from our 
group using R/C line with MLL-ENL (Yeung et al. 2010). Purified c-Kit+ cells from bone marrow 
of Rosa26-Cre/Rosa26-YFP/Ctnnb1fl/fl mouse were transduced with pMSCV-MLL-ENL-
puromycin virus and subjected to RTTA. Although β-catenin was conditionally deleted at the 
early phase of the initiation of MLL-ENL pre-LSC by  adding  20 nM tamoxifen during the 
second round of plating, MLL-ENL transformed c-kit+ cells in the absence of β-catenin exhibited 
similar cloning efficacies and colony morphologies as compared with pre-LSC MLL-ENL with 
Ctnnb1fl/fl cells (figure 4.6).  
 
    








Figure 4.6: In vitro transformation of c-Kit+ MLL-ENL pre-LSC is independent of β-catenin. A) 
Absolute colony numbers (top) and colony morphologies (bottom) of c-Kit+ cells transformed by 
MLL-ENL during replating assay. B) Genotyping of Ctnnb1 on gDNA extracted from c-Kit+ MLL-
ENL transformed cells after deletion of the Ctnnb1 gene with 20 nM tamoxifen and YFP sorting. 
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For in vivo studies, I serially transplanted these pre-LSC cells into sub-lethally irradiated 
syngeneic mice. Mice that received c-Kit+ MLL-ENL pre-LSCs with Ctnnb1fl/fl cells developed 
leukaemia in primary and secondary transplanted mice (median survival = 85.5 and 21.6 days, 
respectively) (figure 4.7). In contrast, c-kit+ MLL-ENL pre-LSC with the complete deletion of β-
catenin could not induce leukaemia (p < 0.001) and could not be detected in recipient mice 
when mice were sacrificed 150 days after transplantation.  





Figure 4.7: Knockout of β-catenin abolishes oncogenic property of c-Kit+ MLL-ENL pre-LSC. A) 
Survival curve of mice transplanted with c-Kit+ MLL-ENL pre-LSCs with Ctnnb1fl/fl or Ctnnb1del/del 
(n=10 for each group) and LSC c-Kit+ MLL-ENL with Ctnnb1fl/fl (n=5). B) Genotyping of Ctnnb1 
on gDNA extracted from bone marrow, spleen, and liver of leukaemic mouse that received pre-
LSC c-Kit+ MLL-ENL.  
Collectively, these results not only confirmed our previously published data obtained 
with a different mouse model for an important role of β-catenin in the development of full-blown 
MLL-ENL LSC derived from haematopoietic stem/progenitor enriched, c-Kit+ cells, but also 





























p < 0.0001 
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4.2 HSC/progenitors purification and their gene expression profiles 
In contrast to c-kit+ cells, which are a mixed population of stem and progenitor cells, 
defined haematopoietic populations can be isolated from mouse bone marrow that have been 
functionally and phenotypically described (Yeung and So 2009).  To this end, bone marrow cells 
from wild type (SJL) and Rosa26-Cre/Rosa26-YFP/Ctnnb1fl/fl mice (n = 5 for each group) were 
sorted (by fluorescent activated cell sorting (FACS) technology) based on their surface marker 
(CD protein) expression. .  While  Lin- c-Kit+ Sca-1+ CD34+, LSK cells were  enriched for HSCs 
with self-renewal property,  non-self-renewing CMP and GMP were Lin- c-Kit+ Sca-1- CD34+ 
CD16/32low/- and Lin- c-Kit+ Sca-1- CD34+ CD16/32high/+, respectively. From the pooled total bone 
marrow cell of 5 mice, I could purify approximately 2 to 3 million lineage negative cells (lineage 
depleted cells; Ter119-, Mac1-, Gr1-, CD3-, CD4-, CD8-, and B220-), which contained an average 
between 70,000 to 90,000 LSK, 200,000 to 300,000 CMP, 400,000 to 600,000 GMP, and 
90,000 to 100,000 MEP cells. In addition to post-sort analysis, which revealed around 90 % 
purity for the individually sorted populations, I also functionally determined the purity of 
HSC/progenitors sorting. To this end, I performed colony forming cells assay (CFS) to classify 
and enumerate the different colony types resulted from LSK, CMP, GMP and MEP to by plating 
1,000 cells of each purified population into methylcellulose medium supplemented with mouse 
cytokines including SCF, IL3, IL6, GM-CSF, and Erythropoietin followed.  After incubation at 37° 
C, 5% CO2 for 5 to 7 days, LSK cells mainly gave rise to Colony-forming unit-granulocyte 
macrophage (CFU-GM, 95.8%) and also in low frequency to Colony-forming unit-granulocyte, 
erythroid, macrophage, megakaryocyte (CFU-GEMM, 1.4%), Colony-forming unit- macrophage 
(CFU-M, 2.4%) and Colony-forming unit-granulocyte (CFU-G, 2.4%) but not to Burst-forming 
unit-erythroid (BFU-E). CMPs gave rise to predominantly CFU-GM (74.8%), CFU-GEMM 
(19.9%), CFU-M (3.9%), CFU-G (1.4%), but not to BFU-E. GMPs, as more mature progenitors 
gave mainly rise to CFU-GM (37.8%), CFU-G (34.4%) and CFU-M (25.6%) and in much lower 
frequency to CFU-GEMM (2.2%) but not to BFU-E. In contrast, MEPs predominantly gave rise 
to BFU-E (75.0%) followed by CFU-G, CFU-M, and CFU-GEMM 8.3% each) but not to CFU-GM 
(figure 4.8). Although in this work I used different mouse strains and slightly different culture 
conditions including methylcellulose and supplemented mouse cytokines from previous reports 
(Akashi 2000, Lieu 2012), similar distributions (in percentage) of classified colony forming unit 
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arisen from each sorted LSK, CMP, and GMP were observed. Thus, I could confirm the 









Figure 4.8: Colony forming cells assay (CFC) of purified HSC (Scheller et al.), CMP, GMP, and 
MEP. Distribution (top) and morphology (bottom) of the different colony forming units (CFUs) (in 
%) outgrown of sorted HSC (Scheller et al.) and progenitors plated into methylcellulose 
medium. Data were obtained from two independent experiments. 
To molecularly confirm the purity of sorted cells and to study the gene expression 
signatures of HSC/progenitors, RNA from around 70,000-100,000 cells per purified populations 
was isolated and subjected to qRT-PCR (quantitative-reverse transcription-polymerase chain 
reaction). Well defined, population specific markers differently expressed in normal HSC and 
progenitors were used to assess the purity of isolated cells.  I was able to detect appropriate 
expression of various markers including Mpl (highly expressed in HSCs, then decreases 
through haematopoietic differentiation) (JC 2011), Cebpα (Highly expressed in GMP, low levels 
in HSC) (Zhang P 2004), and Gata1 (highly expressed in MEP, low levels in CMP) (Gutiérrez L 
2008) . As a result, I also molecularly confirmed the purity of sorted cells based on the different 









































Figure 4.9: Different expression of Mpl, Cebpα, and Gata1 in LSK, CMP, GMP, and MEP 
isolated from wild type mouse. 
To further study the gene expression profiling of HSC/progenitor cells, I next focused on  
expression levels of genes that are critical for self-renewal pathways in both normal 
haematopoietic stem cells as well as leukaemia stem cells including Ctnnb1 (β-catenin), Hoxa9, 
Meis1, Hoxa5, Hoxa7, Hoxa10, Hoxa11, and Hoxb4. I could demonstrate that these genes were 
highly expressed in LSK (HSC-enriched) cells which can self-renew, whereas their expression 
levels progressively decrease during haematopoietic differentiation (figure 4.10). To get high 
resolution global gene expression profiles and to establish novel data sets of gene expression 
signatures in normal mouse HSC/progenitors, RNA from sorted haematopoietic populations 
have been being subjected to high throughput RNA sequencing although the data will not be 
included in this thesis. Together I demonstrated high purity of sorted HSC/progenitor cells on 
several levels including functional (by using colony forming cells assays) and molecular 
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demonstrated high mRNA expression levels of critical self-renewal genes such as β-catenin, 








































































































































































Figure 4.10: Different gene expressions in LSK, CMP, and GMP isolated from bone marrow of 
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4.3 The impact of β-catenin in generating and maintaining LSCs 
from different haematopoietic cell populations 
To define the impact of cellular origins in utilization of self-renewal pathways in LSCs, I 
investigated the functional requirement of β-catenin in different cellular origins transformed by 
various LATFs. To this end, I have purified HSC-enriched Lin-Sca+Kit+ (Scheller et al.), common 
myeloid progenitors (CMPs) and granulocyte-macrophage progenitors (GMPs) for standard 
RTTA.  In my initial experiments using the Rosa26-LacZ/Ctnnb1fl/fl (R/C) mouse, both Hit-and-
run Cre and MEIS1-HOXA9 were co-transduced into different sorted populations isolated from 
wild type and R/C mice for RTTA. After the second round of plating, cells were stained with FDG 
(based on LacZ activity) to assist the isolation of Ctnnb1 (β-catenin) successfully deleted cells 
for continuation of RTTA as described in the previous section.   In addition, I also used purified 
HSC, CMP, and GMP cells isolated from the new mouse line, Rosa26-Cre/Rosa26-
YFP/Ctnnb1fl/fl, to assess the different functional β-catenin requirement of in different cell of 
origins transformed by MN1 and MLL-ENL. I will describe the results for each individual LATFs 
tested starting with MEIS1-HOXA9 using the R/C line.  
4.3.1 LSK but not CMP required β-catenin for the development of LSC transformed by 
Meis1-Hoxa9 
To assess the ability of Meis1-Hoxa9 to transform LSK, CMP and GMP populations 
from both wild type and Ctnnb1fl/fl, I carried out RTTA experiments in which Meis1-Hoxa9 was 
transduced into the different sorted cell populations. As shown in Figure 4.11, Meis1-Hoxa9 
competently transformed all populations from both genotypes, which resulted in similar number 
of colonies and colony morphology.   
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Figure 4.11: Establishment of LSK-, CMP-, and GMP-Meis1-Hoxa9 pre-LSC. Bar chart (top) 
show the absolute number of colonies in each round of plating in Meis-Hoxa9pre-LSCs 
originated from the indicated cell populations. Typical 3rd round colony morphology are shown 
(bottom).   
Next I tested the requirement of β-catenin Meis-Hoxa9 mediated transformation by co-
transducing hit-and-run Cre and Meis-Hoxa9 into different cell populations. FDG positive cells 
were isolated by FACS after the second round of plating, and sorted cells were again subjected 
to RTTA. As a result, Ctnnb1del/del Meis-Hoxa9 expressing LSKs (Figure 4.12C, D) formed 
smaller, more diffused and fewer numbers of colonies than their Ctnnb1fl/fl counterparts in all 
rounds of plating (Figure 4.12A, B). In contrast, CMPs transformed by Meis-Hoxa9 did not show 
any significant difference in terms of colony number and morphology in RTTA (Figure 4.13A, B) 
regardless of β-catenin status (Figure 4.13C, D), suggesting a distinctive functional requirement 
for β-catenin in different cell populations. Thus β-catenin may be critical for establishment of 





































Figure 4.12: Knockout of β-catenin suppresses leukaemogenic potential of LSK-Meis1-Hoxa9 
pre-LSC. A) Absolute colonies number and colony morphologies of LSK cells transformed by 
Meis1-Hoxa9 during replating assay. B) Genotyping of Ctnnb1 on gDNA extracted from LSK-
Meis1-Hoxa9 transformed cells after CRE-ER mediated deletion of Ctnnb1 gene by 20 nM 
tamoxifen treatment and YFP sorting. C) Western blot shows a complete deletion of β-catenin in 









































Figure 4.13: Establishment of CMP-Meis1-Hoxa9 pre-LSC is β-catenin independent. A) 
Absolute colonies number and colony morphologies of CMP cells transformed by Meis1-Hoxa9 
during replating assay. B) Genotyping of Ctnnb1 on gDNA extracted from CMP-Meis1-Hoxa9 
transformed cells after Cre-ER mediated deletion of Ctnnb1 gene by 20nM tamoxifen treatment 
and YFP sorting. C) Western blot shows a complete deletion of β-catenin in CMP-Meis1-Hoxa9 
transformed cells. 
To further investigate whether β-catenin is required for development of Meis1-Hoxa9 
LSCs in vivo,  LSK and CMP pre-LSCs from wild type, Ctnnb1fl/fl and Ctnnb1del/del  were 
transplanted to primary recipient mice (n=5 for each group) for disease development.  While all 
of the mice transplanted with LSK-Meis1-Hoxa9 pre-LSCs from wild type background (n=5) and 
4 of 5 (80%) mice received Ctnnb1fl/fl LSK-Meis1-Hoxa9 pre-LSCs developed leukaemia, mice 
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(Figure 4.14A). Consistently, PCR genotyping of leukaemic cells confirmed their β-catenin 
status (Figure 4.14B).  In contrast, mice transplanted with both Ctnnb1fl/fl (3 of 5; 60%) and 
Ctnnb1del/del (2 of 5; 40%) CMP- Meis-Hoxa9 pre-LSCs developed leukaemia (p = 0.5737) 
(Figure 4.14C), suggesting that β-catenin is differentially required in the establishment of LSCs 
from different cellular origins. PCR genotyping of Ctnnb1 status of leukemic cells showed the 
presence of the floxed or the deleted Ctnnb1 alleles accordingly (Figure 4.4D and 4.14E). 
Together, these results complement my in vitro observations and demonstrate that β-catenin is 











Figure 4.14: LSK but not CMP require β-catenin for the development of Meis1-Hoxa9 LSC. A) 
and (C) Survival curve of mice transplanted with pre-LSC LSK- and CMP-Meis1-Hxa9 with 
Ctnnb1fl/fl and Ctnnb1del/del (n = 5 for each group). Genotyping of Ctnnb1 on gDNA extracted from 
cells of the indicated tissue from leukaemic mice transplanted with pre-LSC LSK-Meis1-Hoxa9 
with Ctnnb1fl/fl (B), pre-LSC CMP-Meis1-Hoxa9 with Ctnnb1fl/fl (D) and Ctnnb11del/del (E). 
























































p = 0.0133 
p = 0.5737 
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4.3.2 MN1 LSCs originate only from CMPs and do not require β-catenin 
To further investigate the potential origins of other LSCs and their β-catenin 
dependencies, I next tested the MN1 oncogene which is frequently over-expressed in AML. 
Sorted HSC, CMP, and GMP cells from bone marrow of Rosa26-Cre/Rosa26-YFP/Ctnnb1fl/fl 
mice were transduced with MN1 retrovirus and subjected to RTTA assay. Genetic deletion of β-
catenin was achieved at the early phase of the development of MN1 pre-LSC by adding 20nM 
tamoxifen in the 2nd round of plating followed by FACS sorting of YFP positive cells. As shown 
in figure 4.15, knockout of β-catenin did not affect the cloning efficacy and colony morphology of 
LSK- and CMP-MN1 pre-LSCs in re-plating assay. However, more differentiated GMP 
progenitor could not be transformed by MN1 oncogene in vitro. Collectively, the results 
indicated that establishment of LSK- and CMP-MN1 pre-LSCs is β-catenin independent, and 









Figure 4.15: GMP not able to transform by MN1 and establishment of LSK- and CMP-MN1 pre-
LSC is β-catenin independent. A) Absolute colony numbers (top) and colony morphologies 
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Genotyping of Ctnnb1 on gDNA extracted from LSK-MN1 and CMP-MN1 transformed cells after 
CRE-ER mediated deletion of Ctnnb1 gene by 20nM tamoxifen treatment and YFP sorting. D) 
Western blot shows a complete deletion of β-catenin in LSK-MN1 and CMP-MN1 transformed 
cells. 
 To further investigate the origin of MN1 LSCs and their β-catenin dependency in vivo,  
LSK-MN1 pre-LSCs with Ctnnb1fl/fl CMP-MN1 pre-LSCs with Ctnnb1fl/fl or with a complete 
deletion of β-catenin were transplanted into recipient mice (n = 5 for each group). Interestingly, 
mice which received LSK-MN1 pre-LSCs with Ctnnb1fl/fl had no sign of leukaemia (cut off = 80 
days), suggesting that LSK may not be the origin of MN1 LSCs. In contrast, mice that were 
injected with CMP-MN1 pre-LSCs with Ctnnb1fl/fl and Ctnnb1del/del developed leukaemia with 
short latency and a median survival of 43 days and 36 days, respectively (figure 4.16). In 
addition, secondary transplanted mice with LSCs CMP-MN1 with Ctnnb1fl/fl and Ctnnb1del/del 
developed leukaemia with very short latency (median survival = 14 days for both groups). 
Together, the results indicated that CMP is the only cell of origin of MN1 leukaemia among all 




Figure 4.16: CMP-MN1 is β-catenin independent LSC. A) Survival curve of mice transplanted 
with pre-LSCs LSK-MN1 with Ctnnb1fl/fl, CMP-MN1 with Ctnnb1fl/fl or Ctnnb1del/del (n=5 for each 
group), and LSC CMP-MN1 with Ctnnb1fl/fl and Ctnnb1del/del (n=5 for each group). B) Genotyping 
of Ctnnb1 on gDNA extracted from bone marrow of leukaemic mice that received pre-LSC 
CMP-MN1 with Ctnnb1fl/fl (357-1 and 357-2) and Ctnnb1del/del (362-1 and 362-2). 
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4.3.3 GMP but not LSK and CMP required β-catenin for the initiation of MLL-ENL LSCs  
Genetic deletion of β-catenin has been previous shown by our group to result in 
eradication of the in vivo oncogenic potential of haematopoietic stem/progenitor cell derived c-
Kit+ MLL-ENL pre-LSC (Yeung et al. 2010). To extend this finding, I further investigated 
whether β-catenin is critical for the development of MLL-ENL LSCs originated from different 
functionally distinct haematopoietic populations (HSC, CMP, and GMP). HSC, CMP, and GMP 
cells of Rosa26-Cre/Rosa26-YFP/Ctnnb1fl/fl mice were transduced with retrovirus carrying MLL-
ENL (pMSCV-MLL-ENL-puromycin) and subjected to RTTA during which tamoxifen-mediated β-
catenin deletion was carried out in the early stage of pre-LSC development.  MLL-ENL 
transformed LSK, CMP, and GMP regardless of β-catenin status with no apparent difference in 














































Figure 4.17: β-catenin is not required for the establishment of LSK-, CMP-, and GMP-MLL-ENL 
pre-LSC. A) Absolute colony numbers (top) and colony morphologies (bottom) of LSK, CMP, 
and GMP cells transformed by MLL-ENL during replating assay. B) Genotyping of Ctnnb1 on 
gDNA extracted from LSK-, CMP- and GMP-MLL-ENL transformed cells after CRE-ER 
mediated deletion of Ctnnb1 gene by 20nM tamoxifen treatment and YFP sorting. C) Western 
blot shows a complete deletion of β-catenin in LSK-MLL-ENL and CMP-MLL-ENL transformed 
cells. D) Typical cell morphologies of LSK, CMP, and GMP cells transformed by MLL-ENL after 
3rd round of replating. E) Immunophenotypic analysis using flow cytometry of pre-LSC LSK-
MLL-ENL with Ctnnb1fl/fl (top) and Ctnnb1del/del (bottom).  F) Immunophenotype of pre-LSC 
GMP-MLL-ENL with Ctnnb1fl/fl (top) and Ctnnb1del/del (bottom).  
Interestingly, knockout of β-catenin resulted in a slight reduction of dividing cells (G2/M) 
in pre-LSC GMP-MLL-ENL, whereas largely undisturbed G0/G1, S, and G2/M phases were 
observed in pre-LSC LSK-MLL-ENL with Ctnnb1fl/fl and complete deletion of β-catenin, 
suggesting that conditional deletion of β-catenin may only have minor impact on the cell cycle in 
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Figure 4.18: Cell cycle analysis of LSK and GMP transformed cells with indicated β-catenin 
genomic status 
To further investigate whether β-catenin is required for the in vivo establishment of MLL 
LSCs originated from certain cellular origins, MLL-ENL pre-LSC were serial transplanted into 
irradiated recipient mice. Both LSK-MLL-ENL with Ctnnb1fl/fl and LSK-MLL-ENL with Ctnnb1del/del 
could induce leukemia in primary recipient animals (8 of 10 mice (80%) median survival = 76.6 
days, and 3 of 5 mice (60%) median survival = 112.3 days, p = 0.1276, respectively) (figure 
4.19), suggesting that genetic deletion of β-catenin, albeit delaying the disease onset, did not 
abolish establishment of MLL LSCs.  Moreover, secondary recipient mice transplanted with LSC 
LSK-MLL-ENL with Ctnnb1del/del developed leukaemia with slightly shorten latency (median 
survival = 20 days) than mice that injected with LSC LSK-MLL-ENL Ctnnb1fl/fl (median survival = 
35.6 days), further suggesting that genetic deletion of β-catenin does not affect LSK-MLL-ENL 
LSCs. Together, these results demonstrated that β-catenin is not required for development of 









Figure 4.19: LSK-MLL-ENL is β-catenin independent LSC. A) Survival curve of mice 
transplanted with pre-LSC LSK-MLL-ENL with Ctnnb1fl/fl (n=10), Ctnnb1del/del (n=5), LSC LSK-
MLL-ENL with Ctnnb1fl/fl or Ctnnb1del/del (n=5 for each group). B) Genotyping of Ctnnb1 on gDNA 
extracted from bone marrow isolated from leukaemia mice transplanted with pre-LSC LSK-MLL-
ENL with Ctnnb1fl/fl and Ctnnb1del/del. C) Western blot shows a complete deletion of β-catenin in 
LSC-LSK-MLL-ENL. 
Similar to LSK, 4 of 5 mice (80%) that received pre-LSC CMP-MLL-ENL Ctnnb1fl/fl 
developed leukaemia with very short latency (median survival = 55 days).  Interestingly, while 
knockout of β-catenin delayed leukaemia onset of mice that transplanted with pre-LSC CMP-
MLL-ENL Ctnnb1del/del (p = 0.0818) (3 of 5 (60%) and median survival = 101 days), no significant 
difference (p = 0.5356) in disease latency of secondary recipient mice that received both CMP-
MLL-ENL LSC with Ctnnb1fl/fl or Ctnnb1del/del (median survival = 21.8 and 21.2 days, 
respectively) was observed (figure 4.20). Collectively, these results indicated that MLL-ENL is 
able to transform and establish LSC originated from committed myeloid progenitor (CMP) and 
that the development of CMP-MLL-ENL LSC is largely β-catenin independent.  
 































p = 0.1276 












Figure 4.20: CMP-MLL-ENL is β-catenin independent LSC. A) Survival curve of of mice 
transplanted with pre-LSC CMP-MLL-ENL with Ctnnb1fl/fl (n=10), Ctnnb1del/del (n=5), LSC CMP-
MLL-ENL with Ctnnb1fl/fl or Ctnnb1del/del (n=5 for each group). B) and (C) Genotyping of Ctnnb1 
on gDNA extracted from bone marrow isolated from leukaemia mice transplanted with pre-LSC 
CMP-MLL-ENL with Ctnnb1fl/fl and Ctnnb1del/del. D) Western blot shows a complete deletion of β-
catenin in LSC-CMP-MLL-ENL. 
In contrast, although 10 of 10 mice (100%) that received GMP-MLL-ENL Ctnnb1fl/fl pre-
LSCs developed leukaemia (median survival = 84.6 days) which was transplantable and 
resulted in much shorter latency in secondary recipient mice (median survival = 19.8 days), 
mice that were transplanted with MLL-ENL with Ctnnb1del/del pre-LSCs (n = 10) did not show any 
signs of leukaemia (p < 0.0001) (figure 4.21), consistent with a β-catenin dependent 
transformation. In summary, my data suggest a contrasting β-catenin requirement for the 
development of MLL-ENL LSCs based on the cell of origins with LSK- and CMP- derived MLL-
ENL LSCs showing β-catenin independency and GMP- derived MLL-ENL LSCs β-catenin 
dependency. Similar results were observed in four independent experiments (data not show). 

































p = 0.0818 







Figure 4.21: β-catenin is critical for the development of GMP-MLL-ENL LSC. A) Survival curve 
of mice transplanted with pre-LSC GMP-MLL-ENL with Ctnnb1fl/fl (n=10), Ctnnb1del/del (n=10), 
LSC GMP-MLL-ENL with Ctnnb1fl/fl (n=5). B) Genotyping of Ctnnb1 on gDNA extracted from 
bone marrow isolated from leukaemia mice transplanted with pre-LSC GMP-MLL-ENL with 
bcatfl/fl. 
To assess the impact of β-catenin deletion on the number of leukaemia initiating cells 
from  MLL-ENL LSCs derived from different cellular origins, I performed the limiting dilution 
assay (Martínez-Hernández A) by injecting serially increasing numbers of leukemic cells (100, 
1,000, 10,000, 50,000, and 100,000 cells for each mouse, n = 3 for each cell number) derived 
from LSK-MLL-ENL with Ctnnb1fl/fl, LSK-MLL-ENL with Ctnnb1del/del and GMP-MLL-ENL with 
Ctnnb1fl/fl. Similar frequencies of leukaemia initiating cells in LSC LSK-MLL-ENL with Ctnnb1fl/fl 
(1/6,773) and LSK-MLL-ENL with Ctnnb1del/del (1/8,625) were observed, suggesting that deletion 
of β-catenin has only a minimal impact on the numbers of leukaemia initiating cells within LSK-
MLL-ENL LSCs. Interestingly, a slightly lower frequency of leukaemia initiating cells was found 
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Figure 4.22: Frequencies of leukaemia initiating cells of LSC LSK-MLL-ENL with Ctnnb1fl/fl, LSC 
LSK-MLL-ENL with Ctnnb1del/del, and LSC GMP-MLL-ENL with Ctnnb1fl/fl. A), (B), and (C) 
Survival curve of mice transplanted with different number of LSC cells (100, 1000, 10,000, 
50,000, and 100,000 cells for each 3 mice) of LSK-MLL-ENL with Ctnnb1fl/fl and Ctnnb1del/del, 
and LSC GMP-MLL-ENL with Ctnnb1fl/fl, respectively. D) Summary of the calculated frequencies 
of leukaemia initiating cells of each MLL-ENL LSC tested  
Together, I could demonstrate a different functional requirement of β-catenin in the 
development of phenotypically similar MLL-ENL LSC derived from different cellular origins. 
Next, I further investigated whether β-catenin is required for the maintenance of GMP 
derived MLL-ENL LSCs. GMP-MLL-ENL LSC with Ctnnb1fl/fl was conditionally deleted by 
employing 20nM of tamoxifen into culture medium (R20/20) for 96 hours. Genetic deletion of β-
catenin after Cre-ER activation was confirmed by PCR and Western blotting (figure 4.23). 
100,000 of LSCs including GMP-MLL-ENL with Ctnnb1fl/fl (control untreated cells) and 
Ctnnb1del/del were transplanted into recipient mice (n = 3 for each group). As a result, all mice 
that receive GMP-MLL-LSC with Ctnnb1fl/fl developed leukaemia with median survival was 35 
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days, whereas no sign of disease was observed in mice transplanted with LSC GMP-MLL-ENL 
with Ctnnb1del/del (p = 0.0246). These results suggest that β-catenin is critical for the 
maintenance of MLL-ENL LSC originated from GMP progenitor. To confirm those preliminary 
finding, I currently repeated these experiment by increasing number of recipient mice as well as 
including the  LSK-MLL-ENL LSC to further investigate whether those LSC requires β-catenin 
















Figure 4.23: β-catenin is required for the maintenance of GMP-MLL-ENL LSC. A) Genotyping 
on genomic DNA extracted from LSC GMP-MLL-ENL with Ctnnb1fl/fl (control untreated) and LSC 
GMP-MLL-ENL with Ctnnb1del/del (after incubation with 20nM tamoxifen for 96 hours). B) 
Western blot shows a complete deletion of β-catenin in LSC GMP-MLL-ENL. C) Survival curve 
of mice transplanted with LSC GMP-MLL-ENL with Ctnnb1fl/fl and Ctnnb1del/del  after Cre-ER 




























p = 0.0246 
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4.4 RNA sequencing reveals potential targets of β-catenin in MLL-
ENL LSCs derived from different cellular origins 
To gain insights into  the global mRNA expression and to further investigate the potential 
targets of β-catenin in MLL-ENL pre-LSCs originated from different origins, I performed RNA 
sequencing on pre-LSCs including pre-LSC LSK-MLL-ENL and pre-LSC GMP-MLL-ENL with 
both Ctnnb1fl/fl and complete deletion of β-catenin.  As summarised in Table 4.1, two biological 
replicas of pre-LSC LSK-MLL-ENL with Ctnnb1fl/fl and Ctnnb1del/del samples showed similarities 
in the number of alignments across the mouse genome as well as a total read (pair end) with  
mean of alignment = 77.6% and mean of total read = 21.5M for pre-LSC LSK-MLL-ENL with 
Ctnnb1fl/fl, and mean of alignment = 78.8% and mean of total read = 23.5M for pre-LSC LSK-
MLL-ENL with Ctnnb1del/del, respectively. In contrast, a reduction in number of alignments was 
observed in both pre-LSC GMP-MLL-ENL with Ctnnb1fl/fl and Ctnnb1del/del samples (4 biological 
replicas) with mean of alignment = 69.7% and mean of total read = 26M for pre-LSC GMP-MLL-
ENL with Ctnnb1fl/fl, and mean of alignment = 68.9% and mean of total read = 23.7M for pre-
LSC LSK-MLL-ENL with Ctnnb1del/del, respectively (Table 4.1).  
Table 4.1: Percentage of alignments to mouse genome and total reads of each pre-LSC sample 
generated by RNA sequencing. 
pre-LSC sample β-catenin status % of alignment Total read (pair end) Experiment 
LSK-MLL-ENL Ctnnb1fl/fl 22M 79.40% 
60.1 Ctnnb1del/del 27M 81.10% 
LSK-MLL-ENL Ctnnb1fl/fl 21M 75.80%  
69.1 Ctnnb1del/del 20M 76.50% 
GMP-MLL-ENL Ctnnb1fl/fl 28M 66.70%  
51.5 Ctnnb1del/del 23M 64.90% 
GMP-MLL-ENL Ctnnb1fl/fl 21M 70.40%  
65.5 Ctnnb1del/del 21M 67.40% 
GMP-MLL-ENL Ctnnb1fl/fl 26M 68.70%  
60.5 Ctnnb1del/del 27M 70.90% 
GMP-MLL-ENL Ctnnb1fl/fl 29M 73.10%  
69.5 Ctnnb1del/del 24M 72.50% 
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At the gene level using a stringent criteria (p-value < 0.05 and fold change > 2.0), I 
could identify 688 genes differentially expressed in pre-LSC LSK-MLL-ENL with Ctnnb1fl/fl 
compared to pre-LSC LSK-MLL-ENL with Ctnnb1del/del using DSeq2.  On the other hand, 86 
genes were differentially expressed in pre-LSC GMP-MLL-ENL with Ctnnb1fl/fl compared to pre-
LSC GMP-MLL-ENL with complete deletion of β-catenin using Limma. Using Vennplex software 
(Cai H 2013) to analyse two different gene expression datasets (figure 4.24), I found that 408 
genes were specifically up-regulated in pre-LSC LSK-MLL-ENL in the absence of β-catenin. 
Among those, several genes have been reported in many types of cancers as well as in 
leukaemia such as Ccl2 (Burgess M 2012) (p < 0.001, log2 fold change = 2.85), as Ccl4  (Yan 
XJ 2011 ) (p < 0.001, log2 fold change = 3.18) (Burgess M 2012), Cxcl1 (Hatfield KJ 2010) (p < 
0.001, log2 fold change = 2.43), Cxcl2 (Burgess M 2012) (p < 0.001, log2 fold change = 2.52), 
Cxcl3 [(Mahadevan D 2009)] (p < 0.001, log2 fold change = 3.13), Maf (Martínez-Hernández A 
2014) (p < 0.001, log2 fold change = 2.85), Mmp8 (Kim Y 2014 ) (p < 0.001, log2 fold change = 
1.15), Mmp9 (Jiang L 2012) (p < 0.001, log2 fold change = 1.74), Pla1a (Paulo P 2012) (p < 
0.001, log2 fold change = 3.00), and Wnt5b (Lu D 2004),(Takeshita A 2014) (p < 0.001, log2 
fold change = 1.82). In contrast, loss of β-catenin resulted in explicit down-regulated of 228 
genes, which are presumably β-catenin targets in pre-LSC LSK-MLL-ENL. Those genes 
included Tifab (p < 0.001, log2 fold change = 2.35), Chpf (p < 0.001, log2 fold change = 2.10), 
Tgfb2 (p < 0.001, log2 fold change = 1.50), Ptprf (p < 0.001, log2 fold change = 2.01), and Ifitm1 
(p < 0.001, log2 fold change = 2.00). In pre-LSC GMP-MLL-ENL, 12 genes were specifically up 
regulated in the absence of β-catenin including Fos (p < 0.001, log2 fold change = 1.40), 
Mogat2 (p < 0.001, log2 fold change = 1.1), Pros1 (p = 0.04, log2 fold change = 1.38), and 
Rhod (p < 0.04, log2 fold change = 1.45). Interestingly, knockout of β-catenin in pre-LSC GMP-
MLL-ENL resulted in down-regulation of several genes involved in hypoxia as well as myeloid 
cells differentiation. Those genes included Stc1 (p = 0.01, log2 fold change = 3.22), Mboat2 (p = 
0.02, log2 fold change = 2.15) and Krt19 (p = 0.04, log2 fold change = 3.43), and Vldlr (p = 0.02, 
log2 fold change = 1.60). Together, RNA sequencing revealed different expression profiles in 
LSK- and GMP-derived MLL-ENL pre-LSCs and different potential β-catenin downstream 
targets which may contribute to the different requirements of β-catenin in phenotypically similar 
MLL-ENL pre-LSCs derived from different cellular of origins (HSC and GMP). 
Despite distinctive expression patterns of many genes after β-catenin knockout across 
origin specific MLL-ENL pre-LSC cells were observed, co-up-regulation and co-down-regulation 
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of certain genes also occurred when LSK- and GMP-MLL-ENL pre-LSCs with knockout of β-
catenin were compared. 21 commonly overexpressed genes were observed; among those were 
several genes critical for tumorigenesis as well as leukaemogenesis including Plk2, CD80, 
Lyx1, Lyz2, Camp, Olfm4, Map6, Trib1, and Ipcef1. Furthermore, 31 genes were co-suppressed 
in these pre-LSCs when β-catenin was deleted. Those could possibly represent β-catenin 
targets in both LSK- and GMP-MLL-ENL pre-LSC and included Samd5, Tgfbr3, Irf4, Ambp, 
Aldoc, Tgm2, and Thbs1 (table 4.2). Expression levels of those genes were confirmed by qRT-
PCR on RNA extracted from pre-LSC LSK- and GMP-MLL-ENL with Ctnnb1fl/fl and Ctnnb1del/del 
(figure 4.25).  In summary, I could identify both origin-specific as well as origin-independent 













Figure 4.24: Schematic of generation of differential expressed genes which were subjected 
Venni to generate Venn diagram (p-value < 0.05 and fold change > 2.0). B) Venn diagram 
shows number of genes that are commonly and differentially expressed in tested samples. 
 
LSK-MLL-ENL Ctnnb1fl/fl  
LSK-MLL-ENL Ctnnb1del/del  
List 2; 688 genes 
GMP-MLL-ENL Ctnnb1fl/fl  
GMP-MLL-ENL Ctnnb1del/del  
List 1; 86 genes 
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Table 4.2: Summary of differentially and commonly expressed genes in LSK- and GMP-MLL-







Genes common expressed in 




















(show 22 of 31) 
Cxcl1 Tgfb2 Mogat2 Ccr2 Olfm4 Samd5 
Tmc3 Wnt9b Serpinb10 C3ar1 Clec4a2 Tgfbr3 
Cd302 Wnt10b Ptafr Dpep2 Ces1d Bpifc 
Dst Tifab Fos Nlrp3 Plekhg1 Irf4 
Slc11a1 Chpf Chi3l1 H2-Ab1 Camp Ambp 
Astn2 S1pr3 Asprv1 Stc1 Lyz1 Aldoc 
Cxcl2 Neurl1b Zfp819 Lrrc32 Lyz2 Zkscan17 
Il1b Ptprf B3galt5 Htra3 Plk2 N4bp3 
Nrp1 Ifitm1 Rhod Dusp4 Cd80 St6gal1 
Ccl2 Dlc1 Tmcc3 Mboat2 Col5a1 Tgm2 
Maf Mamdc2 Fosb Vldlr Serpinb2 Creb5 
Pla1a Pik3ip1 Pros1 Dlk1 Il18 Nrbp2 
Cxcl3 Ndrg2  Gm8773 Slc6a12 Myl10 
Ccl4 Il1r2  Kcnc3 Vcam1 Lpar1 
Mmp8 Elfn2  Pafah1b3 Map6 Tex2 
Mmp9 Slc2a3  Mgarp Bst1 Ccdc85a 
Mmp14 Jak3  G630025P09Rik Hvcn1 Rcor2 
Wnt5b Mmp28  Krt19 Clec4n Thbs1 
Cd38 Slc52a3  Adamtsl5 Pdlim4 Fgf23 
Cd48 Map3k1  Pgbd1 Trib1 Atp7b 
Cxcl10 Cd244  Syn1 Ipcef1 Grin1 
Bax Fn1  Htr2a  Parp16 
 
 








Figure 4.25: Bar chart shows expression levels of downstream targets of β-catenin including 
Irf4, Tgfbr3, and Tgm2 in pre-LSCs LSK-and GMP-MLL-ENL with the indicated genotypes 
To further discover the potential pathways being involved in the process, Gene Set 
Enrichment Analysis (GSEA) was performed with the gene lists described above from the RNA 
sequencing of the different MLL-ENL pre-LSCs.  Using false discovery rate (FDR q Value) less 
than 0.05, 320 activated- and 141 down-regulated pathways were identified LSK-MLL-ENL with 
Ctnnb1fl/fl pre-LSCs when compared to LSK-MLL-ENL with Ctnnb1del/del pre-LSCs (figure 4.26). 
In β-catenin dependent GMP-MLL-ENL pre-LSCs, while 242 pathways were up-regulated, only 
7 pathways (myeloid cell development and ion channel transport) were significantly down-
regulated in the absence of β-catenin. Furthermore, 117 pathways were co-up- and 5 pathways 
were co-down-regulated in both LSK- and GMP-derived pre-LSCs upon β-catenin deletion 
(table 4.3). Collectively, I have globally studied the consequences of β-catenin deletion in MLL-
ENL pre-LSCs derived from different cellular origins on the individual gene and pathway levels. 
Differentially expressed genes and pathways between LSK- and GMP-derived MLL-ENL LSCs 
in the absence of β-catenin may contribute to the differential biological outcome of β-catenin 
















































Figure 4.26: Different genes expression Flow chart of input data to generated Venn diagraph 
(FDR q-value < 0.05). B) Venn diagraph shows number of pathways that common and 










LSK-MLL-ENL Ctnnb1fl/fl  
LSK-MLL-ENL Ctnnb1del/del  
List 1; 461 pathways 
GMP-MLL-ENL Ctnnb1fl/fl  
GMP-MLL-ENL Ctnnb1del/del  
List 2; 249 pathways 
A 
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Table 4.3: Pathways differential and common expressed in pre-LSC LSK- and GMP-MLL-ENL 
when conditionally deletion of β-catenin. 
Pathway differentially 
expressed in pre-LSC  
LSK-MLL-ENL 
Pathway differentially 
expressed in pre-LSC GMP-
MLL-ENL 
Pathway common 
expressed in pre-LSC  
LSK- and GMP-MLL-ENL 
Up  
regulation 
(5 of 203) 
Down 
regulation 
(5 of 136) 
Up 
regulation 
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4.5 Potential molecular interaction between β-catenin and Hox in 
origin specific MLL-ENL LSCs 
Self-renewal pathways are fundamental and essential in normal and/or cancer stem cells, 
and are down-regulated during differentiation in their downstream progenitors.  However, 
certain molecules including Wnt/β-catenin (table 4.4) can promote, when over-expression, but is 
not required for self-renewal, suggesting the presence of alternative pathways to compensate 
for its functions upon genetic deletion.  To search for such a pathway, Hoxa9 has been a top 
candidate that exhibits a similar functional profile as Wnt/β-catenin, which enhances self-
renewal but is largely dispensable for normal HSCs. Consistently, I observed that several Hox 
genes were expressed at a high level in normal HSC and that the expression was reduced 
throughout differentiation (figure 4.10). Consistently, by quantitative RT-PCR, Hoxa9 was 
remarkably expressed at a higher level in pre-LSC LSK-MLL-ENL compared to pre-LSC GMP-
MLL-ENL (figure 4.27). Interestingly, unpublished data in our group obtained from studying the 
role of Hoxa9 in origin specific LSCs carried out by former lab members Dr. Jo Sales and Dr. 
Pedro Veiga, reveal a very similar property of Hoxa9 as compared to β-catenin. It was shown 
that Hoxa9 was strictly required for the transformation of GMPs by MLL-ENL, whereas it was 
dispensable for the generation of LSK derived MLL-ENL pre-LSCs and LSCs (figure 4.28).  
These results are consistent with the RNA-seq data suggesting a possible functional 
compensation and/or molecular interaction between Hoxa9 and β-catenin only in LSKs, and 
provide a strong rationale to study a potential functional crosstalk between β-catenin and Hoxa9 
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Table 4.4; Critical self-renewal pathway and their impact on normal HSC and LSCs; - Negative 
impact, + positive impact, NS not significant (Zeisig 2012).  
 
Self-renewal pathways 
Loss of function Impact on 
HSC LSC 
PTEN - + 
β-catenin NS - 
BMI - - 








Figure 4.27: Graph shows genes expression by quantitative RT-PCR of Hoxb4, Hoxa5, Hoxa7, 
















































Figure 4.28: GMP but not LSK requires Hoxa9 for the development of LSC transformed by MLL-
ENL. A) Bar chart (top) show the absolute number of colonies in each round of plating in MLL-
ENL pre-LSCs originated from the indicated cell populations. B) Survival curve of of mice 
transplanted with pre-LSC LSK-MLL-ENL wild type (n=5), Hoxa9-/- (n=8), LSC LSK-MLL-ENL 
wild type and Hoxa9-/- (n=5 for each group). Unpublished data from the So Lab generated by Dr. 









































pre-LSC LSK-MLL-ENL Wild type
pre-LSC LSK-MLL-ENL Hoxa9-/-















p = 0.4994 
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4.6 Compound knockout of β-catenin and Hoxa9 abolish oncogenic 
potential of MLL-ENL LSCs derived from LSK 
To investigate the possible functional crosstalk between β-catenin and Hoxa9 in the 
development of MLL-ENL LSCs derived from different cellular origins, I have generated a 
conditionally compound knockout mouse line, Rosa26-Cre/Rosa26-YFP/Ctnnb1fl/fl/hoxa9-/- in 
which β-catenin can be inducibly inactivated in Hoxa9 null background.  To test if different 
cellular origins from this new mouse line can be transformed in vitro, I first used E2A-PBX1 
transduced cells to RTTA. As seen in figure 4.29, E2A-PBX1 transformed LSK, CMP, and GMP 
in both wild type and Hoxa9-/-/Ctnnb1fl/fl cells, confirming that E2A-PBX1 does not require Hoxa9 
in the establishment of pre-LSC in vitro. As expected, MLL-ENL transformed LSK and CMP in 
the absence of hoxa9 in vitro whereas genetic deletion of Hoxa9 abrogated the transformation 
ability of MLL-ENL in GMP derived cells (figure 4.30), confirming our previous unpublished data 








Figure 4.29: Establishment of LSK-, CMP-, and GMP-E2A-PBX1 pre-LSC is independent of 
Hoxa9. Absolute colony numbers of LSK, CMP, and GMP cells isolated from bone marrow of 









































Figure 4.30: Knockout of Hoxa9 suppresses transformation efficacy of CMP-MLL-ENL and 
GMP-MLL-ENL pre-LSC. Absolute colonies number of LSK, CMP, and GMP cells isolated from 
bone marrow of wild type and Hoxa9-/-/Ctnnb1flfl mice transformed by MLL-ENL during replating 
assay. 
To further investigate the effects of a combined genetic deletion of β-catenin and Hoxa9 
on the leukaemogenic potential of Hoxa9 independent pre-LSCs, I performed a conditional 
deletion of β-catenin in these cells by adding 20nM tamoxifen into the second round of plating. 
As a result, establishment of LSK- CMP-, and GMP-E2A-PBX1 pre-LSCs were independent on 
both β-catenin and Hoxa9 in RTTA as they were able to give rise into 4th round colonies 
regardless of β-catenin and hoxa9 statuses (figure 4.31), demonstrating that compound 




















































Figure 4.31 Establishment of LSK-, CMP-, GMP-E2A-PBX1 pre-LSC are independent of both β-
catenin and Hoxa9. A) Absolute colony numbers (top) and colony morphologies (bottom) of 
LSK, CMP, and GMP cells transformed by E2A-PBX1 during replating assay. B) and (C) 
Genotyping of Ctnnb1 and Hoxa9 on gDNA extracted from transformed cells after CRE-ER 
mediated deletion of Ctnnb1 gene by 20nM tamoxifen treatment and YFP sorting. 
Next, I investigated whether compound knockout of β-catenin and Hoxa9 could 
abrogate transformation efficacy of β-catenin and Hoxa9 independent LSC, the HSC-enriched 
LSK-MLL-ENL. While MLL-ENL could transform LSK Hoxa9-/- with Ctnnb1fl/fl, it failed to 
transform GMP Hoxa9-/- with Ctnnb1fl/fl. Interestingly, compound knockout of β-catenin and 
Hoxa9 resulted in reduced colony numbers and much-diffused colony morphology in LSK-MLL-










































Chapter 4 Results 
108  
potentials of LSK-MLL-ENL pre-LSCs (figure 4.32). To further investigate and confirm whether 
compound knockout of β-catenin and Hoxa9 could affect the development of LSK-MLL-ENL 
LSC in vivo, these pre-LSCs as well as wild type LSK-MLL-ENL pre-LSC were transplanted into 










                        








Figure 4.32: Combined genetic deletion of β-catenin and Hoxa9 impairs transformation efficacy 
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LSK, CMP, and GMP cells transformed by MLL-ENL during replating assay. B) and (C) 
Genotyping of Ctnnb1 and Hoxa9 on gDNA extracted from transformed cells after mediated 
deletion of Ctnnb1 gene by a treatment of 20 nM tamoxifen and YFP sorting. D) Western blot 
shows a complete deletion of β-catenin in pre-LSC LSK-MLL-ENL with Hoxa9 knockout. 
Consistently with in vitro transformation assay, mice that received wild type LSK-MLL-
ENL (4 of 5) and LSK-MLL-ENL Hoxa9-/-/Ctnnb1fl/fl (3 of 5) pre-LSCs developed leukaemia with 
median survival of 75.7 and 54.7 days, respectively. Interestingly, all 5 mice that received 
compound knockout of β-catenin and Hoxa9 LSK-MLL-ENL pre-LSCs showed no signs of 
leukaemia (figure 4.33) after 100 days of observation (p = 0.0768). Collectively, these results 
provide strong evidence of a compensatory mechanism operating in LSKs involving Hoxa9 and 







Figure 4.33: Combined genetic deletion of β-catenin and Hoxa9 abolish leukaemogenic 
potential of pre-LSC LSK-MLL-ENL in vivo. Survival curve of mice transplanted with pre-LSC 
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p = 0.0768 
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4.7 Identification of Prmt1 as a keys modulator to mediate the 
transformation of MLL-ENL in the absence of β-catenin or 
Hoxa9  
To gain more insights into the relationship between Hoxa9 and β-catenin, RNA 
sequencing was employed to identify critical molecules that mediate the transformation in one 
or another’s absence. To this end, biological replicas of pre-LSCs, LSK-MLL-ENL with 
Ctnnb1fl/fl, LSK-MLL-ENL with Ctnnb1del/del,  LSK-MLL-ENL with Hoxa9-/-/Ctnnb1fl/fl and Hoxa9-/-
/Ctnnb1del/del were generated and subjected to RNA sequencing and compared to LSK-MLL-
ENL Hoxa9-/- RNA sequencing data already existing in our lab.. Using gene set enrichment 
analysis (GSEA), I could identify 26 pathways differentially up- and 60 pathways differentially 
down-regulated in pre-LSC LSK-MLL-ENL with Hoxa9-/-/Ctnnb1del/del (figure 4.34), one of which 
has been the Meis1-Hoxa9 pathway. The following genes, among others within the Meis1-
Hoxa9 pathway were significantly down-regulated (p value < 0.05), Prmt1, Ruvbl1, and Ruvbl2, 
Nolc1, and C1qbp. To confirm the down regulation of these genes, quantitative RT-PCR was 
performed on pre-LSC LSK-MLL-ENL with both Hoxa9-/-/Ctnnb1fl/fl, and Hoxa9-/-/Ctnnb1del/del 
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Figure 4.34: GSEA on genes differentially expressed in pre-LSC LSK-MLL-ENL in the absent of 
β-catenin or Hoxa9 or both of β-catenin and Hoxa9. A) Schematic representation of the different 
comparisons made after RNA sequencing. Differentially expressed genes were then subjected 










Figure 4.35: Bar chart shows expression levels of genes involved in Meis1-Hoxa9 pathway in 
pre-LSCs LSK-MLL-ENL with the indicated genotypes.  
Among the down regulated genes in Meis1-Hoxa9 pathway, Prmt1 has been 
characterised as one of the components in MLL complex and to play an important role in the 
establishment of LSCs by activating a transcription of several targets including Hox genes 
(Cheung et al., 2007).To determine if Prmt1 is a critical mediator for b-catenin/Hoxa9 function in 
the development of MLL-ENL LSCs, I performed shRNA mediated knockdown experiments 
targeting Prmt1 LSK-MLL-ENL Ctnnb1del/del and LSK-MLL-ENL Hoxa9-/- LSCs. After 
transduction with GFP-tagged PRMT1 shRNA  or GFP-tagged vector control, GFP positive cells 
were sorted and quantitative RT-PCR confirmed great reduction of Prmt1 mRNA transcripts in 
both LSC LSK-MLL-ENL Hoxa9-/- and LSC LSK-MLL-ENL Ctnnb1del/del  compared to control 
transduced cells (figure 4.36). Interestingly, when plated in methylcellulose to test for their 
colony forming abilities, knockdown of Prmt1 resulted in substantial reduction of colony 
numbers in LSC LSK-MLL-ENL Hoxa9-/- and LSC LSK-MLL-ENL Ctnnb1del/del (figure 4.37), 
suggesting  that suppression of Prmt1 could impair the transformation efficacy of LSC LSK-
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Figure 4.36: Expression of Prmt1 in LSC LSK-MLL-ENL with the indicated genotypes after 












Figure 4.37 Knockdown Prmt1 suppresses transformation of LSK-MLL-ENL with Hoxa9-/- and 
LSK-MLL-ENL with Ctnnb1del/del LSCs. Absolute colony numbers and of LSCs LSK-MLL-ENL 
with Hoxa9 knockout (A) and LSCs LSK-MLL-ENL with knockout of β-catenin (B) after 
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To further investigate whether suppression of Prmt1 could also impair the 
transformation efficacy of those LSC LSK-MLL-ENL in vivo, I transplanted these Prmt1 
knockdown and empty vector control transduced cells to recipient mice (n = 3 for LSK-MLL-ENL 
Hoxa9-/- transduced with empty vector-GFP, n = 5 for LSK-MLL-ENL Hoxa9-/- transduced with 
Prmt1-shRNA-GFP, LSK-MLL-ENL Ctnnb1del/del transduced with empty vector-GFP, and LSK-
MLL-ENL Ctnnb1del/del transduced with Prmt1-shRNA-GFP). Consistently, all mice (3 of 3) that 
receive LSC LSK-MLL-ENL Hoxa9-/- transduced with empty vector-GFP developed leukaemia 
with very short latency (median survival = 25.7 days). In contrast, mice that were transplanted 
with LSC LSK-MLL-ENL Hoxa9-/- transduced with Prmt1-shRNA-GFP did not show any signs of 
disease up to day 50 (p = 0.0067) (figure 4.38). These results indicate that genetic deletion of 
Hoxa9 together with the suppression of Prmt1 could abolish leukaemogenic property of MLL-
ENL LSC derived from HSC-enriched LSK cells. In vivo experiments with Prmt1 knockdown in 
LSC LSK-MLL-ENL with β-catenin knockout were just set up and I am now waiting for the first 








Figure 4.38: Knockdown Prmt1 impairs leukaemogenic potential of LSK-MLL-ENL LSC with 
hoxa9-/-. Survival curve of mice transplanted with LSC LSK- MLL-ENL with Hoxa9 knockout 
transduced with Prmt1-shRNA or control empty vector control (n=3 for control and 5 for the test 
group). 
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4.8 Transformation of MLL-AF9 LSCs could abolish by combined 
genetic deletion of β-catenin and Hoxa9 
 To extend my work into the functional crosstalk between β-catenin and Hoxa9 in the 
initiation of other AML LSCs, I tested MLL-AF9 as it frequently observed and presented a poor 
prognosis in AML. Here, I described the impact of genetic deletion of the individual gene, β-
catenin and Hoxa9 and a combined genetic deletion of those two molecules in the 
establishment of MLL-AF9 LSCs which derived from different cell of origins. 
Firstly, pools of HSC, CMP, and GMP were purified from Rosa26-Cre/Rosa26-
YFP/Ctnnb1fl/fl mice (5 mice) and subsequently transformed with MLL-AF9. Transformed cells 
were subjected to RTTA following with genetic deletion of β-catenin at the early phase of the 
development of MLL-AF9 pre-LSC by adding 20nM tamoxifen into the 2nd round of plating 
followed by FACS sorting of YFP positive cells. As a result, genetic deletion of β-catenin was 
not result in a suppression of cloning efficacy of MLL-AF9 in all LSK-, CMP-, and GMP-MLL-
AF9 transformed cells (figure 4.39). Thus, establishment of MLL-AF9 pre-LSCs may 
independent on β-catenin. To further investigate whether β-catenin is required for development 
of MLL-AF9 LSCs in vivo,  LSK, CMP, and GMP pre-LSCs from Ctnnb1fl/fl and Ctnnb1del/del  were 
































Figure  4.39: β-catenin is not required for the establishment of LSK-, CMP-, and GMP-MLL-ENL 
pre-LSC. A) Absolute colony numbers (top) and colony morphologies (bottom) of LSK, CMP, 
and GMP cells transformed by MLL-AF9 during replating assay. B) Genotyping of Ctnnb1 and 
gDNA extracted from transformed cells after CRE-ER mediated deletion of Ctnnb1 gene by 
20nM tamoxifen treatment and YFP sorting. C) Western blot shows a complete deletion of β-
catenin in LSK-, CMP, and GMP-MLL-AF9 transformed cells. 
 In vivo, both LSK-MLL-AF9 with Ctnnb1fl/fl and LSK-MLL-AF9 with Ctnnb1del/del could 
induce leukemia in primary recipient animals (p = 0.3538) (5 of 5 mice (100%) median survival = 
46 days, and 5 of 5 mice (100%) median survival = 41 days, respectively) (figure 4.40A). Similar 
to LSK-MLL-AF9 LSC, all mice that transplanted with CMP-MLL-AF9 with Ctnnb1fl/fl (n = 5) and 
CMP-MLL-AF9 with Ctnnb1del/del (n = 5) developed leukaemia (p = 0.9587) with median survival 
= 40 and 35 days, respectively (figure 4.40B). In contract, while all mice (5 of 5) that received 
GMP-MLL-AF9 with Ctnnb1fl/fl showed signs of leukaemia with median survival = 58 days, 
significantly delayed in disease free survival (p value = 0.0020) was observed in mice 
transplanted with GMP-MLL-AF9 with Ctnnb1del/del (5 of 10 mice, median survival = 113 days) 
(figure 4.40C). These results indicated that genetic deletion of β-catenin alone was not sufficient 
to abrogate the transformation of MLL-AF9 LSCs derived from HSC and CMP. However, 
knockout of β-catenin could impair the leukaemogenic potential of GMP-MLL-AF9 LSC. 
Collectively, I could demonstrate the different requirement of β-catenin in the development of 
MLL-AF9 LSCs derived from different cell of origins and eradication of MLL-AF9 LSCs by 
targeting of β-catenin may largely depend on cell of origins.  
B C 








Figure 4.40: Knockout of β-catenin impairs transformation efficacy of pre-LSC GMP-MLL-AF9 
but not in pre-LSC LSK-and CMP-MLL-AF9. A) Survival curve of mice transplanted with LSK-
MLL-AF9 with Ctnnb1fl/fl and Ctnnb1del/del (n = 5 for each group). B) Survival curve of mice 
transplanted with CMP-MLL-AF9 with Ctnnb1fl/fl and Ctnnb1del/del (n = 5 for each group). C) 
Survival curve of mice transplanted with GMP-MLL-AF9 with Ctnnb1fl/fl (n = 10) and Ctnnb1del/del 
(n = 5). D) and (E) Genotyping of Ctnnb1 on gDNA extracted from bone marrow isolated from 
leukaemia mice transplanted with pre-LSC LSK- MLL-AF9 with Ctnnb1fl/fl (532-1), CMP-MLL-
AF9 with Ctnnb1fl/fl (383-1), GMP-MLL-AF9 with Ctnnb1fl/fl (533-1),  and LSK-MLL-AF9 with 
Ctnnb1del/del (525-5), CMP-MLL-AF9 with Ctnnb1del/del (525-9), GMP-MLL-AF9 with Ctnnb1del/del 
(525-13), respectively. 



















































































p = 0.0020 
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Next, I further investigated whether genetic deletion of Hoxa9 alone or combine 
knockout of β-catenin and Hoxa9 could abolish oncogenic potential of MLL-AF9 LSCs by 
targeting purified HSC, CMP, and GMP isolated from bone marrow of Rosa26-Cre/Rosa26-
YFP/Ctnnb1fl/fl and hoxa9-/- mice. In replating assay, MLL-AF9 was able to transform LSK, CMP, 
and GMP regardless of Hoxa9 status. Interestingly, gradually decreased in number of colony 
during RTTA was observed in MLL-AF9 transformed cells with Hoxa9-/- in all sorted populations 
when compared to wild type MLL-AF9 transformed cells (figure 4.41). These finding suggested 








Figure 4.41: Knockout of Hoxa9 supress transformation efficacy of LSK-, CMP-, and GMP-MLL-
AF9 in vitro. Absolute colonies number of LSK, CMP, and GMP cells isolated from bone marrow 
of wild type and Hoxa9-/-/Ctnnb1flfl mice transformed by MLL-AF9 during replating assay. 
In addition to study the impact of single genetic deletion of β-catenin or Hoxa9 in the 
establishment of MLL-AF9 pre-LSCs derived from different cell of origins, I further investigated 
whether compound genetic deletion of β-catenin and Hoxa9 could abolish the transformation 
efficacy of MLL-AF9. Transformed LSK-, CMP- and GMP-MLL-AF9 cells with Hoxa9 knockout 
were conditionally deleted of β-catenin by administration of 20nM tamoxifen into the second 
round of RTTA followed by FACS sorting of YFP positive cells. As a result, genetic deletion of β-
catenin and Hoxa9 could not suppress the transformation efficacy of MLL-AF9 pre-LSCs 
derived from LSK, CMP, and GMP in vitro (figure 4.42). To further investigated whether 
compound knockout of β-catenin and Hoxa9 could abolish the transformation efficacy of those 
pre-LSCs in vivo, LSK-and GMP-MLL-AF9 pre-LSCs with Hoxa9-/-/Ctnnb1fl/fl and compound 

















































Figure 4.42:  Establishment of LSK-, CMP, and GMP-MLL-AF9 pre-LSCs are β-catenin and 
Hoxa9 independent. A) Absolute colonies number and colony morphologies of LSK, CMP, and 
GMP cells transformed by MLL-AF9 during replating assay. B) and (C) Genotyping of Ctnnb1 
and Hoxa9 on gDNA extracted from transformed cells after mediated deletion of Ctnnb1 gene 
by a treatment of 20 nM tamoxifen and YFP sorting. 
 Surprisingly, while mice that receive both pre-LSCs LSK- and GMP-MLL-AF9 with 
Hoxa9 knockout and Ctnnb1fl/fl cells was able to engraft and induce leukaemia (2 of 5 for LSK-
MLL-AF9 and 4 of 5 from GMP-MLL-AF9), compound knockout of β-catenin and Hoxa9 
abolished leukaemogenic property of both LSK and GMP derived MLL-AF9 LSCs in vivo (p = 
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MLL-AF9 LSCs. Moreover, treatment of MLL-AF9 by targeting β-catenin and Hoxa9 may largely 
depend on cell of origin of MLL-AF9 LSCs. Furthermore, targeting multiple self-renewal 
pathways such as β-catenin and Hoxa9 which are dispensable for normal HSC but critical for 








Figure 4.43: Combined genetic deletion of β-catenin and Hoxa9 abolish leukaemogenic 
potential of pre-LSC LSK-MLL-AF9 and GMP-MLL-AF9 in vivo. Survival curve of mice 
transplanted with pre-LSC LSK-  (A) and GMP-MLL-AF9 (B) with Hoxa9-/-/Ctnnb1fl/fl (n=5 for 





































p = 0.1343 
p = 0.0133 
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Chapter 5 Discussion 
Wnt/β-catenin has been characterized as an important molecule controlling normal and 
malignant haematopoiesis (Reya et al. 2003, Staal and Clevers 2005).  Our group recently 
discovered that β-catenin is critical for transformation and mediating drug resistant properties of 
MLL LSCs derived from c-kit+ hematopoietic stem/progenitor cells (Yeung et al. 2010). It has 
also been shown that the expression level of β-catenin in different hematopoietic progenitors is 
essential for the initiation of LSCs by MLL-AF9 and Meis1-Hoxa9 (Wang Y 2010). However, it is 
unclear whether β-catenin also plays an important role in the development of LSC initiated from 
other recurrent LATFs derived from c-kit+ cells or functional distinct hematopoietic populations. 
In this report, I further investigated the impact of β-catenin in the initiation and maintenance of 
LSCs induced by common LATFs derived from both c-kit+ cells and distinct hematopoietic 
populations. Furthermore, I extended my work to the study of a novel functional crosstalk 
between Wnt/β-catenin and Hox pathways in the development of MLL LSCs derived from 
different cell of origins.   
Using in vitro transformation assay (RTTA), conditional deletion of β-catenin did not impair 
the transformation efficacy of MN1, E2A-PBX1, and MLL-ENL pre-LSCs derived from c-kit+ 
hematopoietic stem/progenitor cells. Interestingly, while the development of E2A-PBX1 and 
MN1 LSCs were β-catenin independent, knockout of β-catenin abolished leukaemogenic 
property of c-Kit+ MLL-ENL LSC in vivo. These findings not only confirmed our group’s 
previously published data that β-catenin is critical for the establishment of c-Kit+ MLL-ENL LSC 
(Yeung et al. 2010)  using different mouse strain but also revealed the different functional 
requirements of β-catenin in the development of AML LSCs transformed by different LATFs.  
This finding also challenges the suggestion that β-catenin is generally required for development 
of AML stem cells (Wang et al., 2000).   
MN1, a LATF not requiring β-catenin for development of LSC, is found not only as a fusion 
partner of chromosomal translocation t(12;22)(p13;q22) in several human myeloid leukaemia 
including AML, MDS, and CML but also over-expressed in human leukaemias (Grosveld 2007).  
Subsequent studies showed that MN1 is a very potent AML oncogene (Heuser et al. 2007). 
Here I showed that retroviral overexpression of MN1 in c-kit+ cells resulted in rapid induction of 
leukaemia in murine model regardless of β-catenin status. It has been documented that MN1 
functions as a transcriptional co-activator cooperating with p300/CBP and RAC3 (van Wely et 
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al. 2003). In addition, high expression levels of MN1 correlated with observed ATRA resistance 
in AML patients (Heuser et al. 2007).  Gene expression profiling of MN1 induced cell lines 
revealed that overexpression of MN1 resulted in the up-regulation of several leukaemogeneic 
oncogenes such as MEIS1 and BMI1 (Meester-Smoor et al. 2008). Remarkably, co-expression 
of Hoxa9 was able to enhance transformation efficiency of MN1-TEL leukaemia in mice 
(Kawagoe and Grosveld 2005). Thus c-kit+ MN1 LSC may compensate the absence of β-
catenin with the up-regulation of other self-renewal pathways such as Hoxa9-Meis1 and BMI1 
leading to initiation of MN1 LSC without β-catenin.  
  E2A-PBX1 is one of the most common fusion genes found in acute lymphoblastic 
leukaemia (ALL) and it has been shown that in murine models overexpression of several Hox 
genes such as Hoxa9 and Hoxb4 can accelerate the onset of disease (Bijl et al. 2008), 
suggesting a crosstalk between Hox and E2A-PBX1 in ALL. However, culture conditions in 
RTTA do not support lymphoid growth but are biased towards myeloid growth.  Thus cells 
transformed by E2A-PBX1 in this assay have very different properties than E2A-PBX1 ALL cells 
and do not activate or require Hox genes for transformation (Cheung et al. 2007), suggesting 
that loss of β-catenin is compensated by Hox-Meis1 independent pathways during the 
development of E2A-PBX1 LSCs.  
Interestingly, β-catenin has been recently reported to have a critical role in in another 
haematological malignancy, CML. Hu et al. 2009, demonstrated that purified BCR-ABL 
expressing LSCs (GFP+ Lin- c-Kit+ Sca-1+) isolated from CML mice overexpressed β-catenin 
mRNA  compared to normal HSCs (GFP+ Lin- c-Kit+ Sca-1+) isolated from mice transplanted 
with empty vector transduced normal bone marrow cells. While BCR-ABL transformed BM cells 
with conditional deletion of β-catenin were able to home into the bone marrow of recipient mice, 
these cells failed to induce CML suggesting β-catenin is important in the initiation of BCR-ABL 
positive CML (Hu, 2009). In addition, Hidel et al.  2012, investigated the functional requirement 
of β-catenin for the maintenance of BCR-ABL induced CML. Conditional genetic deletion of β-
catenin by tamoxifen in established CML (2 weeks or later after transplantation) did not result in 
a significant prolongation of the disease-free survival in mice transplanted with BCR-ABL 
transformed BM cells with Ers1-Cre Ctnnb1fl/fl genotype. However, in vivo β-catenin deletion 
led to a significant reduction in the number of CML cells in peripheral blood as well as in the 
total number of Sca-1+ cells in bone marrow compared with tamoxifen treated control mice that 
received wild type BCR-ABL transformed BM cells. Interestingly, serial transplantation of CML 
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LSCs into secondary mice treated together with imatinib targeting BCR-ABL and tamoxifen to 
induce the deletion of β-catenin led to a reduction of Lin- and LSK fraction (enrich for LSC 
property) of CML cells in marrow. Strikingly, significant disease-free survival differences were 
only observed when these cells were serially transplanted into tertiary recipient mice, which has 
been phenocopied when Imatinib and the β-catenin inhibitor indomethacin had been used, 
suggesting that targeting β-catenin in combination with Imatinib may represent a novel 
therapeutic avenue in CML (Heidel FH 2012). Together, these findings reveal a different 
functional requirement of β-catenin in the establishment of LSCs depending on the leukaemia 
initiating events.  
While MN1 and E2A-PBX1 were able to transform and establish AML LSCs in β-catenin 
deficient c-Kit+ cells which are a mixed and heterogeneous population of HSCs and progenitors, 
establishment of c-Kit+ MLL-ENL was β-catenin dependent. Similar to other MLL rearrangement 
leukaemia, MLL-ENL up-regulates several targets critical for the development of leukaemia. 
Zeisig et al, 2004 demonstrated that tamoxifen-inducible MLL-ENL-ERtm could transform and 
immortalise bone marrow haematopoietic cells when the culture medium was supplemented 
with tamoxifen (4-hydroxy-tamoxifen). Interestingly, gene expression analysis on those 
conditionally transformed cells revealed that Hoxa9, Hoxa7 as well as Hox coregulators meis1 
and Pbx3 were up-regulated by MLL-ENL-ERtm. Moreover, while transformation efficacy of 
MLL-ENL-ERtm transformed cells were rendered by co-transduction with Bmi-1 (a known Hox 
repressor), single transduction with Hoxa9, Hoxa7, Meis1 or with both Hoxa7 and Meis1 only 
incompletely blocked differentiation of MLL-ENL-ERtm in the absence of tamoxifen. In contrast, 
MLL-ENL-ERtm cells co-transduced with both Hoxa9 and Meis1 resulted in sustained 
proliferation and arrested differentiation even when MLL-ENL-ERtm was inactivated (Zeisig BB 
2004). Furthermore, Ayton and Cleary, 2003, demonstrated that MLL-ENL could not transform 
progenitor cells (Lin-) in the absent of Hoxa9 or Hoxa7 in vitro. In addition, while mice 
transplanted with wild type MLL-ENL transformed cells developed leukaemia, Lin- Hoxa9 
knockout cells transduced with MLL-ENL did not induce leukaemia in recipient mouse. 
Moreover, co-transduction of Hoxa9 and MLL-ENL into hoxa9 deficient Lin- cells rescued both 
the in vitro clonogenic activity as well as the ability to induce leukaemia in recipient mice in vivo 
(Ayton PM 2003). These findings indicate that Hoxa9 and Meis1 are critical for transformation of 
MLL-ENL leukaemia derived from heterogeneous stem/progenitor cell populations such as c-
kit+ or Lin- cells. Because c-kit+ cells are a mixed population of mostly non-self-renewing 
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progenitors (e.g., CMP and GMP) with a significantly fewer number of self-renewing HSC, I 
hypothesise that β-catenin dependent c-Kit+ MLL-ENL LSC may originate from populations that 
have limited self-renewal options/pathways. To test this hypothesis, I performed FACS sorting to 
purify HSC, CMP and GMP to investigate the origin of LSCs transformed by different LATFs as 
well as to test the different functional requirement of β-catenin in LSCs derived from different 
cell of origins.   
To gain further insight into the cell of origins and role of β-catenin in transformation of 
different haematopoietic progenitors by different LATFs, HSCs, CMPs and GMPs from wild type 
and Ctnnb1fl/fl mice were sorted and subjected to RTTA and subsequently transplanted into 
recipient mice.  In my preliminary experiments I showed that Meis1-Hoxa9 transformed and 
generated pre-LSCs in vitro originated from LSK, CMP, and GMP populations. In line with a 
recent publication (Wang Y 2010), I observed that LSK-Meis1-Hoxa9 pre-LSCs could induce 
leukaemia in mice and that deletion of β-catenin abolished the leukaemogenic property of LSK-
Meis1-Hoxa9 pre-LSCs. Surprisingly,  CMP-Meis1-Hoxa9 pre-LSCs also induced leukaemia in 
mice regardless of the β-catenin status, strongly suggesting a different requirement for β-
catenin by the same oncoprotein in functional distinctive haematopoietic populations. 
Interestingly, although GMP-Meis1-Hoxa9 transformed cells could not develop leukaemia in 
recipient mice, constitutive overexpression of β-catenin in GMP-Meis1-Hoxa9 rescued the 
leukaemogenic capacity of those transformed cells. Gene expression analysis revealed that 
Cycloxygenase-1 (Cox-1) one of prostaglandin receptors (Pstger1) which is involved in the 
Wnt/β-catenin pathway was up-regulated in both LSK-Meis1-Hoxa9 and GMP-MLL-AF9 LSCs. 
Moreover, qRT-PCR and western blot specific to activated β-catenin revealed that β-catenin is 
overexpressed in both LSCs derived from LSK-Meis1-Hoxa9 and GMP-MLL-AF9. Interestingly, 
genetic deletion of β-catenin impaired the leukaemogenicity of GMP-MLL-AF9 transformed 
cells. These results suggested that β-catenin is critical for the establishment of LSK-Meis1-
Hoxa9 and GMP-MLL-AF9 LSCs (Wang Y 2010).  In contrast, my results, for the first time, 
reveal β-catenin independent transformation by Meis1/Hoxa9 in CMP population, suggesting 
that the cell of origin plays a critical role in determining the biology of the disease.  To better 
understand the molecular mechanisms that contribute to β-catenin independence in CMP-
Meis1-Hoxa9 LSCs, subsequent experiments including RNA sequencing on normal CMP 
versus CMP-Meis1-Hoxa9 Ctnnb1fl/fl and Ctnnb1del/del pre-LSCs are required.   
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On the other hand, I demonstrated that MN1 could only transform and establish LSCs in 
the CMP but not in the LSK or GMP population.  Remarkably, similar to c-Kit+ MN1 LSC, 
initiation of CMP derived MN1 LSC was β-catenin independent. This finding was consistent with 
recent report that CMP is the cell of origin of MN1-induced leukaemia (Heuser et al. 2011). 
Interestingly, gene expression signature study revealed that normal CMP and MN1 leukaemic 
cells derived from unsorted bone marrow cells share a common gene expression signature 
including the specific up-regulation of Meis1, Flt3, and Mef2c compared with normal GMP. 
However, no significant differential expression of genes involved in Wnt/β-catenin in normal 
CMP and MN1 leukaemia cells was observed. Thus Wnt/β-catenin pathway may not be 
activated in transformed CMP-MN1 cells, which may at least in part explain its β-catenin 
independence. On the other hand, it has been reported that hoxa9 and hoxa10 are differentially 
overexpressed in MN1 LSC compared to mature myeloid cells, suggesting that initiation of MN1 
LSC correlated with Meis1 and Hoxa9 expression (Heuser et al. 2006, Heuser et al. 2011). 
Consistently, similar to CMP-Meis1-Hoxa9, CMP-MN1 pre-LSC do not require β-catenin for the 
development of LSCs, suggesting that targeting of β-catenin may not be sufficient to eradicate 
LSCs with high Hoxa9 and Meis1 expression originated from common myeloid progenitor 
(CMP).  
Together the data strongly demonstrate a different requirement for β-catenin in the 
development of AML LSCs originated from distinct hematopoietic populations and suggest that 
β-catenin independent LSCs may deregulate other self-renewal pathways such as Meis1/Hoxa9 
in some cell populations to compensate for the loss of β-catenin.  
MLL leukaemia is recognised as one of the most aggressive subgroups of haematological 
malignancies and confers very poor prognosis. It has been documented that MLL-AF9 
transformed HSC as well as more differentiated GMP progenitors. Remarkably, leukaemogenic 
potential of GMP-MLL-AF9 was impaired by genetic deletion of β-catenin and pharmacologic 
targeting of β-catenin with indomethacin resulted in reduced numbers of GMP-MLL-AF9 LSCs 
(Wang Y 2010).  However, it is not known whether HSC and CMP require β-catenin for the 
initiation of MLL-AF9 as well as other MLL fusion leukaemia. Using a different mouse strain, I 
confirmed the published result that loss of β-catenin impaired the leukaemogenic property of 
GMP-MLL-AF9. Surprisingly, I also found that HSC-enriched LSK- as well as CMP-MLL-AF9 
induced leukaemia regardless of β-catenin status. To extend my work to other MLL leukaemias, 
I also studied MLL-ENL, which has been shown as an β-catenin dependent oncoprotein (Yeung 
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et al. 2010).  In addition to demonstrating a similar β-catenin dependence for initiation of MLL 
leukaemia based on cell of origins, I also revealed an absolute dependence of β-catenin for the 
maintenance of the disease induced by LSC GMP-MLL-ENL. To further investigate the 
requirement of β-catenin in the maintenance of β-catenin independent, LSK-MLL-ENL, I have 
just recently repeated the experiment by increasing number of recipient mice as well as 
including LSC LSK-MLL-ENL controls. While additional experiments such as in vivo conditional 
deletion of β-catenin in MLL-ENL LSCs as well as treatment of MLL-ENL LSC transplanted mice 
with pharmacological β-catenin inhibitors are needed to assess the potential therapeutic 
targeting of β-catenin in different MLL-ENL LSCs, my data collectively provide strong evidence 
for different roles of β-catenin in the transformation mediated by the same fusion genes, 
depending on the cell of origins.  
Intriguingly, I also demonstrated that different oncogenes/fusion genes display a different 
dependency of β-catenin. While MLL-ENL and MLL-AF9 require β-catenin for the transformation 
of more mature haematopoietic progenitors GMP, Meis1-Hoxa9 requires β-catenin for the 
development of LSC originated from HSCs-enriched LSKs. In contrast, MLL-ENL and MLL-AF9 
transformed LSKs were β-catenin independent, suggesting LSCs originated from certain 
populations such as the HSC-enriched LSKs display differential β-catenin requirement 
dependent on the initiating events (e.g., Meis1-Hoxa9 vs MLL fusion). As Meis1 and Hoxa9 are 
critical genes upregulated by MLL fusion, these results would imply mechanistically, that other 
additional MLL target genes or deregulated pathways compensate for the loss of β-catenin in 
the development of LSK derived LSCs, and these pathways are absent in LSK-Meis1-Hoxa9 
transformed cells.  From a therapeutic point of view, the implications of these findings are 
twofold. While the oncogenic events influence the biology and therapeutic response of the 
disease, the origin of LSCs may also play an equal, if not more important role. 
Self-renewal is a fundamental property and critical for both normal HSCs and LSCs. MLL, 
Hoxa9, Meis1, and β-catenin (Kroon et al. 1998, Dou et al. 2005, Sierra et al. 2006) are all 
recognized as critical molecules involved in normal HSC and LSC development. MLL increases 
Hoxa9, Meis1 and β-catenin expression levels (Balgobind et al. 2011). However, the expression 
levels of these proteins not only differ in distinct haematopoietic populations but are also 
influenced by the oncogenic events.   In my studies, I demonstrated by q-RT-PCR that HSC-
enriched LSK possessing self-renewal abilities highly express β-catenin, Hoxa5, Hoxa7, Hoxa9, 
Hoxa10, Hoxa11, Hoxb4, and Meis1, whereas down-regulation of those genes were observed 
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during differentiation from HSC to CMP and GMP progenitors. This observation is comparable 
to recent studies on the gene signatures of normal HSC/progenitors (Wang Y 2010). 
Interestingly, non-self-renewing GMP expressing low levels of β-catenin and Hoxa9 required 
both their presence to sustain leukaemic transformation by MLL-ENL and MLL-AF9. On the 
other hand, self-renewing HSC that abundantly express β-catenin, Meis1 and several Hox 
genes could still be fully transformed into LSCs by MLL fusions in the absence of β-catenin or 
Hoxa9. Several hypothese could be drawn from these results: Firstly, the inherent properties of 
the cell of origin determines if β-catenin is required for MLL LSCs. Secondly, MLL fusion target 
gene expression is influenced by the cell of origin resulting in β-catenin compensating pathways 
being activated by MLL fusion only in certain cell of origins resulting in β-catenin  independent 
MLL LSCs. Thirdly,  β-catenin may have different targets in different cell of origins resulting in 
variable outcomes of β-catenin deletion that may be only compensated by MLL fusion target 
gene expression in certain cell types. To address these hypotheses, I performed high 
throughput gene expression analysis on pre-LSCs LSK- and GMP-MLL-ENL with Ctnnb1fl/fl and 
Ctnnb1del/del by using RNA sequencing technology.  As expected, I could identify both origin-
specific (selectively down-regulated in LSK or GMP in the absence of β-catenin) as well as 
origin-independent (common down-regulated in LSK and GMP in the absence of β-catenin) 
putative targets of β-catenin in MLL-ENL pre-LSCs. Interestingly, well defined, cancer-related β-
catenin targets such as c-myc (He TC 1998), Cyclin D1(Tetsu O 1999, Sansom OJ 2005), Axin2 
(Yan D 2001, Lustig B 2002, Jho EH 2002)  were not affected in either LSK- or GMP-MLL-ENL 
pre-LSCs when β-catenin was deleted, suggesting that β-catenin targets in haematopoietic 
LSCs may be unique and different from other tissue-specific cancer stem cells. Moreover, 
knockout of β-catenin in pre-LSC GMP-MLL-ENL resulted in down-regulation of several genes 
involved in hypoxia and the control of myeloid cell differentiation. In contrast, these genes were 
not down-regulated in pre-LSC LSK MLL-ENL upon complete deletion of β-catenin. 
Consistently, Gene Set Enrichment Analysis revealed multiple pathways differentially expressed 
in pre-LSC LSK- and GMP-MLL-ENL with Ctnnb1fl/fl and Ctnnb1del/del. Together, these findings 
suggest that MLL pre-LSCs derived from different cell of origins have different β-catenin targets 
or deregulated pathways that are critical for the establishment of LSCs which in turn may 
determine whether MLL LSCs derived from different cellular origins are β-catenin dependent or 
independent.  
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 In order to address whether β-catenin independent LSCs may utilize other self-renewal 
pathways such as Meis1/Hox to compensate for the loss of β-catenin, I determined the 
expression levels of several Hox genes and Meis1 in LSK- and GMP-MLL-ENL pre-LSCs.  
Hoxa9 was consistently found up-regulated  in pre-LSC LSK-MLL-ENL compared to pre-LSC 
GMP-MLL-ENL using RNA sequencing as well as qRT-PCR,. Interestingly, while hoxa9 
deficient progenitor cells (Lin- cells) can be fully transformed into LSCs by MLL-AF9 and MLL-
GAS7 (So CW 2004), development of MLL-ENL LSC derived from Lin- cells was Hoxa9 
dependent (Ayton PM 2003). Moreover, our group’s unpublished data further revealed that 
GMP but not LSK required Hoxa9 for the development of MLL-ENL LSC. In addition, GSEA 
revealed that Meis1-Hoxa9 mediated pathway was consistently up-regulated in MLL-ENL 
transformed cell upon β-catenin inactivation. My findings suggest the presence of a functional 
crosstalk of β-catenin and Hoxa9 self-renewal pathway, which may operate to sustain β-catenin 
independent LSK-MLL-ENL LSCs.  
 To further investigate the functional crosstalk between β-catenin and Hoxa9 in the 
development of MLL-ENL LSCs, retrovirus carrying MLL-ENL and E2A-PBX1 were transduced 
into purified LSK, CMP, and GMP isolated from bone marrow of Rosa26-Cre/Rosa26-
YFP/Hoxa9-/-/Ctnnb1fl/fl mice and subjected to RTTA. While E2A-PBX1 was able to transform 
LSK, CMP, and GMP regardless of β-catenin and Hoxa9 status, MLL-ENL could not transform 
Hoxa9 deficient GMP cells, which is consistent with our group’s unpublished data. More 
importantly, the transformation efficacy of LSK-MLL-ENL was impaired by combined genetic 
deletion of β-catenin and Hoxa9, while mice that received Hoxa9 deficient LSK-MLL-ENL with 
Ctnnb1fl/fl developed leukemia, demonstrating a functional crosstalk between β-catenin and 
Hoxa9 in sustaining LSK-MLL-ENL LSCs. This result revealed that eradication of MLL LSCs 
may require the targeting of multiple self-renewal pathways.  Interestingly, a critical p16/Arf 
suppression function of Hoxa9 in mediating Bmi1-independent LSC function has been recently 
proposed by our group (Smith et al. 2011), the functional relationship between β-catenin and 
hoxa9 in my work is less clear. 
Globally RNA sequencing analysis on pre-LSC LSK-MLL-ENL with Hoxa9-/- and 
Ctnnb1fl/fl compared with LSK-MLL-ENL with Hoxa9-/- and Ctnnb1del/del revealed deregulation of 
several genes and pathways. Among those, genes involving in Meis1-Hoxa9 pathway including 
Prmt1, Ruvbl1, Ruvbl2, Nolc1, and C1qbp were down-regulated in the compound KO. 
Interestingly, Prmt1 has been identified as a critical epigenetic component in certain MLL fusion 
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complexes critical for transcriptional regulation of hox genes (Cheung et al. 2007). A recent 
report demonstrated that Prmt1 could methylate and stabilise Axin leading to increased levels of 
cytoplasmic β-catenin as well as enhanced β-catenin-dependent transcriptional activity, 
suggesting the presence of a positive feedback loop (Cha B 2011). However, whether molecular 
interactions between β-catenin, Hoxa9, and Prmt1 exist and how these molecules interplay with 
each other to facilitate the development of MLL-ENL LSCs remains unclear. Here, I hypothesise 
that Prmt1 could function as a key modulator in the development of MLL-ENL LSC in the 
absence of β-catenin or Hoxa9.  Thus I performed shRNA-mediated knockdown of Prmt1 in 
LSK-MLL-ENL with Ctnnb1fl/fl and Hoxa9-/- LSCs. Interestingly, knockdown of Prmt1 resulted in 
the  suppression of transformation efficacy of both LSC LSK-MLL-ENL Hoxa9-/- and LSC LSK-
MLL-ENL Ctnnb1del/del in vitro. Consistently, while mice received LSK-MLL-ENL Hoxa9-/- 
transduced with empty vector control were able to develop leukaemia, knockdown of Prmt1 
abolished leukaemogenic potential of LSK-MLL-ENL Hoxa9-/- LSC, strongly suggesting that 
transformation efficacy of LSK-MLL-ENL LSC could be abolished by genetic deletion of Hoxa9 
together with the suppression of Prmt1. Because LSC LSK-MLL-ENL with β-catenin knockout 
has a longer latency than LSK-MLL-ENL LSCs with Hoxa9-/-, I am now waiting for the results of 
the remaining in vivo experiments using β-catenin knockout LSK-MLL-ENL LSCs. In addition to 
MLL-ENL LSCs, I extended my work and investigated the functional crosstalk between β-
catenin and Hoxa9 also in the development of MLL-AF9 LSCs. Using a similar approach, I 
showed that MLL-AF9 transformed and established pre-LSCs of HSC, CMP, and GMP in vitro 
regardless of β-catenin and hoxa9 statuses. Interestingly, leukaemogenic potential of LSK- and 
GMP-MLL-AF9 pre-LSCs were abolished by genetic deletion of both β-catenin and Hoxa9, 
consistent with our finding on MLL-ENL. To exclude the possibility that the observed phenotype 
is solely due to the single loss of hoxa9, I have started control experiments in which LSK- and 
GMP-MLL-AF9 pre-LSCs with Hoxa9 knockout were transplanted into recipient mice (n=5 for 
each group) and I am waiting for in vivo data.     
Together, my work provides the mechanistic foundation and rationale to target β-
catenin and hoxa9 in HSC derived MLL fusion AML stem cells (figure 5.1). To translate these 
findings into the clinic and to achieve best possible treatment outcomes, patients should be 
stratified not only according to their genetic and cytogenetic features, but also their cell of 
origins. Although no robust strategy has been reported to predict on the cell of origin in 
individual AML patients, my results suggest this as one of the utmost important tasks for 
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designing better therapeutic regimes for cancer patients. Targeting multiple self-renewal 
pathways that are critical for LSC while dispensable or having a mild impact on normal HSC 
such as β-catenin and Hoxa9 could be a new therapeutic option to eradicate HSC derived MLL 
LSCs. 
 
Figure 5.1: Diagram summarises the different in functional utilisation of β-catenin and Hoxa9 in 
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Chapter 6 Conclusion 
Molecular dissection of self-renewal pathways critical for normal HSC and LSC is very 
important to understand the biology of AML as well as to explore the effective therapeutic 
strategies. β-catenin is critical for the initiation of MLL LSCs, but is dispensable for normal HSC, 
highlighting it as a potential therapeutic target for selective eradication of LSCs while sparing 
normal HSCs. In this project, besides identification of the potential cell of origins of certain LATF 
transformed LSCs, I investigated the role of β-catenin in the initiation and maintenance of 
different LSCs derived from both c-Kit+ (mixed population of haematopoietic stem/progenitor 
cells) and functional distinct haematopoietic population (HSC, CMP, and GMP) using both 
RTTA (in vitro) and bone marrow transplantation assay (in vivo). LATF transformed LSCs 
derived from c-Kit+ cells showed different requirement for β-catenin in the establishment of AML 
LSC. Thus targeting of β-catenin largely depends on the initiating (LATF) events although it 
cannot be ruled out that also certain LATF transformed subpopulations within the c-kit+ 
compartment contribute to the observed β-catenin dependency. Although committed myeloid 
progenitor (CMP) thought to be the origin of β-catenin independent MN1 LSC, Meis1-Hoxa9 
could transform and establish AML LSCs in LSK and CMP derived cells. Interestingly, while β-
catenin was not required for establishment of CMP-Meis1-Hoxa9 LSC, knockout of β-catenin 
abolish leukaemogenic potential of LSK-Meis-Hoxa9 LSC. These findings further confirm the 
origin of MN1 LSC and indicate a different functional requirement for β-catenin in the 
development of LSCs induced by same LATF in different cellular origins.  
       MLL leukaemia is recognised as one of the most aggressive and poor prognostic 
subgroup of haematological malignancies. In this work, I observed that both MLL-AF9 and MLL-
ENL transformed and established MLL LSCs in HSC, CMP, and GMP. Interestingly, while MLL 
LSCs derived from self-renewing HSC and CMP were β-catenin independent, the more mature 
progenitors, GMPs, required β-catenin for the development of GMP MLL LSC. These results 
strongly suggest functional differences of β-catenin in origin-specific LSCs in spite of their ability 
to induce phenotypically identical leukaemia. As β-catenin plays a crucial role to mediate stem 
cell self-renewal, I postulate the presence of multiple alternative self-renewal pathways in 
normal HSCs and certain progenitors allowing the transformation into origin specific LSCs in the 
absence of β-catenin. Analyzing gene expression data of normal LSK, CMP and GMP as well 
as transformed LSK-MLL-ENL and GMP-MLL-ENL revealed that Hoxa9 is overexpressed in 
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LSK and MLL-ENL transformed LSK compared to GMP and GMP-MLL-ENL transformed cells.  
In addition, our group’s unpublished data revealed that Hoxa9 similar to β-catenin is critical for 
transformation of GMP-MLL-ENL whereas LSK-MLL-ENL LSCs are Hoxa9 independent. To 
further investigate whether Hoxa9 may functionally compensate loss of β-catenin for the 
initiation of MLL LSCs derived from LSK, I created a β-catenin/Hoxa9 knockout model where 
both genes can be inactivated in normal HSC and various myeloid progenitors. As a result, 
combined genetic deletion of β-catenin and Hoxa9 could abolish oncogenic potential of LSK 
MLL LSCs. Furthermore, Gene Set Enrichment Analysis (GSEA) on RNA sequencing data of 
pre-LSCs LSK-MLL-ENL with Hoxa9-/-Ctnnb1fl/fl and Hoxa9-/-Ctnnb1del/del revealed that several 
genes in Meis1-Hoxa9 pathway are down-regulated and which may contribute to the 
transformation into LSK-MLL-ENL pre-LSC. Among those, Prmt1 is recognised as one of the 
critical components in certain MLL fusion complexes and crucial for transcriptional regulation of 
hox genes. Using shRNA knockdown to target Prmt1 in LSK-MLL-ENL LSCs, I observed that 
Prmt1 suppression impaired the oncogenic potential of LSK-MLL-ENL LSC in the absence of β-
catenin or Hoxa9 in vitro. Consistently, Prmt1 depleted LSK-MLL-ENL Hoxa9-/-LSCs could not 
induce leukaemia in recipient mouse, suggesting that Prmt1 may be a critical mediator for β-
catenin function in LSK-MLL-ENL LSC. 
Together, I have demonstrated, for the first time, specific molecular and functional 
differences among origin-specific LSCs, in which crosstalk between multiple self-renewal 
pathways such as β-catenin and Hox inherited from the cell of origins may result in resistance to 















Table A1: Gene differentially up-regulated in pre-LSC GMP-MLL-ENL with Ctnnb1fl/fl versus 

































































Table A2: Gene differentially down-regulated in pre-LSC GMP-MLL-ENL with Ctnnb1fl/fl versus 
Ctnnb1del/del (p-value < 0.05 and fold change > 2.0). 
Gene Expression level (log2 fold change) Gene 
Expression level 
(log2 fold change) 
Samd5 -5.81334 Nlrp3 -1.61536 
Ambp -4.00272 Adamtsl5 -1.61304 
Adm -3.88804 Vldlr -1.60235 
Bpifc -3.63531 Lrrc32 -1.59175 
Myl10 -3.60336 Htr2a -1.48824 
Krt19 -3.43655 4933439C10Rik -1.3937 
Stc1 -3.22298 Kcnc3 -1.34549 
Tgm2 -2.99229 Lpar1 -1.34092 
Creb5 -2.88157 Syn1 -1.32871 
F13a1 -2.58914 Aldoc -1.31789 
Irf4 -2.55722 Htra3 -1.20896 
Tgfbr3 -2.53295 Pgbd1 -1.20839 
Grin1 -2.44999 Zkscan17 -1.19713 
Thbs1 -2.28755 Maml3 -1.19554 
Fgf23 -2.22899 Parp16 -1.11956 
Dusp4 -2.18131 Dpep2 -1.09721 
Atp7b -2.17041 Kank1 -1.07499 
Mboat2 -2.14495 Pafah1b3 -1.06421 
C3ar1 -2.05893 Tex2 -1.02854 
Smtnl2 -2.05633   
Ccdc85a -1.9999   
Mgarp -1.99432   
Dlk1 -1.97149   
N4bp3 -1.96296   
St6gal1 -1.93236   
Nrbp2 -1.89797   
H2-Q10 -1.86999   
Ccr2 -1.84374   
Proser2 -1.77436   
Nckap5 -1.74207   
H2-Ab1 -1.69642   
G630025P09Rik -1.67661   
Gm8773 -1.64746   










Table A3: Gene differentially up-regulated in pre-LSC LSK-MLL-ENL with Ctnnb1fl/fl versus 
Ctnnb1del/del (p-value < 0.05 and fold change > 2.0). 
Gene Expression level (log2 fold change) Gene 
Expression level 
(log2 fold change) 
Ccl4 3.185838563 Ms4a7 2.045212866 
Cxcl3 3.134265284 Cd80 2.044585525 
Pla1a 2.965838519 Lyz1 2.044507986 
Maf 2.855356589 Il1f6 2.04192448 
Ccl2 2.849163441 Il12b 2.028364899 
Clec4n 2.645477259 Trib1 2.026682829 
Nrp1 2.582224497 Ccl3 1.993763386 
Il1b 2.51805741 Emr4 1.993245226 
Cxcl2 2.516556391 Ccl9 1.964412461 
Astn2 2.515305902 Ces2g 1.952953296 
Slc11a1 2.479411774 Clec4a2 1.943782942 
Dst 2.463106384 Plekhg1 1.941066133 
Cd302 2.442715198 Ipcef1 1.917239237 
Tmc3 2.434509527 Mmp13 1.897428425 
Cxcl1 2.428551123 1100001G20Rik 1.89479219 
Csf3 2.394021565 Tlr13 1.890265777 
1300002K09Rik 2.330119216 Wfdc17 1.888834575 
Cd300e 2.325704503 Ces1d 1.888748555 
C5ar1 2.307900969 Aass 1.882922653 
Emr1 2.297342835 Cd14 1.870884623 
Msr1 2.29494177 Igf2bp1 1.868112985 
Orm1 2.266523148 Mfsd6 1.824232342 
Slc7a11 2.239326023 Wnt5b 1.822569926 
Cmklr1 2.224197601 Stfa3 1.821079503 
Ms4a6d 2.21789825 Acsl1 1.820750249 
Btla 2.212623315 Plxna1 1.811609783 
Lox 2.201717482 Dhrs9 1.801665137 
Cd9 2.199803314 Mybpc3 1.800914754 
Il18 2.199471482 Zc3h12c 1.799309817 
Pdpn 2.185685143 Gja1 1.798969127 
Cd86 2.183804196 Kctd12 1.778566292 
Plek 2.173610101 Ccl6 1.777767963 
Fpr1 2.16287787 Fstl1 1.776612646 
Lyz2 2.146090782 Prdx1 1.763221947 
Mmp2 2.133453791 Bst1 1.748395792 
Draxin 2.128094404 Syt7 1.748258198 
Fcgr1 2.102112085 Ppbp 1.747674227 
Marco 2.0912555 Mmp9 1.742736269 
Vcam1 2.09009781 Atp8b2 1.723132243 






Table A3: Continue. 




Scimp 1.709985418 Met 1.511626427 
Mcoln2 1.704496217 Bcl2l11 1.510681754 
Meis3 1.691405539 Procr 1.508639097 
Irg1 1.685161639 Gpr137b-ps 1.506926565 
Dgat2 1.681131588 Gdpd1 1.502388876 
Cd200r4 1.678270373 Slc6a12 1.496163487 
AF251705 1.672229715 Dtx4 1.494113686 
Fpr2 1.664590053 Dpp7 1.49053851 
Abca1 1.657061144 Mrc1 1.487825216 
Pcdh7 1.644845931 Hivep3 1.48515487 
Abca9 1.642201604 Zmat3 1.484243458 
Slc7a2 1.635193838 Adgb 1.48327493 
Il20rb 1.632322913 Mgl2 1.482911425 
Heph 1.629385875 Cfb 1.478430139 
Afp 1.627185459 Sirpa 1.474579363 
Slc15a3 1.619106897 Sgpl1 1.464234927 
Fmn1 1.61414124 Ctsh 1.464061223 
Fcgr4 1.594106013 Serf1 1.463672408 
Gbgt1 1.59348581 Creb3l4 1.454751513 
Gm14023 1.592296058 Abca8b 1.452277117 
Gm14047 1.588806611 Csn2 1.450664248 
Clec4d 1.584564032 Anxa1 1.449400431 
Cybb 1.581345985 Phlda1 1.449257236 
Ift74 1.578540878 Hsd11b1 1.447202349 
Saa3 1.573277737 Clec4a1 1.446979833 
Slc39a14 1.573146133 Rnf149 1.446600223 
Cd200r2 1.572753359 Trim66 1.439411244 
4930515G01Rik 1.571856034 Mpeg1 1.435411694 
Treml4 1.57106439 Rbm24 1.428644271 
Tlr2 1.555798557 Pla2g7 1.427683089 
Olfml2b 1.555024013 Fam212b 1.419331123 
Dse 1.547201887 Col5a1 1.417745726 
Olfm4 1.539790351 Ptplb 1.416049254 
Col4a5 1.537739266 Hspa2 1.401949543 
Ptges 1.536828824 Fam196a 1.398832829 
Tnfaip6 1.536634652 Cachd1 1.393292809 
Khdc3 1.533004596 Il1r1 1.392514538 
Cd300ld 1.529065447 Antxr1 1.388535163 
Trpm2 1.526288602 Zfp385a 1.388167943 






Table A3: Continue. 
Gene Expression level (log2 fold change) Gene 
Expression level 
(log2 fold change) 
Marcks 1.382579938 Lgmn 1.302258517 
Gpr137b 1.379243368 Slfn1 1.302056609 
Serpine2 1.377097761 Fth1 1.301821065 
Csf1 1.375840097 Lrp1 1.295290911 
Rhoc 1.374635659 Itih1 1.291753964 
Col4a2 1.372093442 G630090E17Rik 1.287604819 
Selk 1.371315641 Cd22 1.283654484 
Dcbld2 1.368945431 Pdzd2 1.282659441 
Agpat4 1.368285895 Acsbg1 1.279848127 
Ccl7 1.366810871 Pilrb1 1.277706332 
P2rx6 1.366017578 Wdr52 1.27695564 
Syne1 1.36410232 Arhgef12 1.267589847 
Snord82 1.363780338 Scamp5 1.264453389 
Plk2 1.363082676 Tbc1d9 1.263284325 
Hpgds 1.357516509 4930506M07Rik 1.262494677 
Trim29 1.354991834 H2-M2 1.258338422 
Pdlim4 1.354840415 P2ry6 1.258047605 
Spp1 1.351673797 Havcr2 1.256631619 
Mdk 1.349427447 Cd38 1.255377945 
1810011H11Rik 1.348050213 Ms4a3 1.25507721 
Tmem104 1.346467885 Htra1 1.254694094 
Fcrl1 1.342568887 Gm5416 1.253422405 
Il10 1.34230399 Gstt4 1.252220267 
Pld4 1.341688662 9430069I07Rik 1.252218966 
Adora3 1.337658085 Gpnmb 1.250843765 
Mir1983 1.336658362 Snora75 1.247973851 
Dusp16 1.335241499 Gbp2 1.246757274 
Stab1 1.331600386 Gm16287 1.245225824 
Ms4a6c 1.330276607 Hsph1 1.244731408 
Bud31 1.328123499 Lamc1 1.241335708 
Siglece 1.324837276 Cd36 1.239175238 
Cxcl5 1.323478176 Fat1 1.231713963 
Bcl2a1b 1.323417403 Serpinb2 1.229312593 
Snx7 1.317355994 Pon2 1.22797644 
Il1rn 1.3164436 Csf2rb2 1.227439101 
Cald1 1.312151327 Tlr1 1.226826255 
Hdc 1.308174257 Clec4e 1.2266603 
Hebp2 1.306997944 D330045A20Rik 1.224788172 
Tmem132a 1.303772859 Ntng2 1.223094589 







Table A3: Continue. 
Gene Expression level (log2 fold change) Gene 
Expression level 
(log2 fold change) 
Tg 1.218765731 Ggh 1.159112843 
Sgcb 1.216073648 Lipf 1.158839051 
Fam167b 1.214554029 Vcan 1.154947934 
Atp6v0d2 1.213189561 Eng 1.154281782 
Pmp22 1.205786448 Neto2 1.152537856 
Slc2a6 1.205617326 Lipn 1.151926367 
Neo1 1.204075284 Ndufa4 1.149585389 
Cxcl10 1.202443888 Mmp8 1.149382782 
Snora33 1.201688495 Atp2a2 1.148430285 
Sulf2 1.199776743 Pira2 1.148366957 
N6amt2 1.198858653 Kynu 1.147105389 
Cbr3 1.197119275 Slc7a8 1.145444153 
Hist2h4 1.193110566 Pf4 1.145424603 
E230025N22Rik 1.191548249 Mgam 1.14381944 
Arg2 1.190529123 Piwil2 1.140827191 
Ldhb 1.187994168 Rab36 1.139540155 
Prune2 1.187922581 Ube4a 1.139433717 
Gsta3 1.185863504 Nabp1 1.137557374 
Abcg2 1.181862667 Uros 1.137248753 
Trp53inp2 1.180044667 Ccng1 1.136870447 
Slc25a18 1.178806703 Ephx1 1.136582496 
Mrpl20 1.178551658 Atp6v0b 1.132071218 
Pid1 1.178021211 2010005H15Rik 1.130884616 
Cpeb1 1.176463944 Tmem237 1.130231357 
Peg10 1.175916752 Il6 1.128196199 
Slc39a2 1.175857302 Fam134b 1.126929691 
Mmp14 1.175483523 Slc35e4 1.125479816 
Plcb4 1.174088455 Slc1a2 1.124743427 
Igsf3 1.171603251 P2ry14 1.123342593 
Smim3 1.171423987 Hist1h4h 1.123148143 
Armcx4 1.170867018 Mmp27 1.12257024 
Slc6a8 1.170053453 Tmem150b 1.121896958 
Fam219a 1.168373292 Ifi47 1.120412929 
Ctsd 1.16554581 Mgst1 1.119607264 
Snord12 1.163308839 4732491K20Rik 1.119452849 
Mat2a 1.163128064 5830432E09Rik 1.116448216 
Col5a3 1.163101803 2310042D19Rik 1.115697718 
Tlr3 1.162960697 Degs1 1.115334418 
Orm2 1.162734306 Gusb 1.114351435 







Table A3: Continue. 
Gene Expression level (log2 fold change) Gene 
Expression level 
(log2 fold change) 
Rab15 1.110289103 Pde8b 1.062097733 
Ankrd22 1.109740442 Fosl2 1.061258025 
2900060B14Rik 1.107931645 Tmem251 1.060216452 
Tubb2a 1.107573177 Lilra6 1.059802229 
Bcl2a1d 1.106523206 Gm5531 1.057627921 
Bbs7 1.104550684 Serpinb12 1.056518318 
Bax 1.100460768 9530053A07Rik 1.052030119 
Srxn1 1.098217356 Glyat 1.051576607 
Camp 1.09779431 Rltpr 1.050367853 
Fndc9 1.097760349 Glipr1 1.049893131 
Erp27 1.097015957 Tomm5 1.04945677 
Avpr2 1.095505697 Polr2l 1.048791984 
Dixdc1 1.094950515 Serpinb9 1.048678314 
Gm5483 1.094608334 Adam8 1.048574613 
Hvcn1 1.094316976 Mfsd2a 1.047634989 
Fzd8 1.093937825 Pno1 1.04592583 
Cpeb2 1.093624365 Amh 1.045381495 
Ptger1 1.092255993 Abcb9 1.042339164 
Kcnf1 1.090435907 Tmem62 1.041599529 
Hist4h4 1.090098267 Pqlc2 1.040241743 
Vnn3 1.089581397 Plaur 1.038863987 
Ptprj 1.087331846 Enpp2 1.038481662 
Naa20 1.086420487 Pion 1.037929643 
Dennd5b 1.086182882 Rbm44 1.037763772 
Rps27l 1.086110718 Phlda3 1.035023486 
Pkib 1.084033458 Akr1b8 1.034079382 
Slc31a2 1.083109519 Cyp4a12a 1.034029842 
Fermt1 1.079318276 Tmem216 1.034015236 
Gcnt2 1.075832091 Tpcn2 1.032787448 
Pcdhgb7 1.07420027 Tnni2 1.032650587 
Sall2 1.073912095 Ear11 1.032455144 
Rnf128 1.07255144 Ltf 1.032174111 
Tulp4 1.07092527 Dclre1c 1.03128709 
Tal2 1.069767109 Ppp1r16b 1.029937436 
Nlrp1b 1.068636273 Rnu12 1.028453689 
Cyp4f18 1.06606946 Plb1 1.026827432 
Fam181b 1.065905934 Parp12 1.026787402 
Anapc10 1.065613276 Lrrn4 1.025150035 
Eid3 1.063726042 Pea15a 1.023810279 







Table A3: Continue. 











































Table A4: Gene differentially down-regulated in pre-LSC LSK-MLL-ENL with Ctnnb1fl/fl versus 
Ctnnb1del/del (p-value < 0.05 and fold change > 2.0). 
Gene Expression level (log2 fold change) Gene 
Expression level 
(log2 fold change) 
Myl10 -3.28755 Arhgdig -1.60209 
Bpifc -3.27585 Repin1 -1.59756 
Irf4 -3.0374 AI854703 -1.59486 
N4bp3 -2.98077 Adrb2 -1.57006 
Tgm2 -2.46184 Ccdc85a -1.53342 
Nrbp2 -2.38744 Lpar1 -1.52918 
Tgfbr3 -2.37423 Dennd2a -1.52781 
Tifab -2.35449 Adm -1.52096 
Chpf -2.10224 Tsc22d3 -1.49763 
S1pr3 -2.06511 Tgfb2 -1.49719 
Ambp -2.05765 Creb5 -1.49271 
Neurl1b -2.03408 Bzrap1 -1.4893 
F13a1 -2.0283 Acss1 -1.48811 
Ptprf -2.01235 Gbe1 -1.48476 
Ifitm1 -1.9767 Pou6f1 -1.48339 
Dlc1 -1.9388 Sorcs2 -1.47267 
Zkscan17 -1.93655 Klf9 -1.46504 
Mamdc2 -1.91642 Grin1 -1.46144 
Pik3ip1 -1.91018 Ccbl1 -1.4585 
Ndrg2 -1.87869 Zfp57 -1.44989 
D630003M21Rik -1.86034 Kcnip3 -1.44161 
Elfn2 -1.83288 Kif17 -1.43356 
Slc2a3 -1.80944 Hdac7 -1.42642 
Il1r2 -1.80022 Tmem65 -1.42506 
Vdr -1.7966 Iqgap3 -1.41564 
Maml3 -1.79133 Mef2b -1.41476 
Sbf2 -1.7794 Rftn2 -1.41455 
Unc13a -1.76948 Echdc3 -1.40427 
St6gal1 -1.74666 Dab2ip -1.40226 
Zfp36l1 -1.74068 Selenbp2 -1.39214 
Mxd1 -1.70461 Bcr -1.38846 
Selenbp1 -1.6779 Haao -1.38839 
Rhobtb1 -1.67771 5031414D18Rik -1.38689 
Zfp775 -1.66761 Pycr1 -1.38673 
Zfr2 -1.65069 Kank1 -1.3755 
4933439C10Rik -1.64813 Rnf208 -1.36709 
Smtnl2 -1.63921 Fgf23 -1.35241 
Ddb2 -1.6299 Dkkl1 -1.34745 
Slc27a2 -1.61735 Cables1 -1.34513 






Table A4: Continue. 
Gene Expression level (log2 fold change) Gene 
Expression level 
(log2 fold change) 
Rps6ka5 -1.33933 Sdc1 -1.21849 
Reep6 -1.33114 Klhl24 -1.21552 
Hspb6 -1.33106 Arl5c -1.21393 
Fbxo7 -1.32553 Entpd3 -1.21338 
Rasa4 -1.32173 Zfpm1 -1.21206 
Plekhh3 -1.31286 Kctd19 -1.20566 
Tex2 -1.30957 Rarg -1.20411 
Hid1 -1.30264 Tube1 -1.20306 
Tspan9 -1.29618 Gm7694 -1.20227 
Lancl1 -1.29429 Cask -1.20152 
Ccdc138 -1.28949 Spry2 -1.19966 
Pim1 -1.28509 Proser2 -1.19841 
Samd5 -1.28391 Adm2 -1.18828 
Elavl2 -1.27875 Fbxl8 -1.18721 
2610015P09Rik -1.27842 Cspg5 -1.1856 
Extl1 -1.27736 Slc9a5 -1.1845 
Dact3 -1.27635 Als2cl -1.18391 
Lrrc61 -1.27532 Dmwd -1.18235 
Dsp -1.27266 Etv4 -1.17357 
Plekhg3 -1.27111 Cd244 -1.17222 
Nckap5 -1.26898 Cbx4 -1.1694 
Mt2 -1.26875 4933440M02Rik -1.16756 
BC005764 -1.26398 Isg20 -1.16325 
Tle6 -1.26283 Ndrg1 -1.16269 
Angptl6 -1.25913 Fbp1 -1.15924 
1600014C23Rik -1.25771 Lbh -1.15455 
Prss16 -1.25762 Fam64a -1.15361 
H2-Q10 -1.25754 4931417G12Rik -1.15304 
Grik5 -1.25178 Phf19 -1.15169 
AW011738 -1.25155 Nupr1 -1.15138 
Fn1 -1.24973 Samd10 -1.14784 
Npr1 -1.24371 Nos1ap -1.14697 
Zc3h6 -1.2407 Muc13 -1.14623 
Matk -1.23745 Med12l -1.14478 
Poli -1.23517 Cystm1 -1.14259 
LOC106740 -1.23355 Hdac6 -1.14171 
Smad6 -1.23305 E2f2 -1.14122 
Foxj1 -1.22526 Epm2a -1.13654 
Gm6297 -1.22471 Slc52a3 -1.1343 







Table A4: Continue. 
Gene Expression level (log2 fold change) Gene 
Expression level 
(log2 fold change) 
Map3k1 -1.13064 Kcnq5 -1.06419 
Cdc25b -1.13034 Dpp4 -1.0635 
Adssl1 -1.12863 Tfdp2 -1.06325 
Ptpru -1.12572 Ncapd3 -1.06294 
Pfkm -1.12562 Ttc25 -1.06258 
Thbs1 -1.11993 Nat8l -1.0603 
Kbtbd11 -1.11863 Fancd2 -1.05935 
Stx11 -1.11696 Rnf157 -1.05933 
Rasd1 -1.11615 4921507P07Rik -1.05846 
1700025G04Rik -1.10942 B3gnt8 -1.05799 
Fam83g -1.1088 Morn1 -1.0578 
Wnt9b -1.10235 Tmem51 -1.05623 
Atp7b -1.10181 Slc7a3 -1.05613 
Fgf11 -1.10082 D930048N14Rik -1.05556 
Crispld2 -1.09771 Helb -1.05525 
Wnt10b -1.09716 Gm4759 -1.05468 
Parp16 -1.0963 Wdr65 -1.05352 
Cct6b -1.09362 Zfp618 -1.0484 
Gpr19 -1.093 Cntnap1 -1.04808 
Ccno -1.09185 8430427H17Rik -1.04636 
Gys1 -1.09126 Llgl1 -1.0458 
Rad51b -1.09005 Adck3 -1.04553 
Pask -1.08983 Mmp28 -1.04494 
Dennd3 -1.08699 Ldlrad4 -1.04444 
Cnbd2 -1.08615 Dusp10 -1.042 
Gm1673 -1.08501 Gpr56 -1.04087 
Klhl6 -1.08483 Usp11 -1.03887 
Cep72 -1.08396 Jazf1 -1.03424 
41888 -1.08341 Gbp11 -1.03123 
Cgnl1 -1.08317 Btbd2 -1.0305 
Tecpr2 -1.08273 Aldoc -1.03002 
Lsp1 -1.08049 Me2 -1.02937 
Gpc3 -1.07705 1500015A07Rik -1.02935 
Hs3st6 -1.07612 Dhx34 -1.02591 
Katnal1 -1.07606 Rcor2 -1.0257 
Atp4a -1.07391 Wdr67 -1.02424 
Oas1d -1.07224 Ifitm5 -1.02263 
Kcnn4 -1.0715 C920006O11Rik -1.01948 
Fstl3 -1.06471 Ncapd2 -1.01926 







Table A4: Continue. 







































Table A5: Gene specific up-regulated in pre-LSC LSK-MLL-ENL with Ctnnb1fl/fl versus 
Ctnnb1del/del (p-value < 0.05 and fold change > 2.0). 
Proz Tmem216 Fermt1 Fam134b Slc39a2 
Il13ra1 Cyp4a12a Slc31a2 Il6 Peg10 
AU019990 Akr1b8 Pkib Tmem237 Cpeb1 
Panx1 Phlda3 Rps27l 2010005H15Rik Pid1 
Gm16023 Rbm44 Dennd5b Atp6v0b Mrpl20 
Cd68 Pion Naa20 Ephx1 Slc25a18 
Mrpl41 Enpp2 Ptprj Ccng1 Trp53inp2 
Tram2 Plaur Vnn3 Uros Abcg2 
Cd48 Pqlc2 Hist4h4 Nabp1 Gsta3 
Clec4a3 Tmem62 Kcnf1 Ube4a Prune2 
Gm11201 Abcb9 Ptger1 Rab36 Ldhb 
Hist1h2an Amh Cpeb2 Piwil2 Arg2 
Bzw1 Pno1 Fzd8 Mgam E230025N22Rik 
Coprs Mfsd2a Gm5483 Pf4 Hist2h4 
Fbxl22 Adam8 Dixdc1 Slc7a8 Cbr3 
Peli3 Serpinb9 Avpr2 Kynu N6amt2 
Reep3 Polr2l Erp27 Pira2 Sulf2 
Gpr84 Tomm5 Fndc9 Atp2a2 Snora33 
2500004C02Rik Glipr1 Srxn1 Mmp8 Cxcl10 
BC035044 Rltpr Bax Ndufa4 Neo1 
Tmem208 Glyat Bbs7 Lipn Slc2a6 
Ctsb 9530053A07Rik Bcl2a1d Neto2 Pmp22 
Nmb Serpinb12 Tubb2a Eng Atp6v0d2 
Rab11fip1 Gm5531 2900060B14Rik Vcan Fam167b 
Wdr4 Lilra6 Ankrd22 Lipf Sgcb 
Ccl25 Tmem251 Rab15 Ggh Tg 
Nptn Fosl2 Vwf Rnase4 Ces2c 
Cacna1f Pde8b Gusb Orm2 Ntng2 
4933430I17Rik Lphn2 Degs1 Tlr3 D330045A20Rik 
Pea15a Eid3 2310042D19Rik Col5a3 Clec4e 
Lrrn4 Anapc10 5830432E09Rik Mat2a Tlr1 
Parp12 Fam181b 4732491K20Rik Snord12 Csf2rb2 
Plb1 Cyp4f18 Mgst1 Ctsd Pon2 
Rnu12 Nlrp1b Ifi47 Fam219a Fat1 
Ppp1r16b Tal2 Tmem150b Slc6a8 Cd36 
Dclre1c Tulp4 Mmp27 Armcx4 Lamc1 
Ltf Rnf128 Hist1h4h Smim3 Hsph1 
Ear11 Sall2 P2ry14 Igsf3 Gm16287 
Tnni2 Pcdhgb7 Slc1a2 Plcb4 Gbp2 







Table A5: Continue. 
Gpnmb Adora3 Anxa1 Gm14023 Aass 
9430069I07Rik Pld4 Csn2 Gbgt1 Wfdc17 
Gstt4 Il10 Abca8b Fcgr4 Tlr13 
Gm5416 Fcrl1 Creb3l4 Fmn1 1100001G20Rik 
Htra1 Tmem104 Serf1 Slc15a3 Mmp13 
Ms4a3 1810011H11Rik Ctsh Afp Ces2g 
Cd38 Mdk Sgpl1 Heph Ccl9 
Havcr2 Spp1 Sirpa Il20rb Emr4 
P2ry6 Trim29 Cfb Slc7a2 Ccl3 
H2-M2 Hpgds Mgl2 Abca9 Il12b 
4930506M07Rik Snord82 Adgb Pcdh7 Il1f6 
Tbc1d9 Syne1 Zmat3 Abca1 Ms4a7 
Scamp5 P2rx6 Hivep3 Fpr2 Il1a 
Arhgef12 Ccl7 Mrc1 AF251705 Marco 
Wdr52 Agpat4 Dpp7 Cd200r4 Fcgr1 
Pilrb1 Dcbld2 Dtx4 Dgat2 Draxin 
Acsbg1 Selk Gdpd1 Irg1 Mmp2 
Pdzd2 Col4a2 Gpr137b-ps Meis3 Fpr1 
Cd22 Rhoc Procr Mcoln2 Plek 
G630090E17Rik Csf1 Bcl2l11 Scimp Cd86 
Itih1 Serpine2 Met 6530402F18Rik Pdpn 
Lrp1 Gpr137b Cd63 Atp8b2 Cd9 
Fth1 Marcks Trpm2 Mmp9 Lox 
Slfn1 41699 Cd300ld Ppbp Btla 
Lgmn Zfp385a Khdc3 Syt7 Ms4a6d 
Csn1s1 Antxr1 Tnfaip6 Prdx1 Cmklr1 
Tmem132a Il1r1 Ptges Fstl1 Slc7a11 
Hebp2 Cachd1 Col4a5 Ccl6 Orm1 
Hdc Fam196a Dse Kctd12 Msr1 
Cald1 Hspa2 Olfml2b Gja1 Emr1 
Il1rn Ptplb Tlr2 Zc3h12c C5ar1 
Snx7 Fam212b Treml4 Mybpc3 Cd300e 
Bcl2a1b Pla2g7 4930515G01Rik Dhrs9 1300002K09Rik 
Cxcl5 Rbm24 Cd200r2 Plxna1 Csf3 
Siglece Mpeg1 Slc39a14 Acsl1 Cxcl1 
Bud31 Trim66 Saa3 Stfa3 Tmc3 
Ms4a6c Rnf149 Ift74 Wnt5b Cd302 
Stab1 Clec4a1 Cybb Mfsd6 Dst 
Dusp16 Hsd11b1 Clec4d Igf2bp1 Slc11a1 
Mir1983 Phlda1 Gm14047 Cd14 Astn2 
Cxcl2 Il1b Nrp1 Ccl2 Maf 






Table A6: Gene specific down-regulated in pre-LSC LSK-MLL-ENL with Ctnnb1fl/fl versus  





Tifab Zfp57 Angptl6 Fam64a Cgnl1 
Chpf Kcnip3 1600014C23Rik 4931417G12Rik Tecpr2 
S1pr3 Kif17 Prss16 Phf19 Lsp1 
Neurl1b Hdac7 Grik5 Nupr1 Gpc3 
Ptprf Tmem65 AW011738 Samd10 Hs3st6 
Ifitm1 Iqgap3 Fn1 Nos1ap Katnal1 
Dlc1 Mef2b Npr1 Muc13 Atp4a 
Mamdc2 Rftn2 Zc3h6 Med12l Oas1d 
Pik3ip1 Echdc3 Matk Cystm1 Kcnn4 
Ndrg2 Dab2ip Poli Hdac6 Fstl3 
D630003M21Rik Selenbp2 LOC106740 E2f2 Nfix 
Elfn2 Bcr Smad6 Epm2a Kcnq5 
Slc2a3 Haao Foxj1 Slc52a3 Dpp4 
Il1r2 5031414D18Rik Gm6297 Ptrf Tfdp2 
Vdr Pycr1 Tox Map3k1 Ncapd3 
Sbf2 Rnf208 Sdc1 Cdc25b Ttc25 
Unc13a Dkkl1 Klhl24 Adssl1 Nat8l 
Zfp36l1 Cables1 Arl5c Ptpru Fancd2 
Mxd1 Peli2 Entpd3 Pfkm Rnf157 
Selenbp1 Rps6ka5 Zfpm1 Kbtbd11 4921507P07Rik 
Rhobtb1 Reep6 Kctd19 Stx11 B3gnt8 
Zfp775 Hspb6 Rarg Rasd1 Morn1 
Zfr2 Fbxo7 Tube1 1700025G04Rik Tmem51 
Ddb2 Rasa4 Gm7694 Fam83g Slc7a3 
Slc27a2 Plekhh3 Cask Wnt9b D930048N14Rik 
Gm10560 Hid1 Spry2 Fgf11 Helb 
Arhgdig Tspan9 Adm2 Crispld2 Gm4759 
Repin1 Lancl1 Fbxl8 Wnt10b Wdr65 
AI854703 Ccdc138 Cspg5 Cct6b Zfp618 
Adrb2 Pim1 Slc9a5 Gpr19 Cntnap1 
Dennd2a Elavl2 Als2cl Ccno 8430427H17Rik 
Tsc22d3 2610015P09Rik Dmwd Gys1 Llgl1 
Tgfb2 Extl1 Etv4 Rad51b Adck3 
Bzrap1 Dact3 Cd244 Pask Mmp28 
Acss1 Lrrc61 Cbx4 Dennd3 Ldlrad4 
Gbe1 Dsp 4933440M02Rik Cnbd2 Dusp10 
Pou6f1 Plekhg3 Isg20 Gm1673 Gpr56 
Sorcs2 Mt2 Ndrg1 Klhl6 Usp11 
Klf9 BC005764 Fbp1 Cep72 Jazf1 
Ccbl1 Tle6 Lbh 41888 Gbp11 
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Table A6: Continue. 
Btbd2 C920006O11Rik Arrb1 Prss57 Lzts2 
Me2 Ncapd2 Hif3a Sbsn Pmaip1 
1500015A07Rik Fam169b Apobec3 Hist2h3c2 Plekha6 
Dhx34 Pold1 Tjp3 Hsf4 5430416N02Rik 
Wdr67 Pcsk4 Rnd3 Suv420h2  
Ifitm5 Cenpf D930028M14Rik Jak3  
 
Table A7: Gene specific differentially expressed in pre-LSC GMP-MLL-ENL with Ctnnb1fl/fl 
versus Ctnnb1del/del (p-value < 0.05 and fold change > 2.0). 
Up-regulated gene (12 genes) Down-regulated gene (22 genes) 
Mogat2 Zfp819 Ccr2 Dlk1 
Serpinb10 B3galt5 C3ar1 Gm8773 
Ptafr Rhod Dpep2 Kcnc3 
Fos Tmcc3 Nlrp3 Pafah1b3 
Chi3l1 Fosb H2-Ab1 Mgarp 
Asprv1 Pros1 Stc1 G630025P09Rik 
  Lrrc32 Krt19 
  Htra3 Adamtsl5 
  Dusp4 Pgbd1 
  Mboat2 Syn1 


















Table A8: Genes common differentially expressed in both pre-LSCs LSK- and GMP-MLL-ENL   
with in the absent of β-catenin (p-value < 0.05 and fold change > 2.0). 
Common up-regulated gene (21 genes) Common down-regulated gene (31 genes) 
Olfm4 Hvcn1 Samd5 Rcor2 
Clec4a2 Clec4n Tgfbr3 Maml3 
Ces1d Pdlim4 Bpifc F13a1 
Plekhg1 Trib1 Irf4 H2-Q10 
Camp Ipcef1 Ambp Kank1 
Lyz1  Aldoc Adm 
Lyz2  Zkscan17 Smtnl2 
Plk2  N4bp3 Parp16 
Cd80  St6gal1 Proser2 
Col5a1  Tgm2 4933439C10Rik 
Serpinb2  Creb5 Thbs1 
Il18  Nrbp2 Nckap5 
Slc6a12  Myl10 Atp7b 
Vcam1  Lpar1 Grin1 
Map6  Tex2 Fgf23 
Bst1  Ccdc85a  
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